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ABSTRACT 
 
Animals and microbes coevolved, and thus it is not surprising that the trillions of 
microorganisms that harmoniously inhabit the mammalian gastrointestinal tract (GIT), 
collectively termed the gut microbiome, continue to be implicated in healthy and disease 
states. However, less is known about the mechanisms by which these states are maintained, 
and how deviations from homeostasis (i.e., dysbiosis) occurr. This thesis explores the 
relationship between host-microbe interactions and the central and peripheral nervous 
systems. Specifically, the first chapter of this thesis explores how the microbiome differs is 
patients with multiple sclerosis and how these differences alter diseases outcomes in a mouse 
model of the disease. Next, we introduce the enteric nervous system (ENS), the intrinsic 
nervous system of the GI tract which is supposed as a major conduit of the bidirectional 
communication between the gut and the brain. Lastly, by adopting biotechnologies in gene 
delivery and genetically encoded tools for neuroscience, we introduce a molecular toolkit to 
characterize the ENS in a robust and efficient manner and modulate the ENS to uncover 
novel mechanisms by which innervation of the GI mediates host-microbe interactions.  
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C h a p t e r  1  
                                           INTRODUCTION 
  
 
 
2 
Introduction 
 
The human body consists of organs and organ systems that make, circulate, and utilize our 
life blood. However, often forgotten are the organisms that live on and within us that work 
in synergy with our body to maintain physiologies that are integral to our development, 
health, and survival. Over the years, the consortia of microbes that inhabit the gastrointestinal 
tract, collectively termed the gut microbiome, have been implicated in numerous 
physiologies associated with diverse cell types and organ systems, in both health and disease. 
Such implications range from maintenance and afflictions of the immune system (1), 
metabolism (2), and even behavior and neurological disease (3). Neuroimmunology, the 
study by which neurons in the brain and the periphery interact with the immune system, has 
been of particular interest to those that study the gut microbiome (4, 5). As the immune 
system continues to implicate neurological diseases (6, 7), and conversely, the nervous 
system implicates immunity (8, 9), the microbiome is well documented to have a modulatory 
effect on both the immune and nervous systems. However, the mechanisms of action by 
which the microbiome contributes to health and disease are complex and multifactorial, and 
thus deducing its contribution to the etiology of diseases remains difficult to dissect and is 
poorly understood. 
 
The first aim of this thesis (Chapter 2) is to demonstrate the contribution of the microbiota 
in the progression and/or the protection against multiple sclerosis (MS), a neurodegenerative 
disease that results from the demyelination of neurons in the brain and the spinal cord. The 
cause of MS is unknown, however genetic and immunological mouse models of the disease 
have been developed. Furthermore, given the relapsing and remitting nature of the disease, 
environmental factors have been favorably hypothesized regarding its etiology. In this 
chapter we show that the microbiota differs between human patients with MS and their 
respective household controls. Additionally, we create a humanized gnotobiotic mouse 
model by transplanting the microbiome from MS patients into germ-free mice. In doing so, 
we find that the MS microbiome induces a more pro-inflammatory tissue environment, 
whereas the respective controls have a more anti-inflammatory tone. These humanized mice 
were induced with experimental autoimmune encephalomyelitis, an immunological mouse 
 
 
3 
models of MS. We found that those mice with microbiome transplants from MS patients 
exhibited worsened disease outcomes, implicating the microbiome and its modulation of the 
immune system as a mechanism by which MS and its associated sporadic exacerbations 
develop.  
 
Although this study provides a link between the microbiota, immune system, and 
neurodegenerative disease, it does not explain how the underlying dysbiosis of the gut 
microbiome develops and persists. Animals have coevolved with the microbes that inhabit 
their gastrointestinal tract. Thus, there must have been evolutionary selective pressure on the 
luminal environment to exclude harmful and disease-causing microbes while allowing health 
promoting microbes to thrive. Understanding the mechanisms by which an “unhealthy” 
microbiome develops or how a “healthy” microbiome is sustained may hold the answer to 
novel therapeutic targets, treatments, and preventive measures.  
 
Towards this end, we introduce the enteric nervous system (ENS) which is the network of 
neurons and glia that envelope the entire gastrointestinal tract. The GI ecosystem can be 
largely characterized by the exchange of molecules between and within luminal 
constituents and the host. Environmental and dietary molecules are necessary for host 
survival but, in addition, are important factors that affect gut microbes and the factors they 
produce. How these luminal components, as a whole, interact with the cells and molecules 
of the intestine elucidates complex and coordinated events that occur in the GI tract. 
Homeostatic communication across the intestinal epithelium involves contributions by diet 
and the microbiota, interacting with the mucosal immune system and the ENS. In the GI 
tract, multiple distinct cell types can produce a given modulatory molecule, and conversely, 
a given molecule is able to affect various cell types. This molecular synchrony, and 
deviations from it, impact expansive GI and non-GI physiologies. Yet understanding of 
cellular and molecular interconnections at this critical interface between the body and the 
environment remains largely unexplored. In Chapter 3 of this thesis, we review the diverse 
cellular anatomy of the GI system and discuss the molecules and receptors that various cell 
types use to communicate and function. The unique juxtaposition of a robust enteric 
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nervous and immune system, positioned in a location with the most extensive portal to our 
molecular universe, suggests a vital role for neuro-immune interactions in the gut whose 
effect goes beyond the host (i.e. microbes) and the confines of the GI tract. 
 
In Chapter 4 of this thesis, we introduce an experimental toolbox to characterize and 
interrogate the ENS. As the ENS becomes more implicated in a diverse array of physiologies, 
we believe that it is crucial to thoroughly characterize the ENS and all of its subtleties. This 
is currently difficult to achieve due to the expansive nature of the GI tract and the limitations 
of antibody mediated labelling. Utilizing adeno-associated viral particles loaded with 
genetically encoded fluorescent reporters, we are able to characterize the cellular architecture 
of the ENS. Furthermore, by repurposing biotechnologies used in neuroscience research, we 
begin to define the consequence of in vivo ENS activation. Using a multi-omics assay 
approach, we discover activation mediated changes to the intestinal transcriptome and the 
luminal proteome, metagenome, and metabolome. From our research, we conclude that the 
ENS is capable of mediating a breadth of diverse cellular communications in the GI tract, of 
both host and microbial origin. These findings elucidate novel host-microbe interactions 
mediated by nervous systems and begin to uncover the potential etiological impact of the 
ENS in health and disease states.  
 
We sincerely hope that the findings of this thesis introduce novel biological paradigms that 
inspire innovation in the way health is maintained and disease is treated.  
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ABSTRACT: 
The gut microbiota regulates T cell functions throughout the body. We hypothesized that 
intestinal bacteria impact the pathogenesis of multiple sclerosis (MS), an autoimmune 
disorder of the central nervous system, and thus analyzed the microbiomes of 71 MS patients 
not undergoing treatment and 71 healthy controls. Although no major shifts in microbial 
community structure were found, we identified specific bacterial taxa that were significantly 
associated with MS. Akkermansia muciniphila and Acinetobacter calcoaceticus, both 
increased in MS patients, induced pro-inflammatory responses in human PBMCs and in 
mono-colonized mice. In contrast, Parabacteroides distasonis, which was reduced in MS 
patients, stimulated anti-inflammatory interleukin-10 (IL-10)-expressing human 
CD4+CD25+ T cells, and IL-10+FoxP3+ regulatory T cells (Tregs) in mice. Finally, 
microbiota transplants from MS patients into germ-free mice resulted in more severe 
symptoms of experimental autoimmune encephalomyelitis (EAE) and reduced proportions 
of IL-10+ Tregs compared to mice “humanized” with microbiota from healthy controls. This 
study identifies specific human gut bacteria that regulate adaptive autoimmune responses, 
suggesting therapeutic targeting of the microbiota as a novel treatment for MS. 
 
SIGNIFICANCE: 
For the first time, we have experimentally investigated the immunoregulatory effects of 
human gut microbiota in multiple sclerosis (MS). We have identified specific bacteria that 
are associated with MS and demonstrated that these bacteria regulate T lymphocyte-mediated 
adaptive immune responses and contribute to the pro-inflammatory environment in vitro and 
in vivo. Thus, our results expand the knowledge of the microbial regulation of immunity and 
may provide a basis for the development of microbiome-based therapeutics in autoimmune 
diseases.  
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Introduction 
A major role of the human gut microbiota is to regulate both innate and adaptive immune 
responses during health and disease (1). Most studies of the human microbiome to date have 
focused on analyzing microbial population structures. However, it is equally important to 
investigate how variability in microbial abundance and composition affects host functions 
(2, 3). Exposing primary human immune cells to microbes or microbial products in vitro 
allows functional investigation of immunomodulatory effects by the gut microbiota (4-6).  
 
There is growing evidence of population differences in the gut microbiota in multiple human 
autoimmune diseases (7, 8), including multiple sclerosis (MS) (9-12). While these studies in 
MS were performed with small sample sizes, and did not stratify patient groups by treatment 
with disease modifying drugs, consistent patterns of modest dysbiosis appear to be emerging. 
Furthermore, microbiota have been shown to mediate regulation of immune responses in 
experimental autoimmune encephalomyelitis (EAE), a mouse model of MS (13, 14). MS-
like symptoms in EAE can be exacerbated by T helper 1 and 17 (Th1 and Th17) responses, 
and modulated by regulatory T lymphocytes (Tregs) (15, 16).  
 
This led us to investigate structural and functional changes in intestinal microbiota as a 
potential component of MS pathogenesis. Specifically, we identified differences in microbial 
abundance between MS patients and controls, and investigated how particular MS-associated 
bacteria modulate T lymphocyte responses using both in vitro and in vivo model systems. 
Our results indicate that differences in specific gut bacteria are functionally associated with 
a shift towards a pro-inflammatory T cell profile that may exacerbate or perpetuate 
autoimmune responses, thus potentially identifying a novel environmental contributor to MS 
pathogenesis. 
 
Results 
MS microbiome elicits differential Treg responses and shows modest dysbiosis at genus 
level 
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To investigate whether MS-associated bacteria affect immune functions in the host, we 
stimulated peripheral blood mononuclear cells (PBMCs) from MS patients or healthy 
controls, using extracts from total bacteria isolated from the stool samples of the same 
subjects who were PBMC donors (thus, “self” bacterial extracts). We observed that PBMCs 
from MS patients showed an impaired ability to differentiate or expand CD25+FoxP3+ Treg 
populations (Figure 1A; Treg proportion expressed as fold difference over no-bacteria 
vehicle control). The total CD3+CD4+ T helper lymphocyte population (1.037±0.076 fold 
change in the percentage of CD3+CD4+ cells out of all live lymphocytes) was not altered by 
bacterial extract treatment, and the baseline proportion of CD25+FoxP3+ Tregs out of 
CD3+CD4+ T cells was not different between MS patients and healthy controls. These 
results suggest an immunoregulatory interaction between microbiota and PBMCs of MS 
patients that is functionally different compared to healthy controls.  
 
We subsequently analyzed the microbiome by 16S rRNA gene sequencing of stool samples 
from 71 untreated relapsing-remitting MS patients and 71 healthy controls (demographic 
data, Supplemental Table S1). A subset of 79 subjects was sampled on two consecutive days 
to account for variability over time, and all subjects were used to compare the variability 
within and between subject groups (Supplemental Figure 1). We did not observe major 
global shifts in bacterial community structure in terms of alpha or beta diversity (Figure 1B, 
1C), which is unsurprising given similar findings in other autoimmune diseases (7, 8). 
However, despite similar alpha and beta diversity (Figure 1B, 1C) we did observe differences 
at the level of individual microbial taxa between MS and control subjects (Figure 1D, Figure 
2).  
 
We identified 129 total genera and 1462 total operational taxonomic units (OTUs) in our 
samples. We systematically compared relative abundances of individual microbial taxa 
between MS patients and controls at the genus and OTU levels by negative binomial Wald 
test using Benjamini-Hochberg correction for multiple comparisons (17). Our analysis 
revealed differences in the relative abundance of 247 OTUs (16.89% of total) and 25 
bacterial genera (19.38% of total) that were either significantly increased or reduced in MS 
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(Figure 2A, 2B). All genera that were significantly different between MS patients and 
healthy controls (Figure 2A points above the dotted line) are listed in Table 1, and all 
significantly different OTUs are listed in Supplemental Table S2.  
 
We then selected individual significantly different taxa for functional studies to assess their 
potential contribution to autoimmune inflammation in MS. The specific taxa were selected 
based on the following criteria, here listed in order of importance: 1) identifiable to species 
level or genus level with high overlap between species; 2) culturable, in order to be able to 
study their functions in vitro and in vivo; 3) type strains available from ATCC to ensure 
reproducibility; and 4) previously associated with immunoregulatory effects. 
 
Among the genera significantly increased in MS samples were Acinetobacter and 
Akkermansia, while one of the most significantly reduced genera in MS patients was 
Parabacteroides, with the majority of OTUs mapping to P. distasonis (Figure 2C, 
Supplemental Figure 2). Interestingly, P. distasonis was previously reported to induce a Treg 
phenotype in gnotobiotic mouse models (18, 19). All Acinetobacter species, including A. 
baumannii, A. calcoaceticus and A. lwoffii, are rare in the healthy human gut microbiome 
and share genome-wide homology (20, 21), making them indistinguishable by 16S amplicon 
sequencing. Thus, OTUs that mapped to the genus Acinetobacter did not allow for species-
level discrimination. However, because A. calcoaceticus has been associated with MS in 
prior publications (22), we focused on this organism as a candidate for functional studies of 
immune regulation. Finally, all OTUs that mapped to the Akkermansia genus belonged to the 
species A. muciniphila, which has mostly been studied in the context of metabolism (23), but 
also contributes to inflammation during infection (12, 24).  
 
MS-associated bacterial species reduce Tregs and increase Th1 lymphocyte 
differentiation in vitro 
We hypothesized that bacterial taxa altered in MS patients play functional roles in regulating 
immune responses. To test this hypothesis, we established an in vitro model system by 
exposing PBMCs from healthy donors to a suspension of heat-killed and sonicated individual 
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bacterial species (termed “bacterial extracts”) under different stimulating conditions (e.g. 
Treg, Th1, etc), and used flow cytometry to evaluate T lymphocyte differentiation and 
proliferation. We observed that extracts from A. calcoaceticus reduced proportions of 
CD25+FoxP3+ Tregs among PBMCs (Figure 3A-B). These results suggest that intestinal A. 
calcoaceticus restrains immunoregulatory T cell development consistent with its relative 
increase in the MS cohort. Furthermore, we observed that A. calcoaceticus increased the 
proportion of effector CD4+ lymphocytes, which differentiated into IFNJ-producing Th1 
cells (Figure 3C-D) thereby potentially exacerbating inflammation.  
 
Analysis of A. muciniphila, another bacterial species increased in the MS microbiome, 
revealed an even more pronounced effect on stimulating Th1 differentiation. Extracts from 
A. muciniphila significantly increased healthy donor PBMC differentiation into Th1 
lymphocytes (Figure 4A-D). Furthermore, we discovered that the mere presence of A. 
muciniphila in total stool bacteria was sufficient to increase Th1 lymphocyte differentiation 
in vitro. Specifically, exposing PBMCs to total bacterial extracts isolated from unrelated 
subjects with detectable levels of A. muciniphila increased the differentiation of IFNJ+ Th1 
lymphocytes compared to bacterial extracts that did not have A. muciniphila (Figure 4E, 4G). 
Similarly, subjects with detectable A. muciniphila showed a significant increase in IFNJ+ 
Th1 differentiation in response to extracts of their own bacteria (Figure 4F, 4H). (The 
presence of Acinetobacter in total stool bacteria was not sufficient to skew PBMC responses 
to either increase Th1 or reduce Treg differentiation, likely due to its rarity and low relative 
abundance compared to other bacteria (data not shown)). In summary, we have identified A. 
muciniphila and A. calcoaceticus as examples of common and rare MS-associated bacterial 
species that favor pro-inflammatory T lymphocyte responses in vitro.  
 
We next explored whether individual taxa that are less abundant in MS patients could 
promote immunoregulatory responses. Exposing healthy donor PBMCs to extracts from P. 
distasonis significantly increased the percentage of CD25+ T lymphocytes among the 
CD3+CD4+ T cell population (Figure 5A-B). Furthermore, we observed an enrichment of 
CD25+IL-10+ cells (Figure 5C-D), including CD25+IL-10+FoxP3- Tr1 cells (but not 
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CD25+FoxP3+ Tregs), which have been associated with strong immunoregulatory 
properties (14, 25). Thus, our results demonstrate that P. distasonis is sufficient to skew T 
lymphocytes toward a regulatory profile in vitro.  
 
All immunoregulatory effects described here were at least partially specific to selected 
bacterial extracts. To show that exposure to any differentially abundant bacteria did not elicit 
similar effects, we analyzed the immune effects of Eggerthella lenta, which is significantly 
increased in MS patients, and found that it did not alter Th1 or Treg differentiation 
(Supplemental Figure 3 A, B). In addition, the specificity of P. distasonis, A. calcoaceticus 
and A. muciniphila functions is emphasized by the fact that these bacteria did not alter the 
differentiation of all lymphocyte populations indiscriminately, for example, P. distasonis had 
no effect on Th1 cells, and A. muciniphila had no effect on CD25+FoxP3+ Tregs 
(Supplemental Figure 3 C-E). 
 
While regulation of immune functions by gut microbiota are likely multifaceted and 
complex, we speculate that the observed P.distasonis-associated reduction in 
immunoregulatory T cells could act in concert with the described increases in A. 
calcoaceticus and A. muciniphila and contribute to create an overall pro-inflammatory 
environment in MS patients.  
 
Colonization of mice with single species of MS-associated bacteria recapitulates in vitro 
T lymphocyte differentiation profiles 
To elucidate the role of individual MS-associated bacteria in vivo, we colonized antibiotic-
treated or GF mice with single species A. calcoaceticus, A. muciniphila, and P. distasonis. 
Following colonization, we measured T lymphocyte differentiation in multiple peripheral 
lymphoid tissues. We were unable to observe an effect of A. muciniphila in monocolonized 
mice as described in our in vitro experiments, and we hypothesize that this discrepancy is 
likely due to differences in host (e.g., mice vs. human). However, we were able to replicate 
our key findings with the other two species analyzed.  
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In antibiotic-treated mice A. calcoaceticus inhibited FoxP3+ Treg differentiation, while P. 
distasonis stimulated CD4+IL-10+ lymphocyte differentiation (Supplemental Figure 4 A,B.) 
Furthermore, splenocytes from mice colonized with P. distasonis also displayed induction of 
CD4+IL10+ lymphocytes in response to their bacterial extracts, while this was not observed 
when splenocytes from control SPF mice were exposed to their own bacterial extracts 
(Supplemental Figure 4C).  
 
Furthermore, monocolonization of GF mice with A. calcoaceticus increased T lymphocyte 
differentiation into IFNJ+ Th1 phenotype in cervical lymph nodes (Figure 6A), while 
monocolonization with P. distasonis led to significant increases in CD4+IL-10+ T 
lymphocyte population in mesenteric lymph nodes and spleens (Figure 6B, Supplemental 
Figure 5). Taken together, the in vivo monocolonization results form a consistent 
complement to our in vitro data.  
 
Colonization of mice with MS donor microbiota inhibits Treg differentiation and 
exacerbates disease severity in experimental autoimmune encephalomyelitis (EAE) 
To investigate whether the pro-inflammatory environment established by MS-associated 
bacteria is physiologically relevant, we randomly selected 3 MS and control donor pairs 
(each composed of an untreated RRMS patient and a household control) to perform fecal 
microbiota transplants into groups (n=6-8) of germ-free C57BL/6 mice. Six weeks after 
transplantation, mice were immunized with MOG35-55 to induce EAE. Remarkably, EAE 
disease scores were significantly increased in mice colonized with microbiota from MS 
patients when compared to animals colonized with microbiota from healthy controls and 
germ-free (GF) mice (Figure 7A). This result was recapitulated across all 3 donor pairs tested 
(Supplemental Figure 6), and accompanied by a lack of IL-10+ Treg induction in mesenteric 
lymph nodes from MS-microbiota colonized mice (Figure 7C-F, Supplemental Figure 7). 
RNAseq of spinal cords 35 days after EAE induction revealed hundreds of gene expression 
differences between GF mice humanized with MS and CTRL microbiota. Interestingly, 
when a specific analysis was performed to identify the cellular origin of these changes, a 
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noticeable enrichment towards genes expressed by microglia was observed (Supplemental 
Figure 8).  
 
The inability of fecal bacteria from MS patients to promote Treg responses was observed 
both pre- and post- EAE induction, consistent with the microbiota showing no major 
differences in beta diversity at time points before and after the disease (Figure 7B).  
 
Principal component analysis of beta diversity of the microbiota in recipient animals showed 
a significant separation by donor that was stabilized as early as 7 days after transplantation 
(Figure 7B, Supplemental Figure 9A). This separation was recapitulated by metrics of alpha 
diversity (Supplemental Figure 9B). Interestingly, some of the changes in relative abundance 
of individual bacterial genera, including a decrease in Sutterella and an increase in 
Ruminococcus, were also observed in mice colonized with microbiota from MS-discordant 
twins (Berer et al. accompanying manuscript; Supplemental Figure 9C). Although human 
and mouse microbiota are not directly comparable, the biological pathways represented by 
MS-associated taxa largely overlap in both groups (Supplemental Tables S3, S4).  
 
Collectively, the MS microbial community in vivo enhances EAE disease progression and 
fails to induce IL-10+ Tregs relative to gut bacteria from healthy controls, suggesting a 
functional role for the microbiota in autoimmunity that may be independent of host factors. 
 
Discussion 
Summary and implications 
Here we present a comparative structural analysis of the gut microbiome from patients with 
MS, followed by functional studies of MS-associated microbiota. While no major shifts in 
microbial diversity were identified, specific bacterial taxa were found to be significantly 
under- or over-represented in untreated MS patients compared to healthy controls. In vitro 
studies of MS-associated bacterial species revealed that even modest dysbiosis could drive a 
two-stage, immune deviation mechanism (either sequential or parallel), ultimately resulting 
in skewed T lymphocyte differentiation. Acinetobacter and Akkermansia species induce a 
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pro-inflammatory environment, mediated by reduction in CD25+FoxP3+ Tregs and 
expansion of Th1 lymphocytes. On the other hand, a potential concomitant decrease in P. 
distasonis mediates a relative loss of CD25+IL-10+ T lymphocytes. Furthermore, we show 
that MS-associated microbiota inhibits IL-10+ T lymphocyte responses in vivo and increases 
disease severity in a mouse model of MS. 
 
Our results corroborate the concept of MS as a multi-hit model that combines genetic 
predisposition and environmental factors, one of which is the microbiota. The interaction 
between microbiota and the immune system is likely bidirectional, as suggested by impaired 
lymphocyte responses of MS patients to self microbiota, but no difference in control 
lymphocyte responses to either control or MS non-self microbiota (Supplemental Figure 10). 
Based on our findings, the main function of microbiota in MS is not to cause the disease 
directly, but rather to exacerbate it by creating a pro-inflammatory environment. A reduction 
in Parabacteroides, an increase in Acinetobacter and an increase in Akkermansia can 
together or separately contribute to inflammation and disease severity without being the only 
factors that account for the development of the disease. Thus, it is essential to view our 
findings not as an exclusive list of immunoregulatory microbiota, but rather as the first step 
in investigating the microbial species and pathways that contribute to the regulation of 
autoimmune inflammation in MS and other diseases.  
 
In contrast to recent publications profiling the microbiome in MS and other chronic diseases 
(9, 10, 26, 27), we focused exclusively on patients that were not receiving disease-modifying 
therapeutics at the time of sample collection to decouple the effects of the disease and 
therapy, a valuable strategy highlighted in a recent report on Crohn’s disease (8). In 
concordance with prior studies in MS, we did not observe global changes in microbial 
community structures. However, the larger sample size in our study allowed us to identify 
individual bacterial taxa that are potentially associated with autoimmunity. In addition, in 
contrast to studies on MS microbiota that were limited to identifying correlations between 
microbial taxa and host phenotypes (28, 29), we were able to investigate microbial 
immunoregulatory effects in vitro and in vivo.  
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Our taxa-specific investigation was focused on commensal microbiota, not infectious 
pathogens. Akkermansia and Parabacteroides are commensal and even Acinetobacter, even 
though it is typically contracted as an infection, is not considered a pathogen once it inhabits 
the human gut. We consciously chose to investigate the physiological contribution of 
commensals to systemic inflammation, as their ability to alter T lymphocyte differentiation 
is likely to create a systemic environment that may exacerbate inflammation in the host 
without overt infection, which constitutes a plausible model for MS etiology.  
 
In our admittedly simplistic experimental setup, we used crude bacterial extracts without 
prior fractionation, thus relevant active components may consist of any bacterial products, 
either secreted or intracellular. Known bacterial metabolites with immunoregulatory effects 
fall into multiple categories, including polysaccharides (30), short-chain fatty acids (31), and 
aryl hydrocarbons (32). In addition, although we analyzed the effects of bacterial extracts on 
peripheral immune cells, some bacterial metabolites are able to cross the blood-CNS barrier 
and directly regulate CNS inflammation via microglia (33, 34) or astrocytes (32). Future 
research will likely be directed towards identifying the therapeutic potential of such products 
in MS and other complex diseases.  
 
Potential mechanisms of microbial regulation of autoimmunity in MS 
Our findings indicate that both rare and common microbiota may play a role in the 
exacerbation of autoimmune inflammation in MS. Notably, the presence of a relatively 
common bacterial species, A. muciniphila, in total stool bacteria was sufficient to recapitulate 
its functions of skewing PBMC responses towards pro-inflammatory Th1 phenotype. Apart 
from their A. muciniphila content, the subjects used for this analysis had very variable 
microbiomes based on 16S sequencing, which further supports the hypothesis that A. 
muciniphila is one of the keystone species sufficient to drive the microbiota towards Th1 
induction. Despite this intriguing result, A. muciniphila is unlikely to be the only microbial 
species that is sufficient to induce Th1 differentiation. Instead, the discovery of A. 
muciniphila as a major pro-inflammatory regulator may be considered as the first step in 
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identifying other microbes and microbial pathways that are sufficient for inducing Th1 
differentiation. 
 
Contradictory to our in vitro results, the pro-inflammatory role of A. muciniphila was absent 
in monocolonized mice. This difference may be caused by a discrepancy in mouse and 
human immune cell responses to A.muciniphila. In addition, the main in vivo role of A. 
muciniphila may have little to do with its direct effects on T cells: it may instead shape the 
rest of the microbial community towards more pro-inflammatory phenotype. This function 
would explain why A. muciniphila is more abundant in untreated MS patients both in our 
study and a previous investigation of an independent cohort (12), and is sufficient to induce 
pro-inflammatory functions of total microbial community.  
 
By contrast, Acinetobacter is an example of a species that is rare, but nonetheless was 
revealed to have a higher relative abundance in MS patients. Although it cannot be 
considered as a universal contributor to MS severity due to its rarity, we view it as one of 
multiple environmental contributors that are able to exacerbate the disease. Its role may be 
explained by drawing an analogy to genetics: same as a specific allele, a specific bacterial 
species may be rare overall, but significantly increased in MS patients compared to controls, 
and contribute to disease severity in those few MS patients in which it is present.  
 
Our observed increases in Acinetobacter, which typically only colonizes the human gut 
during an infection, is consistent with previous reports of heightened serum antibody 
responses to Acinetobacter in MS patients compared to healthy controls (22, 35). Strikingly, 
A. calcoaceticus has also been shown to encode peptides that mimic the amino acid 
sequences of myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG) 
(22), both of which are components of the myelin sheath that undergoes autoimmune 
destruction in MS (36). This suggests that molecular mimicry could potentially transform a 
normal immune response towards Acinetobacter into autoimmunity against myelin. 
Recently, another model of molecular mimicry mediated CNS autoimmunity was proposed 
when aquaporin 4-specific T lymphocytes from neuromyelitis optica patients were found to 
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recognize a peptide from C. perfringens and induce a Th17 bias (6) and this organism was 
found to be over abundant in NMO patients compared to HC (37).  
 
Although intestinal A. muciniphila has been extensively studied in the context of diet and 
obesity (23, 38), its role in regulating immune responses is less well understood. Here we 
provide in vitro evidence that A. muciniphila promotes Th1 lymphocyte differentiation. 
Consistent with our observations, A. muciniphila has been reported to exacerbate 
inflammation during infection (24). In contrast, a recent study reported that EAE-resistant 
male TNFR2-/- mice harbor more A. muciniphila compared to disease-susceptible TNFR2-
/- females (39). However, it remains to be addressed whether EAE susceptibility in this 
genotype is driven by the microbiome or by other factors that stem from gender and genetic 
differences. Notably, in a recently published study (12) as well as in the MS-discordant twin 
study that accompanies our manuscript (Berer et al.), Akkermansia was reported to be 
elevated in untreated MS patients. 
 
A growing body of literature has associated both CD25+FoxP3+ Tregs and IL-10 expressing 
T lymphocytes with alterations in gut microbiota. For example, monocolonization of GF 
mice with specific bacterial species is sufficient to drive CD25+FoxP3+ Treg differentiation 
and alter disease phenotype (3). Of interest, P. distasonis has also been shown to induce Treg 
differentiation in GF mice (2). In addition, our findings suggest that in vivo exposure to pure 
P. distasonis is associated with a subsequent immunoregulatory response to this bacterium 
in vitro. This observation is supported by the result that the immune cells of MS patients have 
impaired Treg differentiation in response to autologous (“self”) bacteria. Thus, the initial 
exposure to P. distasonis or other “beneficial” bacteria found in healthy subjects may 
contribute to expanding regulatory T lymphocyte precursor populations, thus promoting anti-
inflammatory responses upon subsequent exposure to the same bacteria.  
 
Furthermore, we observed a consistent association between healthy control microbiota and 
CD25+IL-10+ lymphocyte differentiation both in vitro and in vivo. A similar result is 
presented in the MS-discordant twin study where blocking IL-10 results in increased EAE 
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incidence (Berer et al.). It has been previously reported that IL-10 deficient mice are 
susceptible to colitis induced by transplantation of normal mouse microbiota or simplified 
human microbiota (40, 41). Thus, CD25+IL-10+ lymphocyte differentiation in response to 
healthy microbiota, and especially to a common and highly abundant bacterial species like 
P. distasonis, may serve as a built-in control mechanism to dampen the pro-inflammatory 
characteristics of other microbial species. The loss of this mechanism due to MS-associated 
dysbiosis may then create a pro-inflammatory environment, which may further exacerbate 
the disease.  
 
Microbial transfer of human phenotypes to gnotobiotic mice 
While previous studies using GF mouse models have identified that the absence of gut 
bacteria ameliorates EAE (13, 14), here we show that gut bacteria transplanted from MS 
patients promotes more severe EAE symptoms relative to mice that were transplanted with 
fecal bacteria from household controls. Similar results of microbiota being sufficient to 
transfer a human donor phenotype to GF mice have been reported in the context of obesity 
(42) and IBD (43), and rheumatoid arthritis-associated bacteria were shown to exacerbate 
the disease in a mouse model of colitis (7). However, our study is the first to show that the 
gut microbiota is able to transfer the phenotype in a disease model unrelated to the digestive 
system and suggest a potentially causal role for the gut microbiota in MS. 
 
We view GF mouse monocolonization as an experimental model to study microbial functions 
in vivo. However, its biological relevance has multiple caveats, because monocolonization 
may not represent bacterial functions within the entire microbial community of the gut, and 
it requires using a mouse host for bacteria that presumably have a function in human disease. 
Therefore, it is typical to find that in vivo studies using monocolonized mice do not 
completely replicate in vitro results from human cells. Instead, it may be advisable to 
consider all in vitro and in vivo findings together as the first step for future studies to identify 
which pathways and metabolites are important for Th1 and IL-10+ regulatory T lymphocyte 
production. It will open new avenues for the development of novel, microbiome-based 
therapeutic approaches for autoimmunity.  
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Figure 1. MS patient microbiota alter self-Treg differentiation in spite of similar 
alpha and beta diversity to control microbiota. A. Quantification of CD25+FoxP3+ 
lymphocytes within CD3+CD4+ population in MS patients (n=7) and healthy controls 
(n=9), run in triplicate and results averaged, in response to extracts from total bacteria 
isolated from the stool samples of the same subjects who were PBMC donors (thus, “self” 
bacteria). CD25+ FoxP3+ lymphocyte induction expressed as fold difference over no-
bacteria control. *P <0.05, two-tailed Mann-Whitney test. B-D. Comparison of microbial 
community composition of untreated MS patients (n=71) and healthy controls (n=71). B, 
Chao1 metric of alpha diversity. Error bars, mean±SEM. C, PCoA plot of beta diversity 
(unweighted Unifrac), D, mean relative abundance of microbial genera. Upper box, 
Akkermansia. Lower box, Parabacteroides.  
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Figure 2. Relative abundances of individual microbial genera differ between MS 
patients and controls. A. Volcano plots of relative abundance distribution of microbial 
genera (left) and OTUs (right). X axis, log2 fold of relative abundance ratio between MS 
patients (n=71) and controls (n=71) after variance-stabilizing transformation. Y axis, 
negative log10 of P value, negative binomial Wald test, Benjamini-Hochberg correction for 
multiple comparisons. B. Summary of taxonomic differences between MS and control 
microbiome. C. Relative abundance plots of selected microbial genera (highlighted in A) 
that were found to be significantly different between MS and controls. Error bars, 
mean±SEM.  
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Figure 3. Acinetobacter calcoaceticus inhibits Treg differentiation and stimulates Th1 
differentiation in vitro. A, B. Representative flow cytometry plots (A) and quantification 
(B) of CD25+FoxP3+ cell differentiation within CD3+CD4+ population in response to 
Acinetobacter calcoaceticus (A. calc) (n=6 PBMC donors). C, D. Representative flow 
cytometry plots (C) and quantification (DRI,)1Ȗ7KO\PSKRF\WHVZLWKLQ&'&'
population in response to A. calcoaceticus (A. calc) (n=11 PBMC donors). *P<0.05, 
**P<0.01, two-tailed repeated measures t test. Error bars, mean±SEM.  
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Figure 4. Akkermansia muciniphila increases Th1 lymphocyte differentiation in vitro. 
A-D. Representative flow cytometry plots (A, B) and quantification (C, DRI,)1ȖDQGRI
Tbet+ Th1 lymphocytes within CD3+CD4+ population in response to Akkermansia 
muciniphila (A. muci). n=6 PBMC donors for IFNJ experiment, 7 PBMC donors for Tbet 
experiment. *P<0.05, two-tailed repeated measures t test. E-H. Representative flow 
cytometry plots (E, F) and quantification (G, H RI ,)1Ȗ 7K O\PSKRF\WHV ZLWKLQ
CD3+CD4+ population in response to non-self or self bacteria from subjects with or without 
detected A. muciniphila. n=6 subjects without A. muciniphila, n=12 subjects with A. 
muciniphila. *P<0.05, two-tailed t test. **P<0.01, 2-way ANOVA for repeated measures. 
Error bars, mean±SEM.  
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Figure 5. Parabacteroides distasonis stimulates IL-10+ T regulatory lymphocyte 
differentiation in vitro. A-D. Representative flow cytometry plots (A, B) and 
quantification (C, D) of CD25+ and CD25+IL-10+ lymphocytes within CD3+CD4+ 
population in response to Parabacteroides distasonis (P.dist). n=6 PBMC donors. *P<0.05, 
**P<0.01, two-tailed repeated measures t test. Error bars, mean±SEM.  
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Figure 6. Monocolonization of GF mice with MS-associated bacteria mediates T 
lymphocyte differentiation. A-C. Representative flow cytometry plots (A) and 
quantification (B, C) of CD4+IFNJ+ lymphocytes (B) and CD4+IL-10+ lymphocytes (C) 
within live cell population in GF mice colonized with Acinetobacter calcoaceticus, 
Akkermansia muciniphila and Parabacteroides distasonis. GF mice and SPF mice are used 
as controls. n=3-8 mice per group. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, 1-way 
ANOVA with Tukey adjustment for multiple comparisons. Error bars, mean±SEM.  
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Figure 7. A. Clinical EAE scores of mice that had been colonized with healthy control or 
MS patient microbiota for at least 5 weeks, or kept GF, prior to induction of EAE at 9-10 
weeks of age. Asterisks refer to significance both between MS vs. Control and MS vs. GF 
groups. n=6-8 mice per group. ****P<0.0001, 2-way ANOVA with Tukey adjustment for 
multiple comparisons. Error bars, mean±SEM. B. Principal coordinate analysis (PCoA) of 
mouse microbiota at different time points after colonization with fecal microbiota from donor 
pair #1. n=3-5 mice per group. EAE induction occurs at 35 days after transplantation. C-F. 
Representative flow cytometry plots (C, D) of FoxP3+ lymphocytes within CD4+ 
populations and IL-10+ lymphocytes within CD4+FoxP3+ populations. Frequencies of IL-
10+ lymphocytes within CD4+FoxP3+ populations in mesenteric lymph nodes of mice 
sacrificed prior to EAE induction (E) and at peak of EAE progression (22 days after 
immunization) (F). *P<0.05, **P<0.01, ****P<0.0001, 1-way ANOVA with Tukey 
adjustment for multiple comparisons. Error bars, mean±SEM. 
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Supplemental Figure 1. Microbial community variability within and between 
subjects. A. Comparison of microbial community composition in the same subject between 
consecutive days. Each color indicates a different subject. Controls and MS patients have 
been combined. Unweighted Unifrac measure of beta diversity. B. Comparison of variability 
in microbial community composition within and between groups of subjects. Unweighted 
Unifrac distances. CTRL_CTRL, within healthy control group. MS_MS, within MS patient 
group. CTRL_MS, between healthy controls and MS patients. **P<0.01, Mann-Whitney 
test, Bonferroni correction for multiple comparison.  
 
 
Supplemental Figure 2. Relative abundances of microbial genera in healthy controls. 
X axis, genera (ranked by relative abundance). Y axis, log10 of mean relative abundance in 
healthy controls after rarefaction to 10,000 reads per sample. n = 71.  
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Supplemental Figure 3. Examples of selected bacterial species showing no 
immunoregulatory effect on human PBMCs. A. Quantification of CD25+FoxP3+ cell 
differentiation within CD3+CD4+ population in response to Eggerthella lenta (E. len). B. 
Quantification of IFNJ+ cell differentiation within CD3+CD4+ population in response to 
Eggerthella lenta (E. len). C. Quantification of CD25+IL10+ cell differentiation within 
CD3+CD4+ population in response to Acinetobacter calcoaceticus (A. calc). D. 
Quantification of IFNJ+ cell differentiation within CD3+CD4+ population in response to 
Parabacteroides distasonis (P. dist). E. Quantification of CD25+FoxP3+ cell differentiation 
within CD3+CD4+ population in response to Akkermansia muciniphila (A. muci). n=6 
PBMC donors. Error bars, mean±SEM.  
 
 
Supplemental Figure 4. Monocolonization of antibiotic-treated mice with individual 
bacterial species recapitulates in vitro T lymphocyte differentiation patterns. A. 
Quantification of FoxP3+ cell differentiation within CD4+ population in splenocytes of mice 
colonized with A. calcoaceticus (A. calc) after antibiotic treatment, compared to SPF control. 
B. Quantification of CD4+IL10+ cell differentiation within live cells in splenocytes of mice 
colonized with P. distasonis (P. dist) after antibiotic treatment, compared to SPF control. C. 
Quantification of CD4+IL10+ cell differentiation within live cells from splenocytes of mice 
colonized with P. distasonis (P. dist) or SPF control mice exposed to self bacterial extracts. 
*P<0.05, **P<0.01, two-tailed t test (A, B) or two-tailed repeated measures t test (C). n=5-
7 mice per group. Error bars, mean ± SEM. 
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Supplemental Figure 5. The effects of monocolonization of GF mice with Acinetobacter 
calcoaceticus, Akkermansia muciniphila and Parabacteroides distasonis on T 
lymphocyte differentiation. A-C. Representative flow cytometry plots showing gating 
strategy (A) and quantification (B, C) of CD4+IFNJ+ Th1 lymphocytes (B) and CD4+IL-
10+ lymphocytes (C) within live cell population in GF mice colonized with Acinetobacter 
calcoaceticus, Akkermansia muciniphila and Parabacteroides distasonis. GF mice and SPF 
mice used as controls. n=3-8 mice per group. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001, 1-way ANOVA with Tukey adjustment for multiple comparisons. Error 
bars, mean±SEM. 
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Supplemental Figure 6. Transfer of fecal microbiota from 3 different donor pairs 
(MS patient and healthy household control) into germ-free mice mediates EAE 
outcomes. (A-C) Clinical EAE scores of mice that had been colonized at 3-4 weeks of age 
with healthy control or MS patient microbiota from 3 independent donor pairs for at least 6 
weeks prior to induction of EAE. n=3-8 mice per group. Error bars, mean ± SEM. * = Control 
vs. MS, # = Germ-free vs. MS. */#, P < 0.05, **/##, P <0.01, ***/###, P < 0.0001, 2-way 
ANOVA with Tukey adjustment for multiple comparisons. Error bars, mean±SEM.  
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Supplemental Figure 7. Immunophenotyping of mesenteric and cervical lymph nodes 
of mice colonized with MS and control microbiota from donor pair 1. A. Flow cytometry 
gating strategy. B-E. Quantification of IFNJ+ Th1 and IL-17+ Th17 cell differentiation 
within CD4+FoxP3- population in mesenteric lymph nodes before induction of EAE (B, C) 
and at peak of disease (D, E). F-K. Quantification of IFNJ+ Th1, IL-17+ Th17 cell 
differentiation within CD4+FoxP3- population and IL-10+ cell differentiation within 
CD4+FoxP3+ population in cervical lymph nodes before induction of EAE (F-H) and at 
peak of disease (I-K). n=3-8 mice per group. Error bars, mean ± SEM. 
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Supplemental Figure 8. Microglial gene expression in spinal cords of mice colonized 
with MS and control microbiota. Log2fold difference in microglia-enriched genes at peak 
EAE compared to pre-induction in gnotobiotic mice colonized with microbiota from human 
donor pair #1.  
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Supplemental Figure 9. Differences in microbiome composition of mice colonized 
with MS and control microbiota. A. Principal coordinate analysis (PCoA) of mouse 
microbiota at different time points after colonization with fecal microbiota from donor pair 
#1. Lines connect consecutive time points. B. Alpha diversity of microbiota of human donors 
and recipient mice from donor pair #1. C. Relative abundance of bacterial genera that were 
increased in mice colonized with either healthy control (Sutterella) or MS patient 
(Ruminococcus) microbiota in MS-Discordant Twin Study (Berer et al.).  
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Supplemental Figure 10. CD25+ FoxP3+ Treg differentiation in response to non-self 
bacterial extracts. Quantification of CD25+FoxP3+ cell differentiation within CD3+CD4+ 
population in response to non-self bacterial extracts from healthy controls or MS patients. 
Lines connect averaged responses of the same donor. n = 5 PBMC donors, bacterial extracts 
from 6 MS patients and 6 healthy controls. 
 
 
Supplemental Figure 11. Monocolonization of GF mice. A. Colony forming units (CFUs) 
2 days after the colonization with A. calcoaceticus (AC), A. muciniphila (AM) and P. 
distasonis (PD) after culturing fecal bacteria from monocolonized mice on Brucella BL 
plates anaerobically. B. Gel image indicating bands specific to A. muciniphila (A. muci) and 
P. distasonis (P. dist).  
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Supplemental Figure 12. Antibiotic-mediated reduction in alpha diversity of mouse 
microbial community. Chao1 metric of alpha diversity in mice 2 weeks after treatment with 
broad-spectrum antibiotics (ABX) compared to SPF controls. n = 4 mice per group. Error 
bars, mean±SEM. 
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Supplemental Table S1. Subject metadata. 
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Supplemental Table S1 (continued) 
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Supplemental Table S1 (continued) 
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Supplemental Table S1 (continued) 
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Supplemental Table S2. Differential abundance of microbial genera in MS patients and healthy 
controls.  
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Supplemental Table S3. Results of differential abundance analysis of MS and control 
microbiota, OTU level, Wald negative binomial test to calculate statistical significance. 
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Supplemental Table S3 (continued) 
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Supplemental Table S3 (continued) 
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Supplemental Table S3 (continued) 
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Supplemental Table S3 (continued) 
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Supplemental Table S3 (continued) 
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Supplemental Table S4. Top pathways that separate MS and control samples in the 
human dataset and at least 1 mouse dataset.  
 
 
 
Supplemental Table S5: Top pathways that separate MS and control samples in the 
human dataset and at least 1 mouse dataset, calculated only the differentially expressed 
OTUs.  
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Human fecal sample collection 
Fecal samples were collected from 71 adult patients with relapsing-remitting multiple 
sclerosis that had not received treatment for at least 3 months prior to the time of collection 
and 71 controls without autoimmune disorders at the University of California, San Francisco 
(UCSF) and the Icahn School of Medicine at Mt Sinai (New York, NY). The inclusion 
criteria specified no use of antibiotics or cancer therapeutics in 3 months prior to the study. 
Detailed patient information is available in Supplemental Table 1. All individuals signed a 
written informed consent in accordance with th?.AZQ sampling procedure approved by the 
UCSF and Icahn School of Medicine at Mt Sinai Institutional Review Boards. Samples were 
collected using culture swabs (BD #220135) and stored at -80C until DNA extraction or 
bacterial isolation. 
 
16S rRNA amplicon sequencing and computational analysis of human and mouse 
microbiome samples 
DNA was extracted from samples using MoBio Power Fecal DNA extraction kit (MoBio 
#12830) and amplicons of V4 region of the prokaryotic 16S rRNA gene were sequenced 
using the Earth Microbiome Project standard protocol (44). Analysis was performed using 
QIIME v1.9 as described (45). Essentially, amplicon sequences were quality-filtered and 
grouped to “species-level” OTUs using SortMeRNA method (46) using GreenGenes version 
13.8 97% dataset for closed reference. Sequences that did not match reference sequences in 
the GreenGenes database were dropped from the analysis. Taxonomy was assigned to the 
retained OTUs based on the GreenGenes reference sequence, and the GreenGenes tree was 
used for all downstream phylogenetic community comparisons. Samples were filtered to at 
least 10000 sequences per sample, and OTUs were filtered to retain only OTUs present in at 
least 5% of samples and covering at least 100 total reads. After filtering samples were 
rarefied to 10000 sequences per sample. Alpha diversity was calculated using the Chao1 
method (47). For analysis of beta diversity, pairwise distance matrices were generated using 
the phylogenetic metric unweighted UniFrac (48) and used for principal coordinate analysis 
(PCoA). For comparison of individual taxa, samples were not rarefied. Instead, OTU 
abundances were normalized using variance-stabilizing transformation and taxa distributions 
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were compared using Wald negative binomial test from R software package DESeq2 as 
described previously (17, 49) with Benjamini-Hochberg correction for multiple 
comparisons. All statistical analyses of differences between individual bacterial species were 
performed using QIIME v.1.9 or R (packages DESeq2 and phyloseq).  
 
Comparison of functional pathways expressed by microbiota 
 
ܭ ௝ܱ = σ ൫ ௢ܹ௧௨ ௜՜௞௢ ௝ × ௢௧௨ ௜൯௠௜ୀଵܥ  (1 ݊݋݅ݐܽݑݍܧ)   
 
௞ݕܽݓ݄ݐܽܲ = ෍ܭ ௝ܱ × ܤ ݁ݎ݄݁ݓ ܤ  = ൜
0, ܭ ݂݅ ௝ܱ ௞ݕܽݓ݄ݐܽܲ ݊݅ ݐ݋݊ 
1, ܭ ݂݅ ௝ܱ ௞ݕܽݓ݄ݐܽܲ ݊݅ 
௡
௝ୀଵ
 (2 ݊݋݅ݐܽݑݍܧ)  
 
A matrix of containing samples and OTU counts was obtained for all datasets using QIIME 
(described above). We transformed the raw OTU counts (Cotu) into KEGG Ortholog (KO) 
values by taking the product of Cotu and pre-established OTU contribution weights (Wotu->ko) 
(50). This resulted in matrix of samples and KO values (Equation 1). The KO values were 
then transformed into pathway values by simply taking the sum of all KOs that contribute to 
a pathway (Equation 2). Once every sample had a pathway value for each pathway, we ran 
a logistic regression to determine which pathways were the most important in separating MS 
and control samples. The MS and controls samples separated very well in all three datasets 
(0.81 AUC (area under the curve) Human, 0.98 AUC Mouse 1, and 0.94 AUC Mouse 2). 
For each dataset, the pathway coefficients were used to calculate the odds ratio of each 
pathway. We then took the top 10% of pathways in each of the datasets and checked to see 
if there was any overlap between the human and mouse datasets. Next, we repeated the same 
analysis using only the fraction of OTUs that were differentially expressed in MS and control 
samples. Using this small subset of OTUs, the MS and control samples still separated (0.70 
AUC Human and 1.0 AUC in both Mouse datasets).  
 
Bacterial extract preparation for stimulation of human PBMCs 
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We used a combined experimental approach based on previously published studies to 
prepare bacterial extracts (51) and combine them with human PBMCs (4), followed by 
standard Th1 and Treg differentiation protocols (52, 53). All PBMC responses to bacterial 
extracts were compared to no-bacteria vehicle controls that contained the same protease and 
phosphatase inhibitors. PBMCs were immunostained and analyzed using standard flow 
cytometry protocols (described in detail in Supplemental Materials and Methods). 
 
Total bacteria were isolated from patient or control stool samples by suspending ~0.5mg 
stool sample in 1.5ml PBS, passing it three times through a 40um cell strainer and washing 
twice with 1.5ml PBS by spinning at 8000rpm. Individual bacterial species were ordered 
directly from ATCC. Parabacteroides distasonis (ATCC #8503) was grown on pre-reduced 
OxyPRAS Brucella Blood Agar plates (Oxyrase #P-BRU-BA) or in MTGE broth (Anaerobe 
Systems #AS-778) for 2 days anaerobically. Akkermansia muciniphila (ATCC #BAA-835) 
was grown on Tryptic Soy Blood Agar plates (Anaerobe Systems, #AS-542) or in OxyPRAS 
BHI broth (Oxyrase #BHI-HK) for 3 days anaerobically. Acinetobacter calcoaceticus 
(ATCC #23055) was grown on OxyPRAS Brucella Blood Agar plates or in Brucella Broth 
(Anaerobe Systems #AS-105) for 2 days aerobically.  
 
Human PBMC isolation and stimulation with bacterial extracts 
Peripheral blood mononuclear cells were isolated from healthy controls or RRMS patients 
and stored at -80C in cryovials at 10^7 cells/ml concentration in FBS containing 10% 
DMSO. Before plating, cells were washed in PBS twice, re-counted, and plated at 10^6 
cells/ml concentration in RPMI media supplemented with 10% FBS and 1% 
penicillin/streptomycin/glutamine.  
 
After isolation bacteria were resuspended in PBS supplemented with protease inhibitor 
(Roche #4693159001) and phosphatase inhibitor (Roche #4906845001), heat-inactivated at 
65C for 1h and sonicated for 10min as described previously (48). Protein concentration in 
the resulting suspension was measured using the Pierce BCA protein assay kit (Thermo 
Scientific #23227). Bacterial extracts were added to PBMCs at 0.1µg/ml (A. calcoaceticus) 
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or at 1µg/ml (A. muciniphila, P. distasonis), to represent their relative abundances, 1h after 
plating as described previously (4). Each experiment contained at least 6 independent donor 
samples and was repeated at least twice with no more than 50% overlap between donors. . 
 
For human Treg differentiation, cells were stimulated with anti-human CD3 (BD #555336, 
0.3 µg/ml), anti-human CD28 (BD #555725, 2 µg/ml) and recombinant human TGF-E1 
(R&D #240B002, 2.5ng/ml) for 4 days (50), in presence of bacterial extracts. For human Th1 
differentiation, cells were stimulated with anti-human CD3 (BD #555336, 2 µg/ml), anti-
human CD28 (BD #555725, 2 µg/ml), anti-human IL-4 (BioLegend #500702, 5 µg/ml) and 
recombinant human IL-12 (Thermo Fisher Scientific #NBP143214, 20ng/ml) for 3 days (49), 
in presence of bacterial extracts. After 3 days the culture media was changed and Th1 cells 
were restimulated for 4 hours with 1µM ionomycin and 50ng/ml PMA in presence of 2 µM 
monensin, in absence of bacterial extracts.  
 
Flow cytometry of human PBMCs 
Live/dead cell gating was achieved using Live/Dead Fixable Aqua kit (ThermoFisher 
#L34957). BD Cytofix/Cytoperm kit (BD #554722) was used for staining of intracellular 
cytokines, and FoxP3/Transcription factor staining buffer set (eBioscience #00-5523-00) for 
transcription factors. The following antibodies were used for human PBMC staining: anti-
CD3-PE.Cy7 (BD #563423), anti-CD4-PerCP.Cy5.5 (BioLegend #300530 or BD #560650) 
and anti-CD25-PE (BD #555432) or anti-CD25-BV421 (BD #562442) or anti-CD25-APC 
(BD #555434), anti-IFNJ-FITC (BioLegend #502506), anti-Tbet-PE (BD #561265), anti-
FoxP3-AlexaFluor-488 (BD #560047), and anti-IL-10-PE (eBioscience #12-7108). Flow 
cytometry was performed on BD Fortessa cell analyzer and analyzed using FlowJo software 
(TreeStar). For both mouse and human PBMC flow cytometry, cells were gated to identify 
the lymphocyte population based on forward and side scatter, followed by gating for single 
cell and live cell populations. Unstained, single color, and fluorescence-minus-one controls 
were used to identify stained populations.  
 
Verification of germ-free or antibiotic-treated mouse status  
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The level of bacterial colonization in GF mice was verified in feces by quantifying colony 
forming units in anaerobic conditions (Supplemental Figure 11A). Colonization specificity 
was verified by PCR (Supplemental Figure 11B). In bacterial monocolonization 
experiments, mice were euthanized and immunophenotyping was performed 3-4 weeks after 
colonization. GF mice remained in isolators for the duration of the experiment and 
transferred out when euthanized. GF mice that were subsequently associated with fecal 
microbes or single species of bacteria were taken out of isolators at 3-4 weeks of age and 
colonized with a single oral gavage. In experiments without EAE induction, GF control 
groups were kept in isolators until mice were euthanized for immunophenotyping. In 
experiments with EAE induction, GF mice were removed from the isolators in order to 
induce EAE, and maintained GF outside of the isolators by supplementing drinking water 
with erythromycin and gentamycin until the end of the experiment. In order to ensure that 
the GF animals remained GF both inside and outside the isolators, their stool samples were 
repeatedly plated on Brucella blood agar plates and cultured both aerobically and 
anaerobically. GF mice were determined to be clean after no colonies could be observed on 
the plates after a week of incubation. 
 
To ensure that broad-spectrum antibiotic treatment depletes stool bacteria, total bacteria 
isolated from mouse stool was cultured on Brucella Blood Agar plates and no colonies were 
observed. Antibiotic-mediated depletion of microbiota was further verified by comparing 
community richness in antibiotic-treated mice and SPF controls (Supplemental Figure 12; 
Chao1 metric of alpha diversity). 
 
Mouse colonization with microbiota 
Germ-free (GF) mice were bred and maintained in sterile isolators that were assayed every 
two weeks for GF status by bacterial plating and PCR. Fecal material from human donor 
samples or individual bacteria species at 10^8 CFU/mouse was diluted to a final solution of 
1.5% sodium bicarbonate. For colonization experiments following antibiotic treatment, mice 
were treated with 1% solution of Amphotericin B in drinking water for 3 days, followed by 
2 weeks of antibiotic solution composed of 1% Amphotericin B, 1mg/ml ampicillin, 1mg/ml 
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neomycin, 1mg/ml metronidazole, and 0.5mg/ml vancomycin in drinking water; 1% 
Amphotericin B solution was used as a control. After 2 weeks, we replaced the drinking 
solution by sterile water and mice were gavaged by specific bacteria of interest in a solution 
of 1.5% sodium bicarbonate at 10^8 CFU/mouse every 2-3 days for 2 weeks. SPF mice were 
gavaged with mock culture medium every 2-3 days for 2 weeks to mimic the esophageal 
trauma. 
 
Induction of EAE 
EAE was induced 6-7 weeks after colonization, corresponding to 9-10 weeks of age. Mice 
were subcutaneously immunized in the upper and lower back with 0.1ml MOG35-55 emulsion 
(1mg/ml) mixed with Complete Freud’s Adjuvant and killed mycobacterium tuberculosis 
H37Ra (2-5mg/ml), followed by two 0.1ml intraperitoneal injections of pertussis toxin 
(4µg/ml) approximately 2 and 26 hours later (Hooke Laboratories #EK-2110). Mice were 
scored daily in a blinded fashion for motor deficits as follows: 0, no deficit; 1, limp tail only; 
2, limp tail and hind limb weakness; 3, complete hind limb paralysis; 4, complete hind limb 
paralysis and partial/complete forelimb paralysis; 5, moribund.  
 
Mouse immune cell isolation and intracellular cytokine staining 
Mesenteric lymph nodes, cervical lymph nodes, and spleens were dissected and processed 
by grinding tissues through a 100um cell strainer. Single cell suspensions were incubated for 
4-5 hours with 50ng/ml PMA, 2µg/ml ionomycin in presence of 2µg/ml protein transport 
inhibitor (GolgiPlug, BD #51-2301KZ). Cells were then incubated in 5% mouse serum for 
15 min and stained for 20 min at 4ºC with Live/Dead Fixable Violet kit (Life Technologies 
#L34964) or Live/Dead Fixable Aqua kit (ThermoFisher #L34957) and anti-CD4-PE-Cy7 
(eBioscience #25-0042-82). Cells were fixed and permeabilized with FoxP3/Transcription 
factor buffer set (eBioscience #00-5523-00), and stained with anti-Foxp3-APC (eBioscience, 
#17-5773-82) and anti-IL10-PE (eBioscience #12-7101-82), anti-IFNJ-FITC (eBioscience, 
#11-7311-82), anti-IL17-PerCP/Cy5.5 (eBioscience #45-7177-82). 
 
RNAseq analysis in gnotobiotic mouse spinal cords 
 
 
58 
RNA was isolated from whole spinal cord and sequenced at the New York Genome 
Center. Samples were pair-end sequenced and each sample generated 100 million reads (50 
million read-pairs). Raw reads were then aligned to the Ensemble reference genome 
(mapping rate = 80%). Differential expression of transcripts was analyzed using the DESeq2 
package. We identified transcripts with baseMean (average count value normalized to library 
size) > 5 and a log2 fold change of at least 1.5 between the spinal cord of EAE mice 
transplanted with MS stool samples compared to mice transplanted with control stools. This 
gene list was used to interrogate cell-enrichment gene lists that were generated using the data 
from Zhang et al. (J Neurosci. 2014 Sep 3;34(36):11929-47) 
A gene whose expression was at least 10 folds higher in one cell type than in any other cell 
type was considered cell-specific. Six cell-specific lists were generated: astrocytes, 
myelinating oligodendrocytes, neurons, oligodendrocyte precursor cells, microglia and 
endothelial cells. 
 
Statistical analysis of in vitro data 
Statistical significance of expression changes in markers of T lymphocyte differentiation and 
proliferation was determined using two-tailed Student’s t test to compare samples from 
different donors, two-tailed repeated measures t test to compare samples from the same 
donor, and one or two-way ANOVA to compare samples from different donors in different 
groups based on bacterial presence. When data was non-normally distributed, two-tailed 
nonparametric Mann-Whitney test was used instead. Benjamini-Hochberg adjustment was 
used to account for multiple comparisons. GraphPad Prism 6 software was used to analyze 
and plot the data. P < 0.05 was considered statistically significant. 
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SUMMARY: 
The enteric nervous system (ENS), located along the gastrointestinal (GI) tract, 
enervates an organ that contains a rich collection of cells from the immune system, 
and is exposed to an ever-changing environment. Collectively, interactions between 
the nervous and immune systems enable the gut to respond to a variety of dietary 
products it absorbs, a spectrum of pathogens it encounters, and the diverse 
microbiome it harbors. The ENS senses and reacts to the dynamic ecosystem of the 
GI tract by translating chemical cues from the environment into neuronal impulses 
that propagate throughout the gut, and into other organs in the body including the 
central nervous system (CNS). This review will describe current understanding of 
the anatomy and physiology of the GI tract, focusing on ENS and the mucosal 
immune system. We highlight emerging literature that the ENS is essential for 
aspects of microbe-induced immune responses in the GI tract. While most basic and 
applied research in neuroscience has focused on the brain, the strategic location of 
the ENS in proximity to a rich immune system and the external environment 
suggest novel paradigms for nervous system function await discovery. 
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Introduction 
The gastrointestinal (GI) tract spans 5 meters in length and has an epithelial surface 
area of ~32 square meters (1). It is resident to 70-80% of the body’s immune cells 
(2), over 100 million neurons (3) and 50,000 extrinsic nerve endings. The 
microbiome consists of as many as 40 trillion cells and at least hundreds of different 
species (4, 5). An important function of the GI tract is to sense and respond to external 
cues. Diverse cellular interactions are responsible for interpreting external cues, and 
these interactions must be amenable to the change and flux in the molecular 
environment of the GI tract. Thus, there are countless components that necessitate GI 
function, and equally complex aberrations that can affect it. Accordingly, 70 million 
people in the United States (>20% of the population) are affected by digestive 
diseases every year (6), and GI dysfunction is often a comorbidity with numerous 
non-intestinal conditions. As such, interactions between interdependent, cellular 
pathways in the gut and the periphery may underlie process involved in health and 
disease.   
 
Overview of GI Compartments 
 
Anatomy of the GI tract  
The GI tract consists of the stomach, small and large intestines. Anatomically, the 
tissue of the GI tract can generally be compartmentalized by the mesentery and 
serosa, muscularis, submucosa, lamina propria, epithelium, and lumen (Figure 1).  
 
In the mesentery, recently considered a distinct organ (7), major extrinsic arteries, 
veins, lymphatics, and nerve fibers enter and exit the tissue. Connective tissue 
immobilizes the GI tract within the peritoneum, and adipose tissue insulates nerves 
and vasculature. The mesentery is contiguous with the serosa, which is the outermost 
layer of mesothelium that encapsulates and lubricates the GI tract so that peristaltic 
contractions are uninhibited. The mesentery also encloses the mesenteric lymph 
nodes (MLNs), which are the draining lymph nodes of the intestines.  
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The outermost layers of intestinal tissue proper are collectively called the muscularis. 
This region is made up of an outer longitudinal and inner circular muscle layer. These 
layers are orthogonal to each other, providing stretch and shear flexibility, and are 
also resident to many immune cells (8). Between these two layers of smooth muscle 
lies the myenteric plexus which is the network of neurons and glia that extend 
throughout GI tract. Luminal to the muscularis, vasculature spreads throughout the 
submucosal layer, bringing within it, circulating immune cells that infiltrate and exit 
the tissue. The submucosal plexus also sends neuronal impulses and senses inputs to 
and from cells in the myenteric plexus and mucosa. Immune structures such as 
Peyer’s patches and lymphoid follicles emanate from the submucosa and extend into 
the mucosa. The lamina propria and innermost epithelial layer make up the mucosa. 
The lamina propria contains many innate and adaptive immune cells, but also is made 
of the connective tissue that is important for GI structural identity. Furthermore, the 
vascular, neuronal, and glial processes extend throughout the lamina propria, and the 
diverse cells and molecules associated with these structures are important for enteric 
function. The epithelium is the single layer of cells that separates intestinal tissue 
from the lumen. As will be described later, distinct subtypes of intestinal epithelial 
cells (IECs) are responsible for absorption, communication, and protection, and these 
roles are mediated by diverse effector molecules that function apically and 
basolaterally. Finally, the lumen hosts the molecules excreted and consumed by the 
host and the microbiome that has adapted to survive the GI tract.  
 
Intestinal Epithelium 
The intestinal epithelium is composed of distinct IEC types that mediate 
communication between the host and the luminal environment. The four most 
abundant IECs are enterocytes, goblet cells, Paneth cells, and enteroendocrine cells 
(EECs). Enterocytes are the primary absorptive cells in the epithelium and they 
increase their surface area with apical microvilli structures. Goblet cells are 
responsible for producing and secreting mucin proteins into the lumen. Mucins are 
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heavily glycosylated proteins that not only provide a protective barrier from the 
lumen, but also provide a medium to facilitate molecular exchange between the 
epithelium and the environment (9). Paneth cells reside mainly in ileal intestinal 
crypts and secrete potent antimicrobial products via release of granule contents (10). 
As such, antimicrobial peptides (AMPs) are secreted when the epithelium senses 
microbe associated molecular patterns, and downregulated in germ-free (GF) mice 
(mice free of all microorganisms) (11-13). Finally, enteroendocrine cells (EECs) 
produce a variety of modulatory, neuroendocrine molecules. These cells have been 
commonly referred to as the “taste” cells of the gut (14), as they are popularly known 
for their chemosensation and production of molecules that control aspects of feeding, 
such as appetite.  
 
Other IECs are important for directing innate and adaptive immunological responses 
to luminal antigens. In particular, microfold cells (M-cells) aid in the immunological 
sampling of antigens across the epithelium (15). M-cells are also capable of 
transporting intact bacteria across the epithelium and to gut-associated lymphoid 
tissues (GALT) (16). Thus, M-cells are often found in close association with dendritic 
cells (DCs) on the luminal side of Peyer’s patches and lymphoid follicles. This gives 
immune cells prime position to induce an adaptive immune response. The intestinal 
stem cell compartment is vital to sustain immense epithelial turnover in response to 
high levels of oxidative stress and damage. Finally, cup and tuft cells are not well 
characterized, but the latter has recently been shown to be important for inducing 
type 2 immune responses against parasitic helminths (17, 18).  
 
Transport of molecules to and from the lumen occurs both transepithelially (through 
epithelial cells) and paracellularly (between epithelial cells) (19). Paracellular 
transport is mediated by selective cellular junctions known as tight junctions. 
Transepithelial transport can occur through primary or secondary active transport 
mechanisms– the former requires ATP and carrier proteins and the latter employs 
concentration gradients (20). Furthermore, receptor-mediated transcytosis also 
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occurs across the epithelium. Although a variety of apical stimuli are important in 
mediating IEC function, as will be discussed, basolateral signals can also incite 
effector functions in IECs. Thus, the epithelium mediates critical barrier functions, 
though in a dynamic fashion interacting with both the luminal (e.g., gut bacteria) and 
basolateral (e.g., immune and neuronal cells) compartments of the gut. 
 
The Enteric Nervous System 
The mammalian nervous system is divided into two arms: the central nervous system 
(CNS) and the peripheral nervous system (PNS). The CNS encompasses the brain 
and the spinal cord, and the PNS includes the ganglia, aggregates of neural cell bodies 
where nerve bundles arise from, in the head, neck, and viscera. The autonomic 
(involuntary) nervous system is characterized as sympathetic or parasympathetic, and 
the main neurotransmitters produced are the catecholamines (CCh- norepinephrine, 
epinephrine, and dopamine) and acetylcholine (ACh), respectively. Extrinsic 
connectivity from the CNS to the ENS is comprises of both sympathetic and 
parasympathetic nerve fibers. Upon leaving the hindbrain, the parasympathetic vagus 
nerve travels through the diaphragm and synapses onto the GI tract. Sympathetic 
visceral ganglia also innervate the intestines, and in both instances, nerves can 
synapse directly onto the myenteric ganglia, smooth muscle, and mucosa (21). 
Parasympathetic pelvic nerves originate in the spinal cord and leave via the sacral 
spinal nerve where it ultimately innervates the distal colon and rectum. Furthermore, 
parasympathetic nerves can innervate sympathetic ganglia and modulate their 
sympathetic output onto the GI tract. The intrinsic ENS is the expansive network of 
neurons and glia along the GI tract that can be affected by their connectivity to 
extrinsic sympathetic and parasympathetic nerves (22). Thus, communication 
between the CNS and ENS is bidirectional.  
 
Receptors on enteric neurons mediate important GI functions. Mechanoreceptors are 
responsive to mucosal abrasion and tension receptors are responsive to stretch. 
Chemoreceptors respond to the chemical stimuli of the lumen, such as pH, 
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osmolarity, and nutrients. Furthermore, various receptors are responsible for 
regulating fluid exchange within the gut (23). Subsets of neurons can generally be 
categorized by their connectivity. Intrinsic primary afferent neurons (IPAN), are 
large, multi-axonal, and sensory neurons that are responsible for detecting molecular 
and mechanical aberrations of the GI tract. These neurons relay sensory impulses to 
other IPANS, interneurons, and ultimately intrinsic motor neurons that induce 
effector functions. They comprise 10-30% of the neurons in both the myenteric and 
submucosal plexuses. Intrinsic intestinofugal afferent neurons (IFANs) send 
neuronal impulses from the GI tract to extrinsic, visceral ganglia where efferent 
nerves send sympathetic impulses back to the ENS and complete the reflex arc (10). 
Interneurons synapse with other interneurons as well as motor neurons. They are 
responsible for connecting sensory and motor neurons, and thus propagates a 
neuronal impulse. Muscle motor neurons are found along the entire GI tract in the 
longitudinal and circular muscle layers and mucosa, and they mainly respond to 
signals initiated by mechanoreceptors and tension receptors. Vasodilator and 
secretomotor neurons manage fluid and molecular exchange between the GI 
vasculature, tissue, and the lumen (11, 12)(Figures 1 and 2).  
 
Enteric glial cells (EGCs) are significant constituents of the ENS and have been 
shown to be important benefactors towards mucosal health (13). EGCs in the 
myenteric and submucosal plexuses have been shown to envelop enteric neurons and 
associate with blood vessels and lymphatics (14). As will be described in later 
sections, important EGC-derived signaling molecules implicate the functional 
development of certain cell types important in GI immunity.  
 
Cells, Molecules, and Receptors Implicated in GI Neuro-immunity 
  
Brief Overview of the GI Immune System 
The extensive GI lymphatic system mediates the flux of immune cells that occupies 
the lamina propria. Intestinal granulocytes rapidly produce toxic molecules against 
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intracellular and extracellular bacteria and parasites, while natural killer (NK) cells 
attach virally infected cells. Macrophages, specifically, are important GI innate 
immune cells that are involved in early microbial surveillance, and subsequent 
attraction and activation of other immune cell types. B and T cells carry out adaptive 
immune functions, and this is predicated on activation by antigen presenting cells 
(APCs) such as macrophages and dendritic cells (DCs). Interestingly, it has been 
reported that DCs express IEC tight junction proteins that allows them to extend 
protrusions between IECs and directly sample gut luminal antigens (15). 
Intraepithelial lymphocytes (IELs) and innate lymphoid cells (ILCs) have a common 
progenitor that is distinct from B and T lymphocytes (16), do not require any prior 
activation or maturation to carryout effector immune function, and have been 
appreciated for their role in GI immune homeostasis (17, 18), and more recently in 
the context of the microbiota (19). The GI immune system with respect to its 
microbiome has been extensively reviewed (20); thus we will focus on the specific 
cells and molecules that reveal potential neuro-immune responses to gut bacteria in 
subsequent sections. 
 
Catecholamines 
Catecholamines (CChs) are a class of neuroactive molecules secreted at sympathetic 
nerve endings. The bone marrow, thymus, spleen, and peripheral lymph nodes are 
innervated by sympathetic nerves (24), and accordingly, functional adrenergic 
receptors are expressed on virtually all leukocytes (25). Thus, immunologists have 
long been intrigued by the role of sympathetic, catecholaminergic signaling in the 
immune system, and their effects have been long been studied (26). Recently, 
Gabanyi et. al. discovered potential mechanisms by which the ENS functions to 
polarize intestinal macrophages, spatially and immunologically (27), thus, positing 
on the role of sympathetic innervation of the GI tract. In this study, intestinal 
macrophages, were found to be phenotypically compartmentalized in the muscularis 
and mucosa layers of the GI tract, putting them in close proximity to extrinsic 
innervation and submucosal nerve fibers, respectively. Muscularis macrophages 
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were found to be phenotypically similar to M2 (regulatory) macrophages, whereas 
those isolated in the lamina propria were similar to M1 (proinflammatory) 
macrophages. Naïve peritoneal macrophages became more similar to muscularis 
macrophages when cultured with enteric neurospheres, and this was dependent upon 
engagement of the E-2 adrenergic receptor (E2AR) (Figure 4). Furthermore, 
sympathetic ganglia are activated during Salmonella infection, and this induces a 
E2AR activation-dependent expression of genes associated with muscularis 
macrophages. In another study, ex vivo catecholaminergic treatment of Peyer’s 
patches exhibit lower rates of Salmonella translocation (28), potentially mitigating 
infection. These studies suggest that adrenergic signaling occurs in the GI tract. 
However, tyrosine hydroxylase (an enzyme critical for CCh biosynthesis from 
tyrosine) immunoreactivity persists in the GI tract after extrinsic denervation (29), 
and this suggests that intrinsic, catecholaminergic synthesis, and signaling may also 
be involved in modulating GI immune responses.  
 
In addition to the direct effects that CChs may have in regulating immune response, 
similar effects may occur by modulating their availability in the GI tract. UDP-
glucuronyltransferase is an enzyme that has been studied in the liver, kidneys, brain, 
and GI tract (30) for their ability to transfer glucuronic acid onto endogenous and 
xenobiotic molecules, making them more hydrophilic and often excreted in the 
urine and feces. However, hormones are also glucuronidated, giving them their 
rapid systemic effect. 90% of the dopamine found in the lumen of the GF mouse is 
glucuronidated, and 90% of the dopamine found in the GI tract of SPF mice is not. 
Colonizing GF mice with an SPF microbiota or a consortia of Clostridia species 
can reverse skewing towards glucuronidated products (31). Interestingly, microbes 
isolated from the rodent GI tract have been shown to have endogenous beta-
glucuronidase (GUS) activity (32), and thus, colonizing GF mice with E. coli that 
produce functional GUS enzymes is sufficient for decreasing levels of 
glucuronidated CChs. Conversely, mutant E. coli that is deficient in GUS 
production cannot (31). Thus, gut microbes, and specifically, microbial GUS 
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activity, can shape the molecular activity and availability of CChs, and this may 
affect how leukocytes behave in the GI tract.  
 
Interestingly, bacteria also produce endogenous adrenergic receptors, QseC and 
QseE, through which epinephrine and norepinephrine regulate expression of 
virulence genes in enteric pathogens (33-35). Pathogenicity is diminished in mutant 
strains of Citrobacter rodentium (an enteric pathogen) that are deficient in QseC 
and QseE. Also, wildtype C. rodentium is also ineffective in colonizing mice that 
do not express dopamine beta-hydroxylase (36), the enzyme required for 
norepinephrine and epinephrine synthesis. However, whether glucuronidated CChs 
are ineffective in modulating virulence, or whether bacteria that produce GUS can 
enhance virulence in a mouse is unknown. Regardless, this intriguingly links host 
CCh biosynthetic pathways to bacterial infections, and may provide novel, 
antibiotic-independent strategies towards mitigating intestinal bacterial infections. 
In all, CChs in the GI tract are impactful signaling molecules that affect cells of 
multiple phyla. However, the way in which the cellular source of CChs impacts its 
effect on the immune system is still poorly understood.  
 
Acetylcholine 
Acetylcholine (ACh) is the primary parasympathetic neurotransmitter that is released 
by preganglionic nerve fibers (these fibers arise from ganglia along the spinal cord) 
and the vagus nerve. ACh has been studied for its powerful anti-inflammatory effects 
in the periphery, and vagal stimulation was sufficient in suppressing systemic 
inflammation in response to endotoxin (37). It was later discovered that endotoxemic 
mice deficient in D7-nicotinic acetylcholine receptor (D7-nAchR) display increased 
systemic levels of TNFD, IL-1E, and IL-6, and these mice could not suppress TNFD 
levels upon vagal stimulation. Specifically, D7-nAChR expression on macrophages 
was necessary for the observed ACh-mediated TNFD suppression (38). In another 
study that followed, splenic nerve stimulation also produced similar inhibition of the 
inflammatory TNFD response to LPS (39). However, vagal innervation results in 
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ACh release on the celiac ganglion which in turn sends noradrenergic signals to the 
spleen via the splenic nerve (40). Thus, the question remained on how vagal and 
splenic nerve stimulation is able to produce similar effects, when the vagus nerve 
does not directly innervate the spleen and the splenic nerve does not produce 
acetylcholine, all the while, the immunoregulatory effects appeared to function 
through ACh receptors. In a paradigm shifting study in neuro-immunology, ACh-
producing T cells were discovered to mediate these effects. These T cells secrete ACh 
in response to the activation of their E-adrenergic receptors, and the resulting ACh 
activates D7-nAchR on macrophages to suppress TNFD production (41). The 
functional discovery of ACh-producing T cells has demonstrated the remarkable 
molecular reflexes at the interface of the peripheral nervous and immune systems, 
and such discoveries have immensely expanded the breadth and appreciation of 
previously known neuro-immune interactions. However, research regarding 
cholinergic pathways in the GI tract are only just beginning to appear in the literature. 
For example, it has recently been shown that specific depletion of ACh producing T 
cells results in reduced intestinal AMP levels and relative changes to the microbiota 
(42). Mice deficient in type 3 muscarinic ACh receptors (M3-AChR) have a leaky 
intestinal barrier, higher basal levels of IFNJ, IL-17A, and TNFD, and exhibit delayed 
clearance of C. rodentium (43). Interestingly, these mice also express lower levels of 
IL-4 and IL-13, resulting in the delayed clearance of intestinal parasites (44). 
 
Although the vagus and pelvic nerves have connections along the length of the GI 
tract, with some nerve endings directly innervating the mucosa, they are not the only 
source of intestinal ACh. Intrinsic neurons are also immunoreactive against choline 
acetyltransferase (ChAT), the rate limiting enzyme in ACh synthesis (45). 
Furthermore, these extrinsic nerve endings often synapse onto neurons in the 
myenteric plexus, and thus, it is possible that ACh may induce activation of 
noncholinergic neurons in the ENS, and subsequent release of other neuromodulatory 
compounds. Also, because the ENS can initiate its own neuronal reflexes 
independent of extrinsic inputs, it is possible that the intrinsic circuitry alone can 
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influence immune function. Thus, it is plausible that similar neuro-immune 
paradigms existing in the spleen and the periphery could also exist in the GI tract.  
 
IECs, like immune cells, are in close proximity to neuronal projections in the mucosa. 
However, unlike immune cells, every IEC is in direct association with the lumen. 
This apical and basolateral dichotomy makes IECs an interesting and potential 
mediator of neuro-immune communications that occur between the mucosa and the 
microbiota. Specifically, ACh has been well studied for its effects on Paneth and 
goblet cells (Figure 3). AchR activation is important for both Paneth and goblet cell 
degranulation. As such, bethanechol, an mAChR agonist stimulates degranulation 
(46), while the mAChR antagonist atropine suppresses this function (47). Similarly, 
AChR activation on goblet cells induces mucin secretion (48, 49). AChR activation 
in mice also results in increased goblet-cell-associated antigen passages (GAPs), 
which allow goblet cells to take up luminal antigens and deliver them to DCs in the 
lamina propria (50). This is particularly interesting because it directly implicates ACh 
in the immunological sampling of luminal contents and microbes. Finally, like goblet 
and Paneth cells, cholinergic stimulation of EECs induces its secretion of 
neuroendocrine molecules (51). Although all IECs come from the common intestinal 
stem cell progenitor, Math1 is a distinct transcription factor that determines 
differentiation of Paneth, goblet, and EECs but not absorptive enterocytes (52). Thus, 
it may also be true that ACh sensitivity of certain IECs is a functional determination 
that is developmentally programmed. Ultimately, ACh is a powerful mediator of 
intestinal function, but again, it is unclear what the endogenous source of ACh is, and 
if this distinction affects its functional output on IECs, the ENS, and GI immune cells.  
 
Enteroendocrine Cells  
Many different subtypes of EECs exist along the epithelium of the GI tract. Their 
main function is to secrete a variety of endocrine molecules in response to luminal 
and GI cues (53, 54). Intriguingly, EECs produce molecules that not only affect the 
ENS but are also produced by it (55). As such, the molecules glucagon like peptide 
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1 (GLP-1) (56) and cholecystokinin (CCK) (57) are known mediators of EEC 
function, but also modulate ENS activity. Furthermore, enteric neurons have been 
shown to “synapse” onto EECs (58), and EECs have been shown to secrete their 
intracellular stores of effector molecules in response to membrane depolarization (59, 
60) and heightened calcium levels (61). However, the functionality of these physical 
neuro-epithelial circuits is unknown. Specifically, the secretory output of an EEC in 
response to an action potential from a synapsed enteric neuron is unknown.  
 
Other GI constituents can affect aspects of EEC function. For example, T cell 
receptor mutant mice have lower numbers of CCK producing EECs in the colon (62), 
potentially linking adaptive immune function to EEC peptide production. GF mice 
have fewer EECs (63), and C. rodentium infection decreased levels of 5-HT-
producing EECs (64). Furthermore, EECs express functional TLRs (65), and 
treatment of mice with TLR agonists induce CCK release, and this may not be limited 
to just CCK (66).  
 
As previously described, EECs are oriented such that apical stimuli are translated 
into basolateral signals (Figure 3). Perhaps EECs represent a direct means by which 
microbes can actively remodel the neuromodulatory environment across the 
epithelium, potentially changing the activity of sensory neurons in the mucosa. Given 
the similarity of the molecules that EECs and the ENS utilize to communicate, and 
their potential effects on the immune system, perhaps EECs translate luminal cues to 
the GI neuro-immune system. 
 
Neuropeptides 
Neuropeptides are small protein molecules that are generally used to communicate 
between neurons. However, EECs (67) in addition to enteric neurons (68) produce 
and secrete neuropeptides, and environmental factors such as the microbiota have 
been shown to influence their levels in the CNS (69, 70) and GI tract (63).  
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It has been well documented that neuropeptides can have significant impact on 
immunological function. Peyer’s patches are innervated (Figure 1) by intrinsic, 
peptidergic neurons (71), and immunoglobulin synthesis and lymphocyte 
proliferation in peripheral lymph nodes and GALT are affected by neuropeptide 
exposure (72). Substance P (SP) was the first example of an immunomodulatory 
neuropeptide that enhanced the production of IL-1, TNFD, and IL-6 from human 
monocytes (73). SP also regulates intestinal ion and fluid transport across the 
epithelium, and these effects were through its preferred receptor, neurokinin 1 
receptor, and these effects were abolished by blocking neural transmission with 
tetrodotoxin. Interestingly, engagement of mast cell histamine receptors was 
increased the effect that SP has on fluid secretion (74). Often, intestinal inflammation 
is concomitant with excessive ion and fluid secretion, leading to symptoms such as 
diarrhea. Expectedly, SP was found to be more abundant in the GI tract of patients 
with ulcerative colitis and Crohn’s disease (75). Subsequent research showed that 
many other neuropeptides and their associated receptors are important for immunity. 
For example, in macrophages, neuropeptide Y (NPY) and peptide YY (PYY) 
enhance phagocytosis (76) and mice that are deficient in the NPY receptor 1 display 
impaired macrophage response to endotoxin. Furthermore, these mice also have 
fewer naïve CD4+ T cells in peripheral lymph nodes, and reduced IFNJ production 
following DSS-colitis (77). This suggests that immune cells harbor receptors for 
neuropeptides, and these receptors have an important role in shaping the maturation 
of the immune system. In another study, Th1 and Th2-lineage polarized T cell lines 
were created to have T cell receptors specific for an exogenous peptide. Thus, antigen 
exposure should lead to the production of cytokines representative of each respective 
lineage. Surprisingly, neuropeptide exposure to these T cells is able to induce both 
canonical and non-canonical production of T helper cytokines, without exposure of 
the antigen (78). These results point to intriguing neuropeptide-mediated, 
immunological plasticity and innate-like function from adaptive lymphocytes. These 
initial studies broadened the known impact that neuropeptides can have, but also 
elucidated the complexity of their immunological effects.  
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In contrast to SP and NPY, vasoactive intestinal peptide (VIP) has been the best 
studied anti-inflammatory peptide. VIP induces regulatory (79) and tolerogenic DCs 
(80, 81), both of which are able to induce differentiation of Tregs (82). Furthermore, 
VIP inhibits TGF-B1 (83) and enhances IL-10 (84) production in murine 
macrophages. Also in macrophages, TLR2 and TLR4 stimulation upregulates 
expression of VIP receptor type 2 (85) and conversely, VIP inhibits LPS mediated 
upregulation of TLRs, as well as monocyte to macrophage differentiation (86).  
 
In the GI tract, VIP mitigates trinitrobenzene sulfonic acid (TNBS)-induced intestinal 
inflammation, a mouse model of colitis. As is in macrophages, it also inhibits TNBS 
mediated upregulation of TLRs in macrophages, DCs, lymphocytes, and colon 
protein extracts (87, 88). Furthermore, VIP ameliorates intestinal barrier dysfunction 
in C. rodentium-induced colitis in mice (89). Toxin B from the colitogenic bacterium, 
Clostridium difficile, can activate VIP producing neurons in the submucosa (90). 
However, over time, C. difficile infection decreases overall levels of VIP (91), and 
perhaps by depleting VIP, C. difficile can ultimately exacerbate enteric infection. 
Finally, VIP-deficient mice have multiple GI abnormalities, including deficits in 
goblet cell secretion (92).  
 
Hirschsprung’s disease is often comorbid with enterocolitis (93-96). Although the 
precise etiology of this colitic pathology is unknown, patients with Hirschprung’s 
disease often display mutations in the aforementioned RET tyrosine kinase. In mice, 
RET deficiency results in symptoms similar to patients with Hirschsprung’s disease, 
and VIP is among the most downregulated genes (92, 97). Thus, neuropeptide 
balance is imperative for proper immune function and GI homeostasis, and skewing 
in either direction leads to irregularities in physiology, and potential disease 
pathologies. 
 
Serotonin and Histamine  
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Serotonin (5-HT) is produced by various cell types in the GI tract and has multiple 
physiological roles. 5-HT was first identified for his roles in vasoconstriction and was 
initially found stored in platelets (98). In the GI tract, mast cells and enterochromaffin 
cells, a specific EEC, were established as major sources of 5-HT (99). Currently, 
various leukocyte types, including macrophages, DCs, B and T cells, have been 
found to express either tryptophan hydroxylase (TPH-1, the rate limiting enzyme in 
5-HT biosynthesis), or 5-HT transporters (SERT) which are necessary mediators of 
extracellular 5-HT uptake (100-102). Furthermore, a variety of 5-HT receptors have 
been identified in lymphoid tissues (103), and as a result their expression and function 
have been extensively studied in a variety of immune cells (104). In general, 
serotonergic signaling in leukocytes appears to promote immune function, whether 
by enhancing DC-mediated T cell activation (101, 105), or affecting macrophage 
polarization (106) and phagocytosis (107). 
 
5-HT has been one of the earliest known molecules involved in GI peristalsis (108), 
and it does so by directly modulating ENS activity (109, 110). Mast cells also secrete 
histamine which has also been implicated in the activation of IPANs (111, 112). As 
such, increased histamine and 5-HT levels correlate with increased activation of 
submucosal neurons, and these increases are dampened by 5-HT and histamine 
receptor antagonists (113). Although this is compelling, the significance and 
physiological implications of mast cell mediated ENS activation is poorly 
understood. Interestingly, vagal stimulation decreases intracellular stores of 5-HT in 
enterochromaffin cells, and this appears to be mediated by adrenergic receptor 
activation (114). Also, adrenergic receptor activation on mast cells can enhance IgE 
mediated degranulation of 5-HT and histamine (115). However, amitriptyline, a 5-
HT and norepinephrine uptake inhibitor, inhibits mast cell secretion of histamine but 
not 5-HT (116), suggesting that intrinsic production of 5-HT, as opposed to the 
reuptake of 5-HT, in mast cells may be important for adrenergic receptor-mediated 
5-HT secretion. These data show that similar mechanisms observed in the cholinergic 
anti-inflammatory pathway may affect the levels of 5-HT in the GI tract, but similar 
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shortcomings in mechanistic understanding persist, such as the contribution of 
adrenergic signals from extrinsic sympathetic nerves versus those that are produced 
intrinsically. Nonetheless, these results show that molecules that are traditionally 
associated with leukocytes are capable of modulating the ENS, providing more 
evidence of neuro-immune interactions exist in the GI tract.  
 
Potentially linking the microbiota to these neuro-immune interactions is a study by 
Yano et al. that illustrated how indigenous, spore-forming bacteria, which are 
primarily Clostridia, are sufficient in rescuing 5-HT deficiency in GF mice (117). 
Consistent with this finding, short chain fatty acids (SCFAs), which are fermentation 
products of dietary fibers metabolized by the intestinal microbiota, are also sufficient 
in upregulating 5-HT (117, 118). Interestingly, Clostridia, and specifically butyrate 
producing strains, are important for the induction of regulatory T cells (Tregs) (119-
121). Patients with depression have lower levels of Tregs and serum 5-HT, and these 
Tregs also expressed lower levels of the 5-HT1a receptor (122). Furthermore, anti-
CD25 depletion of Tregs resulted in reductions in 5-HT and led to depression-like 
behaviors in mice. Perhaps it is possible that specific gut bacteria are capable of 
modulating CNS-associated phenotypes by inducing immunological changes that are 
mediated by neuromodulatory compounds. These types of studies would provide 
powerful, mechanistic understanding of how gut bacteria incite changes beyond the 
GI tract and implicate more global physiologies. At the moment, it is appreciated that 
mucosal 5-HT is an important paracrine signaling molecule in the GI tract, however, 
it is less understood how the diverse cell types contribute to such a unified 
physiological response that is dependent on 5-HT.  
 
Enteric Glial Cells, Neurotrophic Factors, and Associated Immune Reactions 
In the GI tract, the most abundant neurotrophic factors (NTFs) are the glial cell-
derived neurotrophic factor (GDNF) family of ligands (GFLs, which include GDNF, 
Neurturin, and Artemin), and they are produced by EGCs and smooth muscle cells 
(123-125). Neurotrophic factors (NTFs) are small protein molecules that can sustain 
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neurons and modulate their function, but unlike their name suggests, their effect 
spans multiple cell types. Firstly, EGCs modulate neurotransmission by inducing 
production of neuropeptides. For example, GDNF promotes enteric neuron release 
of NPY (126) (Figure 2), and GDNF-, NTN-, GFRD1- (receptor for GDNF), and 
RET- (co-receptor for GFL receptors-D1-3) deficient mice have defects in stimulus 
evoked release of VIP and SP. These mice also display significant reduction GI 
contractibility (127, 128), suggesting that EGC-mediated changes in neuropeptide 
levels are sufficient to cause dysregulated ENS activity. But, as previously described, 
GFL modulation of neuropeptides may also illustrate their indirect effects on neuro-
immune interactions in the GI tract. Additionally, EGC derived NTFs have recently 
been shown to directly affect the development of specific GI immunological 
compartments. It has been known that GFL-mediated RET signaling is necessary for 
proper development of Peyer’s patches (129, 130), but in a more recent study by Ibiza 
et al., GFL-mediated RET signaling was found to be necessary for the functional 
development of IL-22 producing innate lymphoid cell type 3 (ILC3) (131). These 
cells are the first innate immune cell to expand in the GI tract following bacterial 
infection (132), and via IL-22, have broadly protective effects on the intestinal 
epithelium (133-136)Ibiza and colleagues found that GFLs directly activate RET 
expressed on ILC3s, and depletion of RET diminishes intestinal IL-22 levels and 
exacerbates enteric inflammation (Figure 4). ILC3s were shown in close proximity 
to EGCs, and as previous studies showed (137), TLR activation induced expression 
of GFLs. Importantly, glial specific depletion of MyD88 displayed marked 
reductions in GFLs and IL-22, and recapitulated inflammatory pathologies observed 
in ILC3 RET knockout mice (131). These findings are the first to show that that EGCs 
directly sense the microbial environment to induce GFL production, and this sensing 
is necessary for the development of GI immunity. This seminal study elucidated 
mechanisms by which components of the ENS can directly shape the immunological 
environment in the GI tract. 
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EGCs and NTFs are also implicated in intestinal neuropathies and inflammatory 
pathologies. Ablation of EGCs results in epithelial and neuronal damage as well as 
severe intestinal inflammation (138). Agangliosis (a lack of enteric ganglia) occurs 
in mice that are deficient in GDNF (139) and RET (the coreceptor GDNF family 
receptors-D1-3) (140), and also in humans with Hirschspring’s disease. Interestingly, 
Hirschsprung’s disease is associated with germline mutations in GDNF (123, 141), 
and its pathology is often comorbid with enterocolitis (96). EGC proliferation is also 
linked to intestinal inflammation (142, 143) and accordingly, GDNF is increased 
during enteric parasitic infections (144), found in intestinal biopsies from humans 
with colitogenic Clostridium difficile infection, and upregulated in humans who 
suffer from ulcerative colitis and Crohn’s disease (145). However, in culture, IL-1E 
appears to dampen their proliferation while IL-10 enhances it (143). Although this 
may appear contradictory, it is possible that intestinal inflammation incites potential 
immunoregulatory functions in EGCs through proliferation and upregulation of 
GFLs, but persistent, hyperinflammatory responses may result in inhibition of these 
processes altogether, thus leading to enteric pathology and disease. In all, it is 
apparent that GFLs have a significant role in maintaining intestinal immune 
homeostasis. It also appears that enteric neurons have the potential to interface with 
the GI immune system via the actions of GFLs, but it is currently unknown whether 
these compartments are in fact, interdependent.  
 
Cytokines 
Cytokines and chemokines are the main effector molecules of immune cells. 
However, enteric neurons and glia are also capable of producing cytokines. As 
previously alluded to, EGCs express functional TLRs (131, 146) and an increase in 
IL-1E is observed upon LPS stimulation of EGCs. Furthermore, ENS cultures 
produce TNFD and IL-6 in response to LPS, and this production is abrogated when 
NF-kB signaling is inhibited (147). Curiously, IL-6 and the IL-6 receptor promote 
the growth and survival of enteric neurons in culture (148), but just as IL-6 has both 
pro- and anti-inflammatory effects in the peripheral immune system (149), it may 
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also have dichotomous effects on the ENS. 
 
As detailed previously, neurotransmitters and neuropeptides alter immune function. 
However, reciprocally, cytokines are capable of modulating neuron activity. The 
abundance and close proximity of neuronal varicosities to immune cells should make 
this unsurprising, but it is important in the study of immune responses to consider the 
effector functions of cytokine molecules on non-immune cell types. For example, IL-
1E is heightened in the intestines of inflammatory bowel diseases (IBD) patients 
(150), and in accordance with prior discussions, IL-1E also induces SP production in 
the ENS (151). Furthermore, IL-1E engagement to its cognate receptor in ex vivo 
ENS preparations suppresses electric-field stimulation (EFS)-evoked release of 
acetylcholine and norepinephrine (152), and IL-1E and IL6 can excite enteric 
secretomotor neurons (Figure 4). The latter also appears to occur by suppressing 
extrinsic noradrenergic and nicotinic activity (153). Thus, it is possible that enteric 
inflammatory symptoms are not only a product of proinflammatory cytokines, but 
also a result of IL-1E mediated upregulation of SP, and subsequent increases in 
secretomotor activity, fluid secretion, and decreased anti-inflammatory signaling 
from cholinergic and adrenergic neurons. This would explain many of the 
aforementioned phenotypes in IBD patients, including the heightened levels of SP, 
IL-1E, and TNFD (154).  
 
Microbes, and the Enteric Immune and Nervous Systems 
 
Microbiota 
The intestinal microbiota is the collection of microorganisms in the GI tract, and its 
constituents are known to be representative of the animals’ diet, habitat, and even 
phylogenetic order(155). It has long been appreciated that the indigenous microbiota 
of the GI tract is important for its development and susceptibility to enteric 
infections(156), but it was not until much later that researchers demonstrated how 
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commensal bacteria have an active role in maintaining GI immune homeostasis. In 
1996, it was found that anaerobic bacteria in human feces was specifically enriched 
in coating by immunoglobulin A (IgA) (157). A few years later, Macpherson et. al. 
discovered T cell-independent mechanisms of IgA binding to commensal gut 
microbes, suggesting an evolutionary innate, immunological adaptation to the 
intestinal microbiota(158). In 2001, Hooper et. al. showed that Bacteroides 
thetaiotaomicrion modulate host genes important for IEC homeostasis (159). In 
2005, Mazmanian et. al. discovered that polysaccharide A (PSA) from Bacteroides 
fragilis is sufficient for the development of adaptive immune responses(160). These 
influential studies expanded the knowledge and incited curiosity towards the 
microbiome, but more importantly, they empirically defined homeostatic roles of the 
intestinal microbiota that were not previously appreciated.  
 
GF animals were first studied and characterized using rats in the 1950s (161) to study 
dental hygiene, and were later used to study microbial colonization resistance (162). 
More recently research groups have implicated the microbiota in stress, anxiety, 
behavioral developmental disorders, and neurological deficits (163-166). This has 
popularized hypotheses on the “gut-brain axis”. However, the role of the ENS and 
GI-resident immune functions are currently understudied as conduits for the gut-
brain axis. Furthermore, the abundance of immune cells in the GI tract and the vast 
connectivity of the ENS (and its direct connectivity to the CNS) make it unlikely that 
the “gut-brain axis” is independent of these interactions.  
 
The microbiota has been shown to be altered during intestinal inflammation and 
immunological disease. Severity of inflammation is mediated and ameliorated by 
pathogenic and commensal bacteria, respectively (167, 168). As mentioned in 
previous sections, microbes or microbial products can actively change TLR 
expression in most cellular compartments of the GI tract, and this alters the host’s 
ability to sense and respond to the microbiota. Antibiotic depletion of the microbiota 
alters TLR expression in mice, and also results in concomitant in changes to GI 
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motility and sensitivity to ACh (169). TLR4 mutant mice have fewer neurons in the 
ENS and this result is also recapitulated in MyD88 knockout and antibiotic-treated 
mice (170). Furthermore, GF animals display morphological defects to the ENS and 
these deficits are ameliorated by housing them in soiled cages from conventional 
mice with a normal flora (171). The microbiota is also necessary for normal 
excitability of neurons in the ENS (172). EGC growth, maturation, and signaling is 
also affected by the microbiota. For example, GF mice and antibiotic-mediated 
depletion of the microbiota results in truncated glial cells that fail to extend through 
the mucosa and into villi structures (173). Antibiotic-treatments also reduce levels of 
GDNF/GFRD1 and RET, and these deficiencies can be reversed by Toll-like receptor 
(TLR) 2 stimulation (174). Furthermore, TLR2-deficient mice also display lower 
levels of GDNF, impaired RET signaling, and heightened inflammation in response 
to dextran sulfate sodium (DSS)-induced colitis. Accordingly, these phenotypes can 
be mitigated by exogenous GDNF administration (174). Exact mechanisms by which 
microbiota modulates neural activity in the GI tract are unknown. However, these 
findings suggest that there exists an active, post-developmental role of the microbiota 
on ENS form and function, and this potentially explains disparities seen in their 
molecular output. 
 
Short Chain Fatty Acids 
The most studied SCFAs are butyrate, propionate, and acetate (175, 176), and these 
microbial metabolites are initially sensed by the intestinal epithelium, but can also 
diffuse across the epithelium (177) where they can be sensed next by enteric nervous 
and immune systems (Figure 3). G-protein coupled receptors (GPR) 41 and 43 are 
activated by acetate and propionate (178, 179), whereas GPR109A is specific for 
butyrate (180).  
 
IECs from mice deficient in GPR41 or GPR43 cannot produce inflammatory 
chemokine and cytokine profiles in response to TNBS-induced colitis and C. 
rodentium infection, and these mice also exhibit delayed clearance of C. rodentium 
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itself (181). In an EEC line, GPR43 is necessary for propionate-mediated secretion 
of PYY and GLP-1 and these results are consistent in vivo (182). Also, PYY inhibits 
gastrointestinal transit and GPR41 deficiency is associated with decreased PYY 
production (183). Accordingly, SCFA-mediated induction of PYY inhibits in colonic 
motility (184). Furthermore, selective agonists for GPR41 and GPR 43 induce GLP1 
secretion from colonic crypt cultures, and purified GPR41+ cells exhibit higher 
expression levels for peptide hormone precursors (185).  
 
Intriguingly, it was found that enteric neurons in both the submucosa and myenteric 
plexus express GPR41. In contrast, immune cells in the lamina propria preferentially 
expressed GPR43. (185, 186) Tregs isolated from the colon and small intestines 
express high levels of GPR43 through which propionate enhances their 
immunosuppressive capabilities (187). Accordingly, propionate administration 
alleviates symptoms during experimental autoimmune encephalomyelitis, a mouse 
model of multiple sclerosis. The mitigating effects of propionate were also found to 
be concomitant with small intestinal Treg induction (188). Mucosal mast cells (189) 
and neutrophils (190) also express GPR43. In neutrophils, bacterial-derived SCFAs 
enhance chemotaxis (191) and propionate induces degranulation (192). Activation of 
GPR109A reduces intestinal inflammation and colon cancer susceptibility in mice 
(193). In human monocytes, activation of GPR109A by nicotinic acid has anti-
inflammatory effects (194), and this is further illustrated by the ability of butyrate to 
inhibit mast cell activation and degranulation (195). Butyrate and butyrate-producing 
bacteria, as previously described, are also sufficient for inducing differentiation of 
Tregs in mice (120, 121). Finally, butyrate is also capable of inducing action 
potentials in both submucosal and myenteric neurons of the ENS (196, 197), and this 
is associated with increases in intrinsic, cholinergic neurons of the myenteric plexus 
(198). This is in agreement with prior evidence showing the potent anti-inflammatory 
effects of ACh, and thus it is possible that ENS sensing of butyrate may be an 
important aspect of coordinating intrinsic, ACh-mediated neuro-immune responses.  
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Lactobacilli and Bacteroides 
Many Lactobacillus species have been studied for their immunoregulatory role. 
Species such as L. rhamnosus, L salivarius, L. reuteri, L. planatrum, L. fermentum, 
and L. casei have been shown to induce Tregs and decrease levels of inflammatory 
cytokines, such as IFNJ and TNFD (199-201). Lactobacilli have also been studied 
for their neuromodulatory capabilites. Rats colonized with L. reuteuri display lower 
thresholds for IPAN activation, higher frequency of action potentials (197, 202), and 
shorter hyperpolarizing potentials, all of which are proxies of increased IPAN 
excitability. However, in an influential study describing the gut-brain axis, Bravo et 
al. discovered that commensal microbes modulate physiologies beyond the GI tract 
and influence behaviors commonly associated with affections in the CNS. 
Specifically, L. rhamnosus can reduce stress-induced corticosterone levels and 
decrease expression of J-aminobutyric acid (GABA) receptors in the CNS, leading 
to concomitant reduction in anxiety and depression-like symptoms in mice. These 
behavioral and neurochemical phenotypes were abolished following chemically-
induced vagotomy (203). In accordance, it was later shown that L. rhamnosus 
increases the rate of spontaneous firing in vagal afferent nerves (204). Furthermore, 
certain strains of L. rhamnosus are known to produce GABA under certain conditions 
(205), and L. reuteuri can produce GABA from its precursor, glutamate (206, 207). 
Thus, direct production of neuroactive molecules by gut microbes has the potential 
of modulating ENS activity, but this has not been specifically addressed.  
 
The Bacteroides genus has also been studied for its immunoregulatory roles in the 
GI tract, and the species have predominantly been focused on B. thetaiotaomicron 
(208) and B. fragilis (168). As described previously, B. fragilis has been studied for 
its role in inducing IL-10 producing FoxP3 Tregs (209, 210). Interestingly, B. fragilis 
mono-associated mice also display enhanced IPAN excitability, and PSA was both 
sufficient and necessary for this phenotype (202). These data illustrate the active role 
that bacteria and bacterial-associated molecules have on the excitability and activity 
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of intrinsic sensory neurons in the ENS, but whether microbe-induced ENS activation 
is necessary for modulating GI immunity is unknown.  
 
Trichinella spiralis 
Trichinella spiralis is a parasitic nematode that infects the intestines (211) and 
induces IL-1 production (212). In mice, T. spiralis infection causes hypophagia, the 
decrease in food intake (213). This infection is also associated with increased CCK 
and 5-HT expression in EECs, both of which have been implicated in hypophagia 
(214, 215). Furthermore, CCK and IL-4 induce contractions in the longitudinal 
muscle (216, 217), and increased contractibility of the GI tract has been implicated 
in T. spiralis expulsion (218). Interestingly, prior T. spiralis infection increases 
sensitivity of mouse enteric neurons to T. spiralis antigens, and this heightened 
sensitivity is abrogated by histamine receptor antagonism (219). IgE binding to mast 
cells induces histamine secretion (220) and enhances T. spiralis explusion (221). 
Taken together, these studies put forth a potential histamine-mediated, adaptive, 
neuro-immune response to pathogenic microorganisms that may be important for 
their clearance.  
 
Perspective 
The GI tract is poised to sense and respond to diverse fluxes of intestinal cues. These 
cues are intrinsic, extrinsic, and environmental. In the viscera, nerves from CNS and 
PNS synapse onto the GI tract. At the mucosa, the host readily and selectively absorbs 
molecules within and across the epithelium. And in the lumen, the microbiota is 
under constant selective pressure from many host factors such as diet, environmental 
exposure, immunity, and exocrine function. Altogether, the exchange of molecular 
information in the GI tract illustrates potential intestinal “reflex loops” that would 
describe how our body utilizes the ENS to physiologically sense and respond to 
changes in the environment.  
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Peristaltic waves are the rhythmic contractions that result in the passage of contents 
from the environment through the host. Segmentation contractions are bouts of 
content mixing that is required for efficient digestion, but also maximizes moments 
when nutrients are readily accessible for host absorption. It would be fascinating if 
the ENS coordinated GI physiology such that absorptive and secretory events 
coincide with immunological sampling of the lumen. However, mechanisms by 
which functional enteric circuits integrate with microbe-mediated GI immune 
responses are poorly understood. For example, it is unknown if the ENS senses the 
microbial environment and initiates an immune response, or whether the ENS senses 
immune responses to subsequently modify, amplify, or propagate those signals. It is 
also unknown how the ENS reciprocally affects the luminal environment to 
potentially shape and alter the microbiota, and whether this effect is mediated by an 
immune response. Further characterization of the connectivity of the ENS with itself 
and other cell types will help understand how molecules in the GI tract dictate the 
body’s ability to immunologically mature and adapt to the microbiota. However, to 
truly dissect mechanisms by which the ENS mediates, potentiates, or responds to 
microbe-induced GI immunological changes, spatial and temporal manipulation of 
the ENS is required. Accordingly, modern advances in neuroscience, such as 
optogenetics and chemogenetics, have recently been implemented in the context of 
the ENS (222-224). While emerging discoveries on neuro-immune interactions in the 
GI tract indicate ENS participation in GI immune development (27, 131), effects of 
the microbiota on these immunological changes remain unstudied. Thus, future 
studies uncoupling the effects of the ENS on GI immune function will provide the 
foundation to study how the microbiota affects these interactions. Furthermore, it 
remains an intriguing possibility that enteric neuro-immune interactions may be the 
preferred route by which the microbiota has more global effects on CNS-related 
behavior.  
 
Communication between the microbiome and the mucosa is essential for the 
maintenance of intestinal homeostasis. Microbes or microbial products can directly 
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affect epithelial cells, but also have mechanisms to pass through them. The direct 
effect of this on immune cells is well documented, but how the ENS may be involved 
in the process is not. Given the diversity and reciprocity of extracellular signaling 
molecules in the GI tract, the ENS has evolved over time to receive and interpret 
these diverse cues, and transmit them throughout the GI tract and ultimately, the 
entire body. As such, the ENS is best adapted to coordinate physiologically related 
responses between different cell types and propagate them over vast regions of the 
GI tract. The cellular biology of the GI tract is inherently complex, necessitating the 
development and testing of interdisciplinary hypotheses, a challenge with immense 
implications for human physiology. 
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Figure 1. Anatomy of the GI Tract  
The GI tract is comprised of distinct cross-sectional compartments. Extrinsic, 
sympathetic and parasympathetic nerve fibers enter the GI tract through the 
mesentery and can extend throughout all layers of intestinal tissue. The myenteric 
plexus and submucosal plexus form the dense nerve network that innervates the 
entire length and depth of the GI tract. Various immune cells are resident to the 
muscularis, but are also highly abundant in the lamina propria, especially in Peyer’s 
patches and lymphoid follicles. These immune cells are also in close proximity to 
neurons and glia. The epithelium shown here is made up of 5 different cell types. 
These include absorptive enterocytes, EECs, goblet cells, Paneth cells, and M-cells. 
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Figure 2. Connectivity of Enteric Neurons and Glia 
Enteric neurons are located in either the submucosal or myenteric plexuses. Both 
plexuses are located in between two muscle layers (see Figure 1). Parasympathetic 
nerve fibers release acetylcholine and sympathetic nerves release norepinephrine. 
These extrinsic nerve fibers can innervate enteric neurons but also associate with the 
cells in the smooth muscle, lamina propria, and the epithelium. Enteric neurons can 
innervate one another or extend towards the lamina propria, and specific 
intestinofugal (IFANs) can synapse onto sympathetic ganglia. Enteric glial cells 
make and release neurotrophic factors, associate with enteric neurons, and extend 
throughout the mucosa. The table associated with this figure lists specific interactions 
that have been described.  
 
GDNF increased NPY, 5-HT, proliferation 
Anitha et al., 2006; Beck et 
al. , 1996; Gianino, 2003 
GDNF-/-, NTN-/-, 
GFRa1-/-, RET-/- 
decreased VIP, SP, GI 
contractability 
Gianino, 2003; Heuckeroth et 
al., 1999 
EGC-/- increases inflammation, enteric neuropathy Bush et al., 1998 
GDNF decreases inflammation Brun et al., 2013 
GDNF-/-, RET-/- agangliosis Sanchez et al., 1996; Schuchardt et al., 1994) 
Purines Activation Gulbranson et al., 2010 
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Figure 3. Interactions at the Intestinal Epithelium 
The intestinal epithelium is where luminal constituents are actively or passively 
transported into the tissue. Extrinsic nerves and neurons are found near the 
epithelium, and thus the molecules that cross the epithelium and those that are 
secreted basolaterally can potentially have an effect on their activity. Microbes or 
microbial parts can cross the epithelium and affect other cell types through M-cells, 
immunoglobulin-mediated transcytosis, goblet cell-associated passages (GAPs), and 
by general leakiness of the epithelium. Dendritic cells (DCs) and macrophages can 
phagocytose microbial antigens and secrete cytokines that can have an effect on 
neurons as well. Parasympathetic fibers release acetylcholine (ACh) and induce 
secretion of intracellular stores of molecules. In goblet cells, ACh also increases rates 
of DC luminal sampling via GAPs. EECs can also release neuroendocrine molecules 
in response to TLR stimulation and SCFAs. These molecules released basolaterally 
can potentially regulate the activity of neurons. Enteric glial cells can also project 
towards the epithelium, potentially allowing microbes to impact their function. 
Enteric neurons can be activated by commensal and pathogenic bacteria, as well as 
short chain fatty acids that diffuse across the epithelium. The table associated with 
this figure lists specific interactions that have been described.  
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GF Mice less neurons and decreased ENS excitability 
Collins et al., 2014; 
McVey Neufeld et al., 
2013 
Antibiotics decreases motility and GI sensitivity to ACh Grasa et al., 2015 
TLR4-/- fewer neurons in ENS Anitha et al., 2012 
Microbiota increases EGC growth Kabouridis et al., 2015 
Antibiotics decreases GDNF, GFRa1, RET Brun et al., 2013 
TLR2-/- decreases GDNF, RET Brun et al., 2013 
TLR-ligand increase GDNF Brun et al., 2013 
Microbiota, 
Clostridia, GUS 
enzyme 
increases CCh availability Asano et al., 2012 
Clostridia, SCFAs 5-HT from enterochromaffin cells Yano et al., 2015; Reigstad et al., 2015) 
GPR 41, GPR43 
activation PYY and GLP-1 release 
Psichas et al., 2014; 
Nohr et al., 2013 
GPR41-/-, GPR43-/- 
deficient inflammatory 
chemokine/cytokine profiles in 
response to C. rodentium infection 
and delayed clearance 
Kim et al., 2013 
Butyrate decreases monocyte activation and mast cell degranulation 
Digby et al., 2012; 
Diakos et al., 2006 
Butyrate Activates intrinsic ENS Neunlist and Dobreva, 1999 
Butyrate increases cholinergic neurons in myenteric plexus Soret et al., 2010 
L. reuteuri increased IPAN excitability Kunze et al., 2009 
L. rhamnosus lowers anxiety via vagus nerve, increases vagal firing 
Bravo et al., 2011; 
Perez-Burgos et al., 
2013 
B. fragilis PSA increased IPAN excitability Mao et al., 2013 
GLP-1, CCK Activate ENS Amato et al., 2010; Ngu, 1985 
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CCh increase virulence 
Hadjifrangiskou et al., 
2011; Moreira and 
Spreandio, 2012; 
Njoroge and Sperandio, 
2012 
mAChR agonist 
bethanechol increases Paneth cell degranulation Satoh et al. 1992 
mAChR antagonist 
atropine decreases Paneth cell degranulation Satoh, 1988 
AChR agonist 
carbahol increases Goblet cell mucin secretion 
Gustafsson et al., 2012; 
Birchenough et al., 2016 
AChR agonist 
carbahol 
increases Goblet cell associated 
passages (GAPs) McDole et al. 2012 
mAChR agonist 
bethanechol increases EEC secretion 
Anini and Brubaker, 
2003 
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Figure 4. Interactions Between GI Immune Cells and the ENS 
Extrinsic nerves, intrinsic neurons, and enteric glial cells (EGCs) are in close 
proximity to each other and to the immune cells in the GI tract. Thus, the molecules 
that are produced by one cell can have an effect on another cell, given that the latter 
expresses a receptor to recognize the molecule. By these parameters, interactions 
between neurons/glia and immune cells are, in theory, abundant, and some of these 
putative interactions are presented here. Immune cells can be influenced by 
neurotransmitters and neuropeptides produced by intrinsic neurons of the ENS (as 
well as those produced by extrinsic nerve fibers), and cytokines produced by immune 
cells can have a reciprocal effect on neurons. The table associated with this figure 
lists specific interactions that have been described.  
 
 
LPS increases IL-1B from EGCs, and TNFa and IL-6 from ENS 
Barajon et al., 2009; 
Burgueno et al., 2016 
Clostridia, Butyrate, 
Lactobacilli, B. 
fragilis 
Regulatory T cells 
Atarashi et al., 2013; 
Furusawa et al. 2013; Foligne 
et al., 2007; Madsen et al., 
1999; Valeur et al., 2004; 
Roud and Mazmanian, 2010, 
Chu et al., 2016 
MyD88-/- on EGCs decreases IL-22  Ibiza et al., 2016 
GFL increases IL-22 from ILC3 Ibiza et al., 2016 
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IL-1B suppresess proliferation Ruhl et al. 2001 
IL-10 enhances proliferation Ruhl et al. 2001 
IL-1B increases SP Hurst et al., 1993 
IL-1B 
suppresses ACh, 
Norepinephrine from 
extrinsic nerves 
Collins et al., 1992 
IL-1B, IL-6 activate secretomotor neurons Xia et al., 1999 
VIP increases IL-10 Delgado et al., 1999 
VIP Regulatory DCs and T cells 
Chorny et al., 2005; Delgado 
et al., 2005b; Ganea et al., 
2006; Delgado et al., 2005a 
Intrinsic peptidergic 
neurons  innervate Peyer's Patches Vulchanove et al., 2007 
SP  
increases Peyers patch, MLN, 
lymphocyte proliferation and 
IgA synthesis 
Stanisz et al. 1986 
VIP, Somatostatin decrease Peyers patch, MLN, lymphocyte proliferation Stanisz et al. 1986 
SP  higher in ulcerative colitis and Crohn's disease Mantyh et al., 1988 
SP increases TNFa, IL-6, IL-1B Lotz et al., 1988 
NPY and PYY enhance macrophage phagocytosis la Fuente et al., 1993 
Neuropeptides affect T cell cytokine profile Levite, 1998; Wheway et al., 2005 
5-HT, Histamine IPAN activation Rosas-Ballina et al., 2008 
5-HT increases DC mediated T cell activation Yamasaki et al., 1983 
5-HT 
enhances macrophage 
polzarization and 
phagocytosis 
Gabanyi et al., 2016 
5-HT receptors expressed on lymphoid tissues D.R. Brown and Price, 2008 
Mast cells major producers of 5-HT and histamine Bergquist et al., 1994 
Leukocytes make or store 5-HT Borovikova et al. 2000 
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AR activation increases mast cell degranuilation of 5-HT H. Wang et al., 2003 
B2AR activation polarizes regulatory macrophages Rosas-Ballina et al., 2011 
CCh 
decreases bacterial 
translocation in Peyer's 
patches 
McLean et al., 2015 
Splenic Nerve 
stimulation decreases TNFa McLean et al., 2015 
dopamine decreases lymphocyte proliferation McLean et al., 2016 
Vagal stimulation decreases TNFa, IL-6, IL-1B Leon-Ponte et al., 2007; O'Connell et al., 2006 
a7nAChR-/- increases TNFa, IL-6, IL-1B (emphasis on macrophage) 
las Casas-Engel et al., 2013; 
Csaba et al., 1975 
B-AR on ACh 
producing T cells, 
a7nAChR on 
macrophages 
decreases TNFa Stefulj et al., 2000 
M3-ACh3-/- increased TNFa, IFNg, IL-17a 
Song et al., 2015; Starodub 
and Wood, 2000; Buhner et 
al., 2009 
M3-ACh3-/- delayed clearance of C. rodentium Espamer and Asero, 1952 
M3-ACh3-/- decreased IL-4 and IL-13, delayed parasite clearance 
Rudd et al., 2005; O'Connell 
et al., 2006; Meredith et al., 
2005 
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ABSTRACT: 
The gastrointestinal (GI) tract coordinates physiological responses throughout the 
body. These responses are initiated by different exposures to environments and are 
shaped by behavioral tendencies such as diet (direct) and stress (indirect). The signals 
are integrated in the GI tract, where complex molecular interactions occur between 
and among diverse cell types including those of both host and microbial origin. Here, 
we sought to further characterize and interrogate the GI nervous system by delivering 
recombinant adeno-associated (rAAV) viral vectors encoding fluorescent reporters 
and/or chemogenetic modulators to specifically map and activate enteric neurons 
with spatial and temporal resolution. We show that rAAV-mediated multi-color 
labelling of enteric neurons is an effective and efficient method to histologically 
characterize the enteric nervous system (ENS). To characterized neuronal cell 
physiology, we delivered GCamP6F, a fluorescent calcium reporter, and performed 
live, in vivo microscopy in anesthetized mice. We report that germ-free mice have 
reduced neuronal innervation in the gut, with altered neuronal firing patterns 
compared to mice with a complex microbiome. Designer receptors exclusively 
activated by designer drugs (DREADDs) were utilized to induce activation of GI 
neurons that express choline acetyltransferase (ChAT+) and tyrosine hydroxylase 
(TH+). Using a multi-omics assaying approach, we measured changes to the intestinal 
transcriptome, host and microbial proteome, metagenome, and metabolome. In doing 
so, we uncover novel associations between the activation of specific neuronal subsets 
in the GI tract and changes to the intestinal microbiota and molecular physiology. 
Importantly, activation of specific neuronal subsets specifically in the gut results in 
physiological changes reminiscent of increased intestinal motility, diarrhea-like 
symptoms, and altered secretory components. The experimental tools described 
herein and the findings they produced encourage the study of cellular and 
physiological responses mediated by the neural inputs in the GI tract and motivates 
novel hypotheses regarding human health and disease etiology. 
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INTRODUCTION: 
The gastrointestinal (GI) tract consists of a diversity of cells. These cells (immune, 
epithelial, endothelial, endocrine, muscle, neuronal, adipocytes, and microbial) and 
their associated molecules are responsible for conducting and coordinating many 
physiological processes (1). This complex cellular network requires synergy in their 
molecular communication; however, the extent and scope of this communication is 
not well understood.  
The GI tract receives extrinsic neuronal signals from over 100,000 nerve 
fibers that originate in from the sympathetic (SNS) and parasympathetic (PNS) arms 
of the peripheral nervous system (2). The GI tract is also innervated by an expansive 
intrinsic nervous system that has over 100 million neurons organized into distinct 
compartments of the GI tract, namely the myenteric and submucosal plexuses- this 
is collectively termed the enteric nervous system (ENS) (3). In recent years, extrinsic 
and intrinsic innervation of the GI tract has been implicated in various host responses, 
from digestion (4) and immunity (5, 6), to even behavior (7). Our understanding of 
how the GI tract coordinates diverse physiological processes remains limited; 
however, recent advances made in the development of experimental neuroscience 
tools has positioned the study of neurogastroenterology to experience momentous 
progress– such tools will help define the nature of neural communication in the gut. 
Towards this end, we introduce novel experimental paradigms using 
bioengineered viral constructs to broadly characterize the ENS, and model the 
complex, coordinated physiologies altered by in vivo activation of the GI nervous 
system. Adeno-associated viruses (AAVs) have been characterized for their ability 
to delivery genes to eukaryotic cells (8). Using an engineered AAV capsid variant 
AAV-AAV-PHP.S (9) that has enhanced tropism for the ENS, we achieved robust 
expression of genetically encoded fluorescent reporters and neural activators. We 
also expressed the fluorescent calcium reporter GCaMP6F in enteric neurons to 
measure ENS activity in live animals by confocal microscopy. In doing so, we 
present methodological advances to immunohistochemistry (IHC) and calcium 
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imaging that allow us to broadly assay ENS cellular architecture in intact GI tissue 
and measure its activity, in vivo.  
Lastly, we investigate how activation of different neuronal subsets within the 
ENS affects diverse cellular and molecular responses. ChAT and TH are the rate 
limiting enzymes in acetylcholine and catecholamine biosynthesis, respectively and 
are the key chemical mediators of neurotransmission in the PNS and SNS. However, 
the extent to which they impact GI physiology via the ENS is less understood. To 
begin filling this gap in knowledge, we transduced GI neurons with chemogenetic 
modulators (10) in transgenic mice that express the Cre recombinase at the ChAT 
and TH loci (ChAT-Cre and TH-Cre, respectively). We discover that stimulating 
neural activity in the GI tract via DREADDs alters the transcriptional and molecular 
landscape of the intestines, with complementing alterations to the gut microbiota, the 
consortia of microorganisms that inhabit the GI tract. The experimental tools 
described herein advance promote the study of the GI nervous system and its complex 
etiological impact on diseases of the GI tract and the periphery. 
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RESULTS: 
Use of AAV-delivered Fluorescent Proteins Enables Vast, High-Resolution 
Labelling of the ENS 
The general morphology and neurochemistry of the ENS has been well-characterized 
(1). However, current methods of immunohistochemistry (IHC) are hindered by 
many physical aspects of the GI tract: its relatively large size (~40cm long in a 
mouse), dynamic nature (i.e., with or without luminal contents, relaxed vs. contracted 
smooth muscle), and regional anatomic differences (i.e., small vs. large intestine, 
proximal vs. medial vs. distal regions). Furthermore, the ENS is localized to two 
distinct plexuses of the GI tract. Current studies often only characterize myenteric 
neurons by microdissection of the longitudinal muscle/myenteric plexus (LMMP) 
tissue layer (11), a severe manipulation of the tissue that overlooks the organization 
of submucosal neurons.  
To address these limitations, we took a viral approach to label the ENS and 
employed tissue clearing techniques to enhance visualization of intact GI tissue. The 
AAV capsid variant AAV-PHP.S was used as it was optimized for systemic delivery 
(12) and characterized for its heightened tropism to the peripheral nervous system 
(9), specifically the ENS. Here, AAV-PHP.S genetic cargo that expresses under the 
ubiquitous CAG promoter or the neuron specific, human Synapsin 1 (hSYN1) 
promoter. This efficiently transduced cells throughout the ENS with a single delivery, 
inducing expression of genetic constructs in both myenteric and submucosal 
compartments of the ENS. AAV9 has been used in the past for viral delivery to the 
ENS (13). In comparison, AAV-PHP.S exhibits greater infectivity in the GI tract as 
seen by increased cellular expression of nuclear localized CAG-mNeonGreen 
(Figure 1A). Furthermore, 90% (±1.5%) of neurons labelled with antibodies against 
protein gene product 9.5 (PGP9.5), a pan-neuronal protein, co-localize with the 
expression of constructs driven under the hSYN1 promoter and delivered in AAV-
PHP.S (Figure 1B). 
The physical length of the GI tract also makes thorough characterization of 
the ENS by IHC intractable and costly. With AAV-mediated labeling, a single 
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systemic injection of AAV-PHP.S:hSYN1-mNeonGreen at 1012 viral genomes (vg) 
is sufficient to label expansive regions of ENS as seen in the small (Supplemental 
Figure 1A and 1B) and large intestines (Figure 1C). This minimizes the technical 
variability inherent to IHC and enables uniform imaging of millimeters of tissue at a 
micron resolution across many samples. From these images, it is apparent that there 
is spatial diversity in ENS structure, even within a distinct intestinal region (insets in 
Figure 1C). Coupling viral-labeling with tissue clearing methods, such as passive 
clarity technique (PACT) or a sorbitol-based clearing method (ScaleS) (14-16), we 
were able to preserve the structure of intestinal tissue. This garnered a more holistic 
understanding of the ENS such as how extrinsic nerves synapse with the ENS 
(Supplemental Figure 1C), how ENS architecture changes when it associates with 
Peyer’s patches (small intestinal lymphoid tissues) (Supplemental Figure 1D), or 
even the differences that occur when the tissue is fixed with or without luminal 
contents (Supplemental Figure 1E-1G).  
Furthermore, when equal vector genomes of three separate viruses encoding 
either PHP.S:hSYN1-mTurquoise, PHP.S:hSYN1-mNeonGreen, or PHP.S:hSYN1-
mRuby (together AAV-PHP.S:hSYN1-XFP) are delivered together at a dose of 1012 
vg, stochastic and combinatorial viral transduction of cells results in multi-color 
labelling of neurons. This accentuates cellular boundaries (Figure 1D) and 
morphologies (Figure 1E) more clearly than IHC. This method is also tunable by the 
design of genetic promoters. This versatility can be seen by the labeling of enteric 
glial cell bodies with virally-expressed tdTomato driven by the glial fibrillary acidic 
protein (GFAP) promoter (Figure 1F). 
 Lastly, tissue clearing also facilitated confocal imaging by enabling the 
capture of both myenteric and submucosal neurons within the same image stack 
(Figure 1G)– an important aspect of ENS phenotyping that is commonly overlooked. 
These histological advances allow for the direct imaging of the ENS in intact GI 
tissue via whole mount microscopy, eliminating the need to microdissect distinct 
layers of the GI tract, prepare thin sections, and use antibodies altogether. In all, this 
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labelling paradigm provides an effective and economical method to label the ENS at 
a high resolution, with or without the use of transgenic animals. 
 
Characterizing and Quantifying ENS Architecture and Physiology 
The small and large intestines have developed both divergent and synergistic 
functions and the ENS plays a critical role in regulating these physiologies (17). 
However, it remains poorly understood how the cellular architecture and physiology 
of the ENS contributes to the functional diversity within the GI tract. For example, 
the intestinal immune system has evolved regional specialization to effectively cope 
with the constant exposure to environmental, dietary, and microbial antigens (18). 
Furthermore, digestion of dietary lipids, proteins, and carbohydrates occurs in the 
proximal small intestine and absorption occurs distally (19), whereas gut bacteria 
mediate the digestion and fermentation of soluble fibers in the large intestines (20). 
Thus, as the role of the ENS in regulating complex intestinal physiologies continues 
to be explored, the need for thorough GI phenotyping becomes increasingly 
important. However, current characterization of the ENS focuses on only a single 
region of the myenteric plexus, resulting in an incomplete understanding of GI 
innervation and therefore its contribution to overall health and disease states.  
To address this, wild-type mice were transduced with AAV-PHP.S:hSYN1-
XFP, as described above, to label enteric neurons (Figure 2A). We found no 
significant differences in the relative abundance of viral vector genomes from the 
regions sampled in the small and large intestines (SI and LI) (Supplemental Figure 
2A), outside of a small ~1.5cm section of the medial large intestinal tissue which as 
excluded from further characterization. Seven regions of the small intestine and two 
regions of the large intestine were sampled, proximally to distally. Using ScaleS 
tissue clearing methods, we imaged and enumerated neurons in both myenteric and 
submucosal plexuses, normalizing these counts to the number of crypts to account 
for the variability of similar tissue regions between animals at the time of fixation. 
Importantly, no difference was found in crypt diameter along the GI tract 
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(Supplemental Figure 2B), ensuring that normalizing neuron counts in this way was 
appropriate.  
Here, we characterized ENS architecture in all assayed regions by quantifying the 
number of neurons and ganglia, as well as the size of ganglia (i.e., the number of 
neurons in each ganglion) in the myenteric and submucosal plexuses (Figure 2B-2G). 
Notably in the SI, the number of neurons and ganglia increase in the distal portions 
of the myenteric plexus compared to proximal regions while the converse is true for 
neurons and ganglia in the submucosal plexus (i.e., lower numbers in the distal 
regions relative to proximal regions) (Figure 2B and 2C). Additionally, the size of 
the ganglia increased in the distal regions of the SI myenteric plexus, but this was not 
observed in the submucosal plexus (Figure 2D). Although the number of neurons is 
unchanged in the proximal and distal regions of the LI neural plexuses (Figure 2E), 
the number of myenteric ganglia is increased (Figure 2F) while the size of each 
ganglion decreases in the distal LI (Figure 2G). Interestingly, LI submucosal neurons 
are localized to the natural folds that form in the colon (Figure 2A, lower right 
panels), and these ganglia appear smaller in the distal colon. Importantly, our labeling 
method enables simultaneous analysis of myenteric and submucosal neurons and 
motivates the characterization of multiple intestinal regions, uncovering changes to 
neural architecture throughout the GI tract. 
Next, we developed a method to measure baseline calcium transients in the 
ENS of live mice. Existing methods to measure calcium levels in the ENS include ex 
vivo preparations of intestinal tissue (21) or surgically implanting an abdominal 
window to obtain in vivo ENS calcium recordings (22). These methods face 
significant limitations such as they involve extensive manipulation of tissue to obtain 
access to the LMMP, uncouple the ENS from its extrinsic neural connectivity, and 
require technically difficult and permanent surgical procedures.  
In our method, we systemically delivered a fluorescent calcium reporter, 
GCaMP6F (23), to the ENS through viral delivery with AAV-PHP.S. Unstimulated 
calcium transients in the proximal large intestine were recorded in individual neurons 
by in vivo confocal microscopy (Figure 2H and Supplemental Video 1). Analysis of 
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neuronal calcium fluxes show an average spike rate of 29.1 spikes/minute with an 
interquartile range of 19.0 - 37.7 spikes/minute (min. = 7.0 spikes/min., max. = 63.0 
spikes/min) (Figure 2I). Time between calcium spikes was calculated for each cell, 
and the average peak interval was 2.6 seconds with an interquartile range of 1.6 - 3.2 
seconds (min. = 1.0 seconds, max. = 8.6 seconds) (Figure 2J). Heatmaps (Figure 2K) 
and traces (Figure 2L) constructed from GCaMP6F fluorescence intensities also 
depict the heterogeneity of neuronal firing among cells and within them (i.e., tonic 
vs. phasic, small vs. large fluorescence delta, duration of spike). This underscores the 
granularity and resolution of our methods in achieving single cell measurements of 
neuronal activity. The relative ease of the histological and live imaging techniques 
described above, facilitated by viral transduction of fluorescent reporters, can be 
applied broadly to many disease models to provide meaningful, in vivo, 
characterization of basal ENS activity– an important aspect of ENS phenotyping as 
it becomes increasingly implicated in health and disease.  
 
Characterizing the Effect of the Intestinal Microbiome on ENS Architecture 
and Physiology 
The complex community of microorganisms that inhabit the GI tract is collectively 
known as the intestinal microbiota. It impacts both GI and host function. In an effort 
to illuminate how the microbiota affects cellular architecture of the ENS, previous 
studies have shown that germ-free (GF) animals, void of all microorganisms, display 
stunted development in the GI tract evidenced by lower innervation (24-26). We 
aimed to benchmark our viral-mediated labelling to prior IHC studies and further 
characterize the effects of microbial influence on the ENS.  
To this end, GF and specific pathogen free (SPF) (mice harboring a complex 
microbiota) mice were infected with PHPS-hSyn-XFP, as described above (Figure 
3A). To ensure equal infectivity of GF and SPF mice, we found that the relative 
abundance of viral vector DNA from the small and large intestines was similar 
between the two groups (Supplemental Figure 3A). Seven regions of the small 
intestine and three regions of the large intestine were sampled, proximally to distally. 
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Using ScaleS tissue clearing methods, we imaged and enumerated neurons in both 
myenteric and submucosal plexuses, normalizing these counts to the number of 
crypts. Importantly, no difference was found in crypt diameter between GF and SPF 
(Supplemental Figure 3B), ensuring that normalizing neuron counts to the number of 
crypts was appropriate.  
Notably, GF mice were found have fewer myenteric and submucosal neurons 
in the along many regions of the small intestine (Figure 3B and 3C) and the medial 
large intestine (Figure 3D and 3E). GF mice also have fewer neurons per cluster of 
neurons, or ganglion (Supplemental Figure 4C and 4D). However, there was 
generally no difference between GF and SPF mice when quantifying the normalized 
number of ganglia, except in the submucosal neurons of the proximal small intestine 
(Supplemental Figure 4E and 4F).  
To better understand when the microbiota is most important in shaping ENS 
architecture, an antibiotic cocktail (ABX) containing ampicillin, vancomycin, 
neomycin, and metronidazole was administered, ad libitum, to GF and SPF mice at 
different developmental timepoints to deplete the microbiome. ABX treatment 
generally reduced the numbers of neurons in the SPF small intestine down to the 
levels of GF mice (Supplemental Figure 4A-4F), irrespective of when antibiotics 
were first administered (prenatally, or 3 and 8 weeks postnatally). The adult ENS has 
been shown to be actively maintained by a balance of apoptosis and neurogenesis 
(27), and our findings indicate that the microbiome also influences postnatal 
remodeling of the ENS.  
Next, we developed a method to measure baseline calcium transients in the 
ENS of live mice. Existing methods to measure calcium levels in the ENS include ex 
vivo preparations of intestinal tissue (21) or surgically implanting an abdominal 
window to obtain in vivo ENS calcium recordings (22). These methods face 
significant limitations such as severe manipulation of tissue to obtain the LMMP, 
uncoupling the ENS from its extrinsic innervation, and use of a technically difficult 
surgical procedure. 
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We systemically delivered virally encoded GCaMP6 to GF and SPF mice as 
previously mentioned. Prior studies have shown that enteric neurons from GF mice 
exhibit reduced excitability as measured by lower resting potentials and heightened 
refractory periods (28, 29). These studies clearly show a link between the microbiome 
and ENS electrophysiology, but were limited to the study of a single cell type. To 
expand upon these findings, we recorded in vivo, intracellular calcium influx in 
enteric neurons from GF and SPF mice. Average fluorescence did not change 
between the GF and SPF ENS (Supplemental Figure 5A), however, GF mice have 
modestly higher rates of calcium influx than do SPF mice (Figure 3F), indicating 
higher baseline activity. Accordingly, time between calcium maxima for all 
measured peaks (peak interval) is decreased in GF mice (Supplemental Figure 5B). 
Although there is no difference in the average peak interval per cell, there are 
significant differences in the its variance (F-test) between GF and SPF (Figure 3G 
and Supplemental Figure 5B). This method of measuring GCaMP6F allows for a 
more global characterization of in vivo ENS activity, with extrinsic nerves intact. A 
heatmap generated from GCaMP6F signals from GF and SPF mice (Figure 3H and 
3I) and example traces of raw fluorescent data (Supplemental Figure 5C and 5D), 
suggest potential dysregulation of ENS activity indicated by variability in the time 
between calcium maxima.  
 
Characterizing and Modulating Neuronal Subpopulations of the ENS in ChAT-
Cre and TH-Cre Transgenic Mice 
Research in the central nervous system was initially predicated on IHC 
characterization; however, as genetically encoded neuroscience tools (e.g. AAVs, 
neuronal reporters and modulators) became available for neuroscience, neural 
populations were re-characterized using transgenic mouse models so that they could 
be leveraged, in tandem, to systematically characterize neural circuits. Similarly, a 
deeper understanding of the ENS will depend on histological recharacterization that 
can be coupled to functional modulation. 
 
 
133 
We started this process by histologically characterizing the ENS in ChAT- 
and TH-Cre animals. Cholinergic and catecholaminergic neurons are fundamental to 
the peripheral nervous system, innervating the body’s internal organs and relaying 
information to and from the CNS. Though ChAT+ and TH+ neurons are intrinsic to 
the GI tract, they have yet to be systematically characterized for their active role in 
modifying local GI physiology. To do so, genetic constructs can be engineered to 
have the transgene be in double-floxed inverse orientation (DIO), such that the 
transgene is flipped and expressed only in the presence of Cre-recombinase (Cre). 
Thus, packaging these Cre-dependent vectors into AAV-PHP.S and delivering them 
to transgenic mouse lines that express Cre at the ChAT and TH genomic loci allow 
for their expression in potential subsets of neurons that are neurochemically distinct. 
In lieu of viral transduction, similar labelling can be achieved through transgenic 
crosses (e.g. Rosa26-DIO reporter strains crossed with Cre-mice); however, this 
requires extensive mouse husbandry and ultimate antibody use to verify neuron 
specificity. 
To this end, we transduced ChAT-Cre or TH-Cre mice with AAV-
PHP.S:hSYN1-DIO-XFP to visualize these subsets of neurons. Surprisingly, the 
labelled cells in each mouse line occupied spatially distinct layers of the GI tract as 
ChAT-Cre+ neurons were localized to the myenteric plexus whereas TH-Cre+ 
neurons were primarily localized to the submucosal plexus (Figure 4A-4B). Also, 
distal regions of the small intestine in TH-Cre mice show increasing proportion of 
myenteric neurons, though much lower than what is found in ChAT-Cre mice (Figure 
4B). Conversely in the large intestine, the ratio of myenteric and submucosal neurons 
does not change between ChAT- and TH-Cre mice. These data suggest that spatial 
localization of enteric neurons is genetically encoded and thus may also be 
functionally distinct. To the best of our knowledge, this is the first characterization 
of the unique spatial distributions of ChAT- and TH-Cre+ neurons in the ENS. As 
previously mentioned, characterization of submucosal neurons in the ENS has been 
technically limited. Without the tools implemented in this experiment, identifying 
and defining this overlooked compartment of neurons in the ENS would not have 
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been possible. Furthermore, the abundance of neuron-specific, Cre-expressing mouse 
lines affords tremendous opportunity for (re)discovery.  
 
Activation of ChAT-Cre+ and TH-Cre+ Neurons in the GI Tract Alters the 
Intestinal Transcriptome 
The spatial organization of TH and ChAT neurons hinted at distinct functional effects 
in the GI. To address this question, ChAT- and TH-Cre mice were infected with Cre-
dependent genetic constructs encoding activating DREADDs (AAV-PHP.S:hSYN1-
DIO-hM3Dq-mRuby2). hM3Dq is a modified neurotransmitter receptor that is 
designed to induce neuronal activation when exposed to Compound 21 (C21), its 
“designer drug” that activates only this receptor (30). Accordingly, C21 induces a 
long calcium transient in a Cre-expressing neuron, as shown by the gradual increase 
in GCaMP6F fluorescence in an intestinal explant (Figure 4C). Thus, this method 
enables activation of subsets enteric neurons with temporal resolution. 
We next developed a novel experimental paradigm to test and assay the direct 
and indirect impact of chronic neuronal activation on various intestinal biological 
processes in a freely moving animal. To do this, ChAT- and TH-Cre mice were 
infected with activating DREADDs or a control virus expressing the reporter protein 
alone (AAV-PHP.S:hSYN1-DIO-mRuby2). C21 was administered intraperitoneally, 
once daily for 10 consecutive days to all mice (Figure 4D). One hour following the 
last C21 injection, 1cm of tissue from the distal small intestine (dSI) and proximal 
large intestinal (pLI) was harvested, and bulk tissue gene expression was profiled by 
QuantSeq, a 3’ mRNA-sequencing technology. We hypothesized that the ENS is 
involved in propagating signals to the cells that reside in the GI tract, and thus chronic 
ENS activation would alter the intestinal transcriptome. Furthermore, we believed 
that the transcriptional changes induced in ChAT- and TH-Cre mice would be 
generally different given their distinct spatial localization of enteric neurons. 
In neurons, the rapid and transient expression of immediate early genes 
(IEGs) is widely used as a measure of heightened neural activity (31). Accordingly, 
the IEGs Fos, Egr1, Jun, Klf2 (Figure 4E-4H) were among the most significantly 
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upregulated transcript in the small and large intestines of both ChAT- and TH-Cre 
mice- further justifying our experimental paradigm as a model for in vivo ENS 
activation (Figure 4I). Moreover, IEGs are upregulated during growth and 
differentiation of highly active cell-types such as immune cells (32, 33), smooth 
muscle cells (34), and intestinal epithelial cells (35). As IEGs often function as 
transcriptional regulators in both neurons and non-neuronal cell types, this result 
shows how activation of the GI nervous system can induce broad mechanisms of 
transcriptional regulation throughout the intestinal transcriptome (Figure 4E-4H).  
In the dSI, DREADD activation produced similar numbers of differentially 
expressed genes (DEGs; padj.<0.05) in ChAT-Cre mice (162 DEGs) (Figure 4G) and 
TH-Cre mice (165 DEGs) (Figure 4E). Interestingly, ~73% of the DEGs were 
upregulated upon ChAT-Cre activation (118 up, 44 down) and only ~42% of the 
DEGs were upregulated upon TH-Cre activation (69 up, 96 down). This parallels the 
number of upregulated IEGs in the dSI of ChAT-Cre mice (29 IEGs) compared to 
those in TH-Cre mice (5 IEGs) (Figure 4I), with a few IEGs (i.e., Hbegf, Soca3, 
Mcl1) actually being downregulated in TH-Cre mice (Figure 4G). In the pLI of both 
ChAT- (253 DEGs- 169 up, 84 down) (Figure 4F) and TH-Cre mice (192 DEGs – 
130 up, 62 down) (Figure 4H), similar proportions transcripts were upregulated (~67-
68%). 
We then sought to contextualize our DEGs with the broader landscape oc 
cellular function and known signaling pathways using Gene Set Enrichment Analysis 
(GSEA) to identify differences in gene ontology (GO) annotations between treatment 
groups (Figure 4J-4M). Remarkably, the most enriched GO term in the dSI of ChAT-
Cre mice was “regulation of smooth muscle cell proliferation” (Figure 4J), whereas 
in TH-Cre mice it was the “response to bacteria” (Figure 4L). This is evidence that 
ENS activation alters the intestinal transcriptome, from IEGs and transcriptional 
regulators to their downstream gene targets, and the functional consequence of neural 
activation may be influenced by their spatial localization. In the proximal large 
intestine, we see more similarity in the ChAT- and TH-Cre mice GO pathways that 
are affected by DREADD activation (Figure 4K and 4M). Strikingly, this supports 
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the fact that spatial localization may drive transcriptomic signatures of ChAT+ and 
TH+ neurons, given the fact that these neuronal subsets are both highly abundant in 
the myenteric plexus of the pLI (Figure 4B). Interestingly, the enriched biological 
processes upregulated in ChAT-Cre mice, where neurons exist in both myenteric and 
submucosal plexuses, portray the breadth of changes that neuronal activation has on 
the diverse cell types that exist in the GI tract, including endothelial, epithelial, 
immune, and fat cells (Figure 4J).  
 
GI Neural Activation Alters Host and Microbial Proteome in the GI Lumen 
The gut mucosa serves as a portal to the molecular environment, where the host, 
microbes, and dietary constituents exchange chemical signals and ultimately alter 
intestinal and peripheral physiology (36). To determine how activation of the 
neuronal subsets alters the luminal environment and if this alters host-microbe 
interactions, we first performed label-free proteomics (LC-MS/MS) on cell-free 
supernatants of cecal contents in ChAT- and TH-Cre mice. The cecum a large 
compartment at the juncture of the small and large intestines and has an abundance 
of microbes and luminal contents to assay. Samples were collected one hour 
following the final C21 dose (Figure 4D). In doing so, we assayed for host- and 
microbe-associated proteins and tested whether in vivo ENS activation altered the 
luminal environment. 
Pancreatic digestive enzymes were the most significantly upregulated 
proteins in lumen of the activated mice (Figure 5A). These include chymopasin 
(CTRL), chymotrypsinogen 1 (CTRB1), and pancreatic lipase related protein 2 
(PNLIPRP2). Accordingly, network analysis of upregulated proteins showed that 
KEGG pathways associated with digestion represent the majority of the network 
(Figure 5B). This also implicates cholinergic, viscerofugal neurons that send signals 
from the GI tract to other organs of the digestive system, such as the pancreas (3).  
Interestingly, Niemann-Pick C1-Like 1 protein (NPCL1) is upregulated in the 
cecum of ChAT-Cre mice. NPCL1 is expressed on the apical surface of enterocytes 
(37) and is an integral protein involved in the absorption of free cholesterol in the 
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lumen, the precursor of bile acids. Goblet-cell related proteins also trended upwards, 
specifically Mucin-19 (MUC19) and Zymogen granule 16 (ZG16) (Figure 5A), a 
protein localized to secretory granules (38). Conversely, one of the most 
downregulated proteins was an aldehyde dehydrogenase (Q3U367) encoded by the 
Aldh9A1 gene. It is involved in the catalytic conversion of putrescine (39), a molecule 
produced by the urea cycle and gut bacteria (40), to gamma-aminobutyric acid 
(GABA), a major inhibitory neurotransmitter. Acetylcholine produced by cholinergic 
neurons is known to be excitatory. However, this is the first example of enteric 
downregulation of GABA biosynthesis by cholinergic activation, potentially 
augmenting the excitatory signal in the GI tract. 
Activation of TH+ neurons also altered the luminal proteome. Interestingly, 
88% (52/59) of the differentially abundant proteins (padj < 0.25, pnom < 0.021) are 
distinct from those identified in activated ChAT-Cre mice (padj < 0.25, pnom < 0.042). 
Also 90% of these proteins were upregulated (53/59), whereas only 18% of proteins 
in ChAT-Cre mice were upregulated (20/112), suggesting that activation of distinct 
neuronal subsets is associated with largely distinct changes in GI function. There are 
also heightened protein-protein interactions in activated TH-Cre samples, evidenced 
by increased levels of network nodes and connections (Figure 5C and 5D). When 
TH-Cre+ neurons were activated, Filamin B (FLNB) and spectrin beta chain, non-
erythrocytic 1 (SPTB2) were some of the most significantly enriched proteins (Figure 
5C). These proteins are associated with the intestinal brush border and membrane 
vesicles (41, 42). Accordingly, vesicle-mediated transport was a major protein 
network identified (Figure 5D) and relatedly, coatomer proteins also trend upwards 
(COPA and COPB2) (Figure 5C). These vesicle associated proteins are known to 
package apolipoproteins, which are secreted luminally from enterocytes. Other 
enriched protein interaction networks that emerged were associated with the immune 
system, metabolic pathways, and ribosomes (Figure 5D). For example, immune 
related proteins such as IgA (in ChAT-Cre) and IgG2b and complement c3 (in TH-
Cre) trend upwards (Figure 5A and 5C). These findings are in accordance with the 
immune-related biological processes identified in analysis of gene expression after 
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activation (Figure 4J-4M). It also provides novel mechanistic insights of the 
regulation of luminal immunoglobulins which have an important role in regulating 
host physiology through the intestinal microbiome (43-46).  
Perhaps the most intriguing observation from this experiment was the strong 
depletion of acidic mammalian chitinase (CHIA) upon activation of TH-Cre mice 
(Figure 5C). Chitin is a natural polysaccharide that is a major component of fungal 
cell walls. However, to the best of our knowledge, intestinal chitinases are poorly 
studied in mice and CHIA has not been investigated for its role in regulating fungal 
populations. Because our peptide samples are made up of host and microbial proteins, 
the identified peptide sequences were also searched against microbial protein 
databases. Remarkably, the decrease in CHIA abundance was accompanied by a 
large increase in the proportion of fungal-associated peptides in the microbiome 
(representing ~59% of peptides mapped to any microbe) (Figure 5E). Furthermore, 
~45% of the enriched eukaryotic proteins are involved in fermentation, the process 
that is responsible for chitin biosynthesis (Supplemental Figure 6A). In contrast, 
fungal peptides represented only ~0.4% of enriched peptides in the lumen of ChAT-
Cre mice (Figure 5F) and all enriched GO terms are bacterial (Supplemental Figure 
6B).  
Taken together, the described activation-mediated alterations to the luminal 
proteomic environment model the molecular exchanges and physiological changes 
that occur at the interface of the GI tract and the environment. Furthermore, it is 
through these experiments that we uncover initial insights towards novel host-
microbe interactions. It is clear that neuron-mediated host responses in the GI tract 
are vast and complex. Continued characterization with additional Cre-expressing 
mouse lines will highlight the breadth of changes that can result, enabling 
mechanistic studies regarding the ENS’ role in modulating physiology. 
 
Changes to the Gut Microbiome upon Activation of the GI Nervous System  
Given that we observed robust changes in the gut proteome, including factors 
associated with microbial communities in the gut, we reasoned that neuronal 
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activation in the ENS would also result in changes to the composition and structure 
of the gut microbiome. For example, digestive enzymes can alter the nutrient 
composition and availability not only for the host, but also for the gut microbiome. 
Also, changes to GI immunity could have a potent effect on the resulting diversity 
and abundance of microbes in the GI tract. We believe the methods described in this 
study can be used to model host-microbe interactions and dysbiosis that are 
influenced by the neural activation of the GI tract. 
To address this, we performed shotgun metagenomics on feces (pre-C21 
samples, and at 1, 5, and 9 days after initial C21 dose) and cecal contents (10 days 
after initial dose) (Figure 4D). In ChAT-Cre mice, Faith’s phylogenetic diversity 
decreases by day 9 in the feces and also in the cecum on day 10 (Figure 6A). This 
can also be seen by the large number taxa that are less abundant in activated samples 
(Supplemental Figures 7 and 8). In TH-Cre mice, phylogenetic diversity remained 
unchanged between groups. However, there is a trend towards a decrease in diversity 
from pre-C21 samples to 5 days post activation, and this decrease recovers by day 9 
in the feces (Figure 5A and Supplemental Figure 8B). We then measured differences 
in the composition of microbial communities using weighted UniFrac distances were 
calculated and principle coordinate analyses (PCA) were performed. There is clear 
separation between control and activated groups in the feces and cecal contents of 
ChAT-Cre mice and this shift was largely absent in samples from TH-Cre mice 
(Figure 6B-6G). Interestingly, over the experimental time course, Verrucomicrobia 
was largely enriched in activated ChAT-Cre mice (Figure 6H). To discover 
differentially abundant bacterial taxa, we used linear discriminant analysis effect size 
(LEfSe) (47) and then visualized the data into cladograms depicting the phylogenetic 
relationship of differentially abundant taxa (Figure 6I and 6K). Family level changes 
to cecal bacterial communities are described in ChAT- and TH-Cre mice (Figure 6J 
and 6L). Akkermansia muciniphila appears to drive the increase in Verrucomicrobia 
in activated ChAT-Cre mice (Figure 6M) and this increase is absent in respective 
TH-Cre mice (Figure 6N). A. muciniphila is known to metabolize host-derived 
mucus as a growth substrate, and this corresponds to the increase in luminal mucin 
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proteins (MUC19) in activated ChAT-Cre mice. A. muciniphila is implicated in many 
diseases, such as obesity (48, 49), multiple sclerosis (50, 51), and seizures (52). Here 
we show that activation of ChAT+ neurons may affect the abundance of this microbe 
that appears to be intricately linked to human health. 
Lastly, metagenomic analysis allows for the investigation of gene families 
and pathways that are differentially abundant in the microbiota. Only ChAT-Cre 
mice showed activation-mediated changes in beta-diversity of both gene families and 
pathways (Figure 6O-6R), and these shifts occurred in the cecum and feces collected 
9 days after activation. The colors of the arrows represent different gene families and 
pathways and their direction is indicative of the influence that each feature has on the 
separation of control and activated groups. Thus, the most distinguishing features are 
highly represented in the control groups and downregulated in activated ChAT-Cre 
mice. The families and pathways that distinguish the control groups (Supplemental 
Figure 8C and 8D) are mainly associated with bacterial activity, such as nucleotide 
biosynthesis and metabolism, and protein translation and transport. The 
downregulation of these gene families and pathways in activated ChAT-Cre mice 
supports the corresponding decreases in bacterial diversity (Figure 6A). 
From these data, it is apparent that neuronal activation has an active role in 
shaping the gut microbiome at a community, species, and genetic resolution. Thus, 
health-promoting communities or pathological dysbiosis may be predicated on 
nuanced differences and perturbations to the innervation and activation of the GI 
tract, integrating both host and microbes’ impact on GI and peripheral physiology.  
 
Metabolomic Changes Upon Neural Stimulation  
Lastly, we assayed for small molecular changes in the cell-free supernatants of GI 
cecal contents by performing untargeted metabolomics using LC-MS/MS. 
Metabolomics offers unique insight to host and microbial metabolism of luminal 
constituents, complementing the changes already observed in the host and microbial 
proteome and microbiome.  
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In ChAT- and TH-Cre mice, we see a strong, activation-dependent clustering 
of cecal samples (Figure 7A-7B) taken one hour following the last C21 injection. In 
the fecal samples of ChAT-Cre mice, we see the separation of control and activated 
groups by day 5 following the initial C21 injection, and this separation persists at 9 
days (Figure 7C-7F). Interestingly, we also observed a decrease in diversity in feces 
and cecal contents of these mice at the end of the experimental time course (Figure 
6A). In TH-Cre fecal samples, there appeared to be a plate effect driving the 
separation of control and activated groups on one axis of the PCA. Thus, the samples 
were plotted on axes that minimized this experimental bias, and it appears that the 
samples also begin cluster by day 9 post-activation (Figure 7G-7J). Furthermore, 
there is clear separation between cecal metabolites in ChAT- and TH-Cre mice upon 
GI activation (Supplemental Figure 9A and 9B) and such separation occurs in the 
feces by Day 9 of the activation time course (Supplemental Figure 9C-9F). All of this 
suggests there are distinct metabolites that are altered in the feces and cecal contents 
of ChAT- and TH-Cre mice following activation.  
The Global Natural Products Social Molecular Networking (GNPS) (53) tool 
is an open-access mass spectroscopy repository and analysis pipeline, from which we 
are able to visualize the data by producing molecular networks based on MS2 spectral 
similarities of small molecules and their analogs, both annotated via spectral matches 
against all available public reference spectral libraries and the purchased NIST17 
CID library and unannotated. The feature based molecular networking workflow on 
GNPS (54) was utilized in order to analyze the spectra associated with the feature 
tables produced using the open source software MZmine version 2.51 (55). In the 
cecal contents of ChAT and TH-Cre mice, metabolic networks consisting of both 
annotated and unannotated molecules are shown (Figure 7K and 7L). Annotated, 
non-networked metabolites were chosen for their differential abundance in either 
control or activated samples. 
Annotations, when available, help the discovery of potential direct and 
indirect consequences of neural activation on the luminal metabolome (Figure 7M-
7N and Supplemental Table 1). All annotations produced by GNPS using spectral 
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matching against the reference libraries for this dataset are considered either level 2 
or level 3 based on the Metabolomics Standards Initiative (MSI) (56). In both ChAT- 
and TH-Cre mice, the molecular networks largely consist of level 3 annotations of 
compounds belonging to the bile acid molecular family and their conjugates, as well 
as unannotated analogs. Spectral matches to primary and secondary bile acid families 
show changes upon activation status. Primary bile acids are known to be host 
associated, while secondary bile acids have shown to be metabolized by gut (57, 58). 
 Interestingly, metabolites with their closest spectral match being the primary 
bile acid cholic acid (ID: 108, 114, 215, 219, 221, 224, 259) are significantly enriched 
in the cecum of activated ChAT-Cre mice (Figure 7K and Supplemental Table 1). 
Additional metabolites that closely resemble the spectra of tauro-conjugated primary 
bile acids trend upwards, such as taurocholic acid (ID: 234, 238) and taurohyocholic 
acid (ID: 235). Conversely, features with spectral matches to the family of secondary 
bile acids and bile acid metabolites such as ursodeoxycholic acid (ID: 13), 
deoxycholic acid (ID: 100), beta-hyodeoxycholic acid (ID: 1, 143) and 12-
ketodeoxycholic acid (ID: 19, 138) are decreased in activated mice (Figure 7K and 
Supplemental Table 1). Remarkably, this finding is concomitant with the decrease in 
microbial diversity observed in the cecum of ChAT-Cre mice (Figure 6A). This 
suggests that in ChAT-Cre mice, activation of the ENS is capable of modulating bile 
acids in the GI tract by influencing of their secretion and/or metabolism via the 
microbiota. It is noteworthy that increases in primary bile acids coincide with 
increases in the cholesterol transporter, NPCL1. Cholesterol, as previously 
mentioned, is an necessary precursor in bile acid biosynthesis. In TH-Cre mice, there 
are no significant differences in bile acid abundances. However, there were strong 
increases to non-networked metabolites in activated TH-Cre mice whose closest 
spectral matches were linoelaidic acid (ID: 626), oleanolic acid methyl ester 
(ID:378), and coproporphyrin I (ID: 378), and metabolites that spectrally resemble 
xanthine (ID: 259), genistein (ID: 846), and trans-Ferulic acid (ID: 707) were 
decreased (Figure 7L and Supplemental Table 1). All annotations identified using 
GNPS should be verified in future analyses with exact standards to attain level 2 MSI 
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annotation. Characterization small molecular changes in the lumen of the GI tract can 
help describe the functional metabolic consequences ENS activity, and such insights 
can help model the metabolic output not only in the GI tract, but also in systemic 
circulation.  
 
DREADD Activation Alters GI Physiology 
We hypothesized that gross physiological changes would accompany the abundant 
molecular alterations observed. First, water content of fecal pellets was measured 
over the 5 hours following neural activation. Water content of individual fecal pellets 
reached a maximum in ChAT-Cre mice 1-2 hours after a single dose of C21, but this 
increase was absent in TH-Cre mice (Figure 8A-8F). Linear regression analyses of 
percent water content 0-2 hours after C21 administration determined a significant 
increase in the slope of the best fit line of ChAT activated mice vs ChAT control and 
TH activated mice (Figure 8D and 8F). However, no differences were identified in 
TH control mice vs TH activated and ChAT control mice (Figure 8C and 8E). Finally, 
average percent water content of fecal pellets per mouse, over the 5 hour time course, 
was significantly increased by ~10% only in activated ChAT-Cre mice (Figure 8G). 
Next, activation-mediated secretion was assayed by measuring the mass of luminal 
contents, normalized to the body weight of the animal, 1 hour after C21 
administration. Using this measure of secretion, there was a 71% increase in TH-Cre 
mice and a 65% increase in ChAT-Cre mice (Figure 8H). This is surprising because 
the increase in water abundance was only observed in the cecal contents of ChAT-
Cre mice. Thus, alternative explanations, such as heightened water resorption in 
activated TH mice, the inhibition of it in activated ChAT mice, or a difference in the 
composition of ions and molecules secreted in the lumens of TH and ChAT mice, 
could explain these seemingly contrasting results. Lastly, transit time is decreased in 
both activated TH and ChAT-Cre (Figure 8I) mice, and accordingly, the rate of fecal 
output is significantly increased (Figure 8J). To determine potential confounding 
behavioral changes, open field testing was performed. This test identified a decrease 
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in locomotion in only activated ChAT-Cre mice as seen by a 35% and 33% decrease 
in distance travelled and movement duration (Supplemental Figure 10A and 10B).   
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DISCUSSION 
We present a viral approach towards delivering genetically encoded fluorescent 
reporters and neural modulators to characterize the ENS and activate the neural inputs 
to the GI tract. To date, broad histological characterization of the ENS has been 
restricted by the limitations of current antibody labeling approaches (59). Viral-
mediated expression of AAV-PHP.S allows for vast infectivity of enteric neurons 
with a single systemic injection, without the use of transgenic animals, and makes it 
much simpler to perform histology of the ENS in intact GI tissue.  
Dysbiosis of the gut microbiota continues to be implicated in seemingly 
dissimilar diseases such as those of the immune and nervous systems (60). Similarly, 
innervation of the GI tract is responsible for mediating communications both 
internally (i.e., intestinal immunity) and externally (i.e., the CNS) (61). In this study, 
chronic enteric neural activation altered the gut microbiome, at the gene and protein 
level. Furthermore, GI activation altered metabolic byproducts of families of host 
molecules known to be mediated by the microbiome, such as bile acids. If enteric 
innervation and activation can explain both dynamic changes of the microbiome and 
long-lasting alterations to it, then perhaps gut bacteria do not only affect disease, but 
also serve as novel biomarkers for those with ENS-originating etiologies. Thus, as 
medicine continues to adopt microbiome-based interventions, it is important to 
understand and address the underlying mechanism of dysbiosis. Additionally, 
characterizing the luminal molecular environment and its ability to influence 
microbial taxa, genes, and metabolic pathways will be important towards the 
development of drugs that target the microbiome. Further studies, such as the transfer 
of gut microbes from “activated” mice or disease model outcomes with or without 
GI neural activation are necessary to dissect the role of the microbiome as a direct 
effector of physiology and/or a biomarker for neural dysregulation.  
Neurogastroenterology research is at an inflection point where tools in 
neuroscience can be adapted for studies in the GI tract. This study provides a 
methodological proof-of-principle necessary to begin dissecting the histological and 
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functional complexity of the GI nervous system. The GI tract, in particular, is an ideal 
tissue to model the diverse interactions between neurons and non-neural cell types. 
As such, recent studies have highlighted the role of ENS signaling and integrating 
signals from other cell types including immune cells, enteroendocrine cells, and even 
the gut microbiome (5, 62-66). The genetic tools and multi-omics assay approach 
used in this study holistically outline the breadth of complex, multicellular 
interactions that are responsible for the molecular and microbial output of the GI tract 
and encourage the study of the ENS as a central motivator of physiology. 
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Figures and Legends 
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Figure 1. Advantages of Viral labeling in the ENS 
 
Figure 1A 
Viral-mediated expression of nuclear localized (NLS) GFP driven by the ubiquitous 
CAG promoter. Quantification of virally labelled cells in AAV9 vs. AAV-PHP.S in 
the longitudinal muscle, myenteric plexus, and circular muscle of the stomach. (N = 
4-5 mice, each data point represents the average from 3 representative fields). 
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Figure 1B 
Representative images of small and large intestines in mice infected with AAV-
PHP.S:hSYN1-TdTomato and immunolabelled with the pan-neuronal antibody, 
PGP9.5. Inset: quantification of TdTomato+ cells / PGP9.5+ cells (N = 3 mice, each 
data point represent the average from 3 representative fields). 
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Figure 1C 
Tiled, whole mount microscopy showing widespread labelling in the proximal large 
intestine (>1cm of tissue) from a single injection (1012 VGs-vector containing 
AAVs). 
 
 
Figure 1D 
PaCT tissue clearing coupled with multicolor labelling of the intestine, showing 
structural and anatomical resolution in Z. 
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Figure 1E 
Left: Antibody-labelled myenteric plexus of the proximal large intestine. Right: 
Viral-mediated multicolor labelling of a comparable region. AAV-PHP.S:hSYN1-
(mTurq2/mNeonGreen/TdTomato) (AAV-PHP.S:hSYN1-XFP, 3e11 VGs each).  
 
 
Figure 1F 
High resolution confocal microscopy showing cell morphology when labelled with 
AAV-PHP.S:hSYN1-XFP vs. traditional IHC with PGP9.5.  
 
 
Figure 1G 
Left: IHC with anti-PGP9.5 and anti-GFAP Right: Viral expression of AAV-
PHP.S:hSYN1-mNeonGreen and AAV-PHP.S-GFAP-TdTomato  
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Figure 2. Quantifying ENS Architecture and Measuring ENS Activity with 
GCaMP6F 
 
Figure 2A 
Representative images from proximal and distal, small and large intestines of AAV-
PHP.S:hSYN1-XFP infected mice. 
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Figure 2B-2G  
Quantification of neurons in 7 regions from the small intestine, and 2 regions from 
the large intestine, sampled proximally to distally (N = 3-4 mice per group, per 
intestinal region. Data points are averages from 2-3 images per mouse, per region; *: 
p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.001, 2-way ANOVA with Sidak’s 
multiple comparisons test) 
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Figure 2H 
Experimental setup to capture GCaMP6F fluorescence in a live, anesthetized 
animal. 
 
Figure 2I 
Frequency distribution of calcium spike rate 
 
 
Figure 2J 
Frequency distribution of calcium peak interval 
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Figure 2K 
Heatmap of GCaMP6F fluorescence (dF/F) over time. Each row represents 
fluorescent time course of a single cell. Data was cutoff at 83.64 seconds.  
 
Figure 2L 
Representative GCaMP6F fluorescent traces. 
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Figure 3. Microbiota influences ENS cellular architecture and activity 
  
Figure 3A 
Representative images from small intestines of PHPS-hSyn-XFP infected SPF and 
GF mice. 
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Figure 3B-3E 
Quantification of neurons in 7 regions from the small intestine, and 3 regions from 
the large intestine, sampled proximally to distally (N = 3-4 mice per group, per 
intestinal region. Data points are averages from 2-3 images per mouse, per region; #: 
significance between regions, color of symbol corresponds to GF or SPF, *: 
significance between GF and SPF at each region; #,*: p<0.05, ##,**: p<0.01, 
###,***: p<0.001, ####,****: p<0.001, 2-way ANOVA with Sidak’s multiple 
comparisons test)  
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Figure 3F-3G 
(F) Number of calcium peaks per minute (Data was collected from N = 54 (GF) – 68 
(SPF) cells from 3 mice/group). (G) Frequency distribution of the average peak 
interval (time between calcium maxima) per cell. F-test measures significant 
differences in variances between groups. (Data was collected from N = 51 (GF) – 65 
(SPF) cells from 3 mice/group, p-value determined from unpaired t-test with Welch’s 
correction). 
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Figure 3H-3I 
Heatmap of GCaMP6F fluorescence (dF/F) over time. Each row represents 
fluorescent time course of a single cell. Data was cutoff at 83.64 seconds.  
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Figure 4. Characterizing Enteric ChAT-Cre+ and TH-Cre+ Neurons and Assaying 
Activation-Mediated Transcriptomic Changes 
 
Figure 4A 
Representative images from cross sections (x-section), myenteric, and submucosal 
plexuses in ChAT-Cre and TH-Cre mice infected with AAV-PHP.S:hSYN1-DiO-
XFP. 
 
 
 
Figure 4B  
Quantification of myenteric:submucosal cells ratio in ChAT- and TH-Cre mice. (N 
= 3 mice, each data point represent the average from 3 representative fields) 
 
 
 
 
 
161 
Figure 4C 
Fluorescence time course of GCaMP6F in an ex vivo preparation of ChAT-Cre SI 
following C21 administration. 
 
 
 
Figure 4D 
Experimental paradigm- 10 consecutive days of C21 injections, with feces sampled 
in between and tissue and cecal contents collected at the end. 
 
 
 
Figure 4E-4H 
Volcano plots of differentially expressed genes in DREADD Activated vs Control, 
in (E) ChAT-Cre dSI, (F) ChAT pLI, (G) TH-Cre dSI, and (H) TH-Cre pLI. (Dotted 
vertical: Fold Change (FC) = +/- 1.5; Dotted horizontal: padjusted <0.05. Annotated 
transcripts are IEGs and are highlighted in green. N = 10 mice per group) 
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Figure 4I 
Fold changes of upregulated IEGs (padj < 0.05) as defined by Wu et al. 2017 (31)  
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Figure 4J-4M 
Gene set enrichment analysis of gene ontology (GO) terms for (J) ChAT-Cre dSI, 
(K) ChAT pLI, (L) TH-Cre dSI, and (M) TH-Cre pLI. 
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Figure 5. ENS Activation Alters Host and Microbe-Derived Luminal Proteins 
 
Figure 5A 
Volcano plot of differentially expressed host proteins identified in the cecal contents 
of Activated ChAT (N=8) vs. Control ChAT mice (N = 9 mice), 1 hour after C21 
administration. 
 
 
Figure 5B 
STRING network analysis of host proteins that were more abundant in ChAT-
activated mice (pnom. < 0.2) 
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Figure 5C 
Proteomic volcano plots of TH-activated vs. TH-control mice (N = 7 mice per group) 
after C21 administration 
 
Figure 5D 
STRING network analysis of upregulated host proteins in TH-activated mice (pnom. 
< 0.2) 
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Figure 5E 
Unipept metaproteomic analysis of upregulated microbial proteins (pnom. < 0.2) in 
activated TH-Cre mice (N = 7-9 mice per group) 
 
 
 
Figure 5F 
Unipept metaproteomic analysis of upregulated microbial proteins (pnom. < 0.2) in 
activated ChAT-Cre mice (N = 7-9 mice per group) 
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Figure 6. ENS Activation Alters the Microbiome 
 
Figure 6A  
Faith’s phylogenetic diversity of feces and cecal contents over 10 days of neural 
activation in ChAT- and TH-Cre mice. Day -1 (1 day before first injection), Day 
+1/5/9 (1, 5, 9 days after first injection), Day +10 (Cecal contents collected at 
experimental endpoint) (**p<0.01, ***p<0.001 determined by Kruskal-Wallis 1-
way ANOVA). 
 
 
Figure 6B-6G 
Weighted UniFrac principle coordinate analysis (PCA) of Activated vs. Control in 
ChAT- and TH-Cre mice with PERMANOVA p-values. 
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Figure 6H 
Stacked bar graph showing phylum level changes in relative abundance, 5 and 9 days 
post-injection in feces and 10 days post-injection in cecal contents. 
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Figure 6I-6L 
Cecal Microbiome LDA Effect Size (LEfSe) Analysis: (I,K) Cladograms showing 
differential phylogenetic clusters and (J,L) LDA plots of family level differences 
between Activated and Control mice (Cutoff: log10(LDA Score) > 2 or < -2) in (I,J) 
ChAT-Cre and (K,L) TH-Cre mice 
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Figure 6M-6N 
Changes in relative abundance of Akkermansia muciniphila in feces and cecal 
contents of (M) ChAT-Cre and (N) TH-Cre mice. (n = 11-14 mice per group, per 
time point; red=control, green=hM3Dq-Activated, *p<0.05, **p<0.01, significance 
determined by multiple t-tests with Holm-Sidak correction for multiple comparisons) 
 
 
 
Figure 6O-6R  
Beta-diversity of bacterial gene families and pathways in the (O-Q) cecum and (P-R) 
post-9 feces of control and activated mice. Diversity was determined with 
Aitchison’s PCA and analyzed using the DEICODE toolbox. The direction of 
defining features is indicated with colored arrows. These gene families and pathways 
are annotated by the color of the feature arrow (Supplemental Figure 6C and 6D) 
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Figure 7. ENS Activation Alters the Host and Microbe-Derived Luminal 
Metabolites  
 
Figure 7A-7J 
Canberra PCA of the cell-free, luminal metabolome of control (red) and activated 
(green) cecal contents in ChAT-Cre and (B) TH-Cre mice. (C-J) Fecal metabolome 
assayed at different timepoints before and after C21 administration in (C-F) ChAT-
Cre and (G-J) TH-Cre mice. 
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Figure 7K-7L 
Metabolic networks constructed from identified cecal metabolites in (K) ChAT-Cre 
and (L) TH-Cre mice. Each node is labelled with an ID number, corresponding to 
annotations, mass-to-charge ratios, rentention times, fold changes, and significance 
values found in Supplemental Table 1. Each node is colored by its upregulation 
(green) or downregulation (red) in activated groups. IDs in bold text have an 
annotation in GNPS and are colored by classes class of metabolite (primary bile 
acids, secondary bile acids, and other metabolites). Metabolite IDs are distinct by 
genotype (N = 12-14 for each group analyzed, *: p<0.05, **: p<0.01) 
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Figure 8. ENS Activation Alters Gross GI Physiologies 
 
Figure 8A and 8B 
Scatter plot of %(water content) of individual fecal pellets. (A) TH-Cre (B) ChAT-
Cre mice 0-5 hours post C21 administration. (N = 10 mice per group, > 4 fecal pellets 
collected per mouse over 5 hour period) 
 
 
 
Figure 8C-8F 
Linear regressions of %(water content) data from 0-2 hours (C) TH control vs. TH 
activated (D) ChAT control vs. ChAT activated (E) TH control vs. ChAT control (F) 
TH activated vs. ChAT activated . (N = 10 mice per group, > 4 fecal pellets collected 
per mouse over 5 hour period, p-values correspond to slopes of line of best fit) 
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Figure 8G-8K 
(G) Average %(water content) of feces from mice over a 5 hour period following 
C21 administration. (H) Mass Ratio of cecal contents : animal, 1 hour post C21 
administration (I) GI transit time upon C21 administration. (J) Average fecal output 
rate upon C21 administration (G-J: N = 10-11 mice per group, statistics performed: 
2way ANOVA with Sidak’s method for multiple comparisons) 
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Supplemental Figures, Tables, and Legends 
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Supplemental Figure 1. Viral Labeling Enables a Holistic Understanding of the 
ENS 
 
Supplemental Figure 1A-1D 
(A-B) Tiled images of the ENS in the mouse small intestine. Mice are infected with 
AAV-PHP.S:hSYN1-XFP (C) Inset of panel (A) showing extrinsic nerves and 
neurons connecting to intrinsic ganglia of the ENS (D) Inset of panel (B) showing 
alterations to ENS architecture surrounding intestinal lymphoid follicles such as 
Peyer’s patches 
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Supplemental Figure 1E-1G 
(E) Tiled image of the ENS in the large intestine with insets showing how the (F) 
absence or (G) presence of luminal contents changes the appearance of neuronal 
density in the ENS. 
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Supplemental Figure 2. Similar Viral Transduction Along the GI Tract  
 
Supplemental Figure 2A and 2B 
(A) Quantification (qPCR) of AAV transduction in different regions of the mouse 
small and large intestines (B) Diameter (Pm) of intestinal crypts in small and large 
intestines (N=3-4 mice per group) 
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Supplemental Figure 3. Similar Viral Transduction in GF and SPF Mice 
 
Supplemental Figure 3A and 3B 
(A) qPCR of Viral DNA in GF and SPF mice in small and large intestines (B) 
Diameter (Pm) of intestinal crypts in small and large intestines (N=3-4 mice per 
group) 
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Supplemental Figure 4. AVNM Antibiotic Treatment Mirrors GF ENS 
Phenotype  
 
Supplemental Figure 4A-4F 
(A-F) Quantification of myenteric and submucosal neurons in GF, SPF, and 
antibiotic treated animals. (A,B) GF and SPF data is same data as presented in Figure 
2 of manuscript. Experimental groups were conducted in parallel. (A) Myenteric and 
(B) submucosal neurons normalized by the number of crypts. (C) Myenteric and (D) 
submucosal neurons per ganglion. (E) Myenteric and (F) submucosal ganglia 
normalized by the number of crypts. GF: Germ Free, SPF: Specific pathogen free, 
8wk-ABX: SPF AVNM treatment at 8 weeks of age, 3wk-ABX: SPF AVNM 
treatment at 3 weeks of age, GF-pABX: prenatal GF AVNM treatment, SPF-pABX: 
prenatal SPF AVNM treatment. 2way ANOVA with Dunnett’s multiple comparisons 
tests to SPF group. N = 3-4 mice per group, per intestinal region. Values are averages 
from 2-3 images quantified per animal per region. 
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Supplemental Figure 5. GF and SPF ENS Activity Differs 
 
Supplemental Figure 5A-5D 
(A) Average, background-subtracted fluorescence for each cell over the duration of 
recording. (B) Time between all calcium peaks recorded from all cells. (C-D) 
Representative fluorescent traces of (C) GF and (D) SPF mice infected with PHPS-
CAG-GCaMP6F. 
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Supplemental Figure 6- Microbial GO terms Annotated from Luminal Proteins 
 
Supplemental Figure 6A 
Enriched GO terms for enriched proteins in the metaproteome identified in the 
cecal contents of TH-Cre mice corresponding to Unipept analysis in Figure 4E 
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Supplemental Figure 6A (continued) 
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Supplemental Figure 6B 
Enriched GO terms for enriched proteins in the metaproteome identified in the cecal 
contents of ChAT-Cre mice corresponding to Unipept analysis in Figure 4F 
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Supplemental Figure 6B (continued) 
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Supplemental Figure 7. Annotated Changes to Gut Bacteria 
 
Supplemental Figure 7A 
Species-level enrichment of cecal bacteria in activated and control ChAT-Cre mice 
(corresponding to main text Figure 6I). Sampled 10 days after initial C21 injection 
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Supplemental Figure 7B 
Species-levels enrichment of cecal bacteria in activated and control TH-Cre mice 
(corresponding to main text Figure 6J). Sampled 10 days after initial C21 injection 
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Supplemental Figure 8. ENS Activation-Mediated Changes in Feces 
 
Supplemental Figure 8A 
LEfSe Cladograms for feces on Day 9 of ChAT-Cre mice. Annotations are labelled 
in the tables below the cladogram 
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Supplemental Figure 8B 
LEfSe Cladograms for feces on Day 5 of TH-Cre mice. Annotations are labelled in 
the tables below the cladogram 
 
 
 
  
 
 
190 
Supplemental Figure 8C and 8D 
Microbial gene family and pathway annotations for the defining features labelled on 
the DEICODE PCA plots in Figure 6O-6R. Colors in ID column refer to the color of 
feature arrows labelled in main figure.  
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Supplemental Figure 9. General Differences in ChAT-Cre vs. TH-Cre Metabolites 
Upon Activation. 
 
Supplemental Figure 9A-9F 
Canberra PCA analysis comparing activation-mediated changes to the (A-B) cecal 
and (C-F) fecal metabolome in ChAT-Cre versus TH-Cre mice (A) Cecal 
metabolome of control mice (B) Cecal metabolome of activated mice (C) Pre-C21 
feces of control and (D) activated mice (E) Fecal metabolome during activation time 
course for control and (F) activated mice. 
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Supplemental Figure 10. ENS Activation Alters Locomotion in only ChAT-Cre 
Mice 
Effect of DREADD activation on locomotor activity during open-field testing in TH- 
and ChAT-Cre mice. (A) Distance travelled (cm) in 10 minutes and (B) % of Time 
spent moving. (N = 10-14 mice per group; *p < 0.05; 2way ANOVA with Sidak’s 
multiple comparisons test) 
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Supplemental Table 1 
Extended annotations for networked (bold), MS/MS spectra in cecal luminal 
contents- corresponds to Figure 6K and 6L in ChAT-Cre and TH-Cre mice, 
respectively. 
 
 
 
 
 
194 
 
272 
Spectral Match to 
Cholic acid from 
NIST14 
373.2732 4.435 M+H-2H2O 0.87 0.1293 
111 N-(.alpha.-Linolenoyl)tyrosine 165.0538 0.337 
M+H-
C18H31ON 0.87 0.0000 
48 
Spectral Match to L-
Tryptophan from 
NIST14 
205.0963 0.993 M+H 0.80 0.0009 
192 Ile-Thr 233.1488 0.609 M+H 0.71 0.0515 
30 Spectral Match to Abrine from NIST14 188.0697 0.985 
M+H-
CH3NH2 0.68 0.0006 
246 Val Glu Leu 360.2118 2.762 M+H 0.59 0.1675 
53 
Spectral Match to L-
Arginine from 
NIST14 
175.1169 0.239 M+H 0.58 0.0591 
277 Gln Val Ile 359.2275 2.387 M+H 0.56 0.0840 
12 
Spectral Match to L-
Tyrosine from 
NIST14 
182.0803 0.336 M+H 0.47 0.0027 
102 .beta.-Muricholic acid 391.2837 4.891 M+H-H2O 0.32 0.4044 
99 hyocholic acid 373.2733 4.801 M-2H2O+H 0.04 0.8915 
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Supplemental Table 1 (continued) 
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Supplemental Table 1 (continued) 
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Supplemental Table 1 (continued) 
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Materials and Methods 
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Mice 
All mouse experiments were performed in accordance with the NIH Guide for the 
Care and Use of Laboratory Animals using protocols approved by the Institutional 
Animal Care and Use Committee at the California Institute of Technology. TH-Cre 
(from Viviana Gradinaru at Caltech. Originally from Ted Ebendal B6.129X1-
Thtm1(cre)Te/Kieg) (67) and ChAT-Cre mice (Jackson Laboratories, Bar Harbor, 
ME- Stock# 028861) were obtained from Jackson Laboratories, and homozygous 
Cre-mice were bred to wild-type mice to yield male and female heterozygous Cre-
mice used for our studies. Wildtype specific pathogen free (SPF), C57BL/6 (Jackson 
Laboratories, Bar Harbor, ME Stock #000664) males and females were used for 
breeding and experiments involving germ free C57/B6 mice. Germ free mice were 
bred under gnotobiotic conditions in flexible film isolators, and once taken out were 
placed in sterile cages with autoclaved water supplemented with 10µg/ml 
erythromycin and 100µg/ml gentamicin.  
 
Virus Production 
Virus was produced using methods described in Challis et. al. (68) Briefly, human 
embryonic kidney (HEK293T) cells were triple-transfected with pUCmini-iCAP-
AAV-PHP.S, pHelper Plasmid, and one of the following pAAV genomes (hSYN1-
mRuby2, hSYN1-DiO-mRuby2, hSYN1-mNeonGreen, hSYN1-DiO-mNeonGreen, 
hSYN1-mTurquoise2, hSYN1-DiO-mTurquoise2, and hSYN1-DiO-hM3Dq-
mRuby, CAG-GCamP6F). Cells were grown in DMEM + 5% FBS + non-essential 
amino acids, penicillin-streptomycin. Virus is precipitated from cells and supernatant 
with an 8% PEG solution (wt/vol), and purified by ultracentrifugation using 15%, 
25%, 40%, and 60% stacked iodixanol gradients. 
 
Systemic Delivery of AAV 
Mice were anesthetized using 2% isoflurane. Virus was tittered to 1012 VGs, 
resuspended to a volume of 100µl with sterile PBS, and injected retro-orbitally.  
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Quantitative PCR of Viral Abundance 
AAV-PHP.S:hSYN1-mNeonGreen was delivered systemically to WT GF and SPF 
mice at 6-8 weeks of age. 3-4 weeks following viral infection, 1cm of proximal, 
medial, and distal small and large intestines were harvested and flash frozen in 
TRIzol (ThermoFisher Scientific, Waltham, MA- Cat. No. 15596018) and RNA was 
extracted per manufacturer’s instructions. Viral ssDNA is present in the RNA 
fraction. Contaminating RNA was eliminated with RNase treatment (ThermoFisher 
Scientific, Waltham, MA- Cat. No. AM228) per manufacturer’s instructions. 
Quantitative PCR was performed on viral DNA with primers against WPRE 
(Forward: 5’-GGCTGTTGGGCACTGACAAT-3’; Reverse: 5’-
CCGAAGGGACGTAGCAGAAG-3’) and values were normalized to ubiquitous 
mitochondrial gene, mtRNR2 (Forward: 5’-CCGCAAGGGAAAGATGAAAA-3’; 
Reverse: 5’-TCGTTTGGTTTCGGGGTTTC-3’). Plotted relative abundances are 
mean values across three regions sampled in either small or large intestines. 
Threshold cycle value (Ct) for both WPRE and mtRNR2 were unchanged between 
GF and SPF. 
 
Neural activation of the GI tract 
TH-Cre and ChAT-Cre mice are used for these experiments. “Activated” mice are 
infected with AAV-PHP.S:hSYN1-DIO-hM3Dq-mRuby2 and “Control Mice” are 
infected with AAV-PHP.S:hSYN1-DIO-mRuby2. This is to control for both AAV-
PHP.S-mediated expression and the effects of Compound 21 dihydrochloride (C21) 
(HelloBio, Princeton, NJ- HB6124). C21 was injected intraperitoneally at a dose of 
3mg/kg in both activated and control mice. Mice for time course experiments were 
single housed in sterile cages and autoclaved water following first C21 
administration, and administered C21 for 10 consecutive days.  
 
GI Transit Time (Carmine Red), %(Water Content) in Feces, Fecal output rate 
Mice were administered C21 (3mg/kg) intraperitoneally, and soon after were 
gavaged with 100µl of 6% Carmine Red in 0.5% methylcellulose in water (69). Mice 
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were single housed in cages void of bedding. Time of fecal pellet expulsion was 
recorded for each pellet, and each pellet was collected in pre-weighed, 1.5mL 
microcentrifuge tubes. This was done for 5 hours. Each pellet collected was checked 
for the presence of Carmine red, and time of initial Carmine red pellet expulsion was 
recorded for GI transit time. Mass of collected fecal pellets was calculated, and was 
left to dry in a 80oC oven for 2 days to ensure evaporation of fecal water content. 
Tubes with fecal pellets were reweighed to obtain dry mass of feces, and %(water 
content) was calculated. Fecal output rate is the total number of pellets expelled 
during the 5 hour time course post-C21 administration divided by the time last fecal 
pellet was expelled (per mouse) during that time.  
 
Open field testing 
TH-Cre and ChAT-Cre mice were systemically infected with PHPS-hSyn-DIO-
hM3Dq-mRuby2 or PHPS-hSyn-DIO-mRuby2. 3-4 weeks after infection, mice were 
administered C21 (3mg/kg) and 45 minutes later, were placed in a 50cm x 50cm 
white plexiglass arena, recorded with an overhead camera, and tracked and analyzed 
using the EthoVision XT 10 software package (Noldus Information Technology; 
Leesburg, VA, USA) for 10 minutes. The arena was disinfected between trial runs 
using Rescue disinfectant (Virox technologies).  
 
Antibiotic Treatment 
Broad-spectrum antibiotic cocktail consisted of ampicillin, vancomycin, neomycin, 
and metronidazole (AVNM). Concentrated antibiotics were filter sterilized and 
added to autoclaved drinking water to obtain a final concentration of 1g/L of AVNM 
in 2% sucrose. Antibiotics were given ad libitum. Wildtype, SPF animals were placed 
on AVNM at 3 weeks or 8 weeks of age until mice were 11-13 weeks of age. For 
prenatal exposure, 6-8 week old GF and SPF mice were placed on AVNM for 2-3 
weeks prior to breeding. Dams will be kept on AVNM until offspring are weaned, at 
which point offspring will be kept on AVNM until 11-13 weeks of age.  
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Tissue preparation, immunohistochemistry, and Imaging 
Euthasol (Virbac, Carros, France) was administered, and perfused with 30mL of 
phosphate buffer solution (PBS) and next with cold 4% paraformaldehyde (PFA) in 
PBS. GI tract was post-fixed in 4% PFA overnight at 4oC, and stored in PBS + 
0.025% sodium azide. Tissues that underwent subsequent immunohistochemistry 
were made transparent by use of the passive CLARITY technique (PACT) (70) 
.Briefly, perfused and postfixed tissues were embedded with polymerized 4% 
(wt/vol) acrylamide, and lipids were eliminated using 8% (wt/vol) SDS solution. 
Tissues were blocked in 3% donkey serum and permeabilized with PBS + 0.3% 
Triton (PBST). Primary antibodies were incubated in PBST for 48 hours and washed 
with PBST for 24 hours (replacing wash 3 times). Tissues were next incubated in 
secondary antibodies (and DAPI) for 24 hours and washed in PBS for 48 hours, 
intermittently replacing the wash solution with fresh PBS. Primary antibodies used 
were rabbit PGP9.5 (1:300; Millipore Sigma AB1761-I) and chicken GFAP (1:500, 
BioLegend Cat #829401). Secondary antibodies used were goat anti-chicken Alexa 
647 (Life Technologies A-21450) and donkey anti-rabbit Alexa 568 (Life 
Technologies A10042). Tissues imaged just for virally expressed, endogenous 
fluorescence were made transparent using sorbitol-based optical clearing method, 
ScaleS (16). Tissues were mounted in respective mounting mediums, on a glass slide 
with a 0.5mm spacer (iSpacer, SunJin Lab Co.). Images were acquired on Zeiss LSM 
780 or 880, and microscope, laser settings, contrast, and gamma remained constant 
across images that were directly compared. All confocal images were taken with the 
following objectives: Fluar 5× 0.25 M27 Plan-Apochromat 10× 0.45 M27 (work- ing 
distance 2.0 mm) and Plan-Apochromat 25× 0.8 Imm Corr DIC M27 multi- 
immersion.  
 
Live, in vivo, imaging (GCaMP6F), Video Processing, and Analysis 
AAV-PHP.S-CAG-GCaMP6F (1012 VGs) was delivered systemically to Germ Free 
(GF) and specific pathogen free (SPF) mice. 3-4 weeks after infection, mice were 
anesthetized with 2% isoflurane on a heating pad (Kent Scientific, Torrington, CT- 
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DCT15) with plastic sleeve covers (Kent Scientific, Torrington, CT- DCT1520P). 
The abdominal cavity was surgically opened to expose the intestines. The proximal 
large intestine was identified, and this portion was placed on top of a stack of 4-6 
glass microscopy slides (depending on size of animal) (VWR, Radnor PA- Cat. No. 
48300-026). Tissue was secured onto glass slide with a biorthogonal silicon 
elastomer (Kwik-Sil) (World Precision Instruments, Sarasota, FL- KWIK-SIL), and 
a glass coverslip. Once elastomer stiffens, anesthetized mouse is placed under an 
upright confocal microscope (Zeiss LSM 880). Using a 10X objective, GCaMP6F 
fluorescence was taken at 5Hz (1 image every 200ms). Cell tracking was performed 
in 2D by using TrackMate ImageJ plugin (https://imagej.net/TrackMate) and 
fluorescence intensity was recorded from cells. Average background was determined 
by taking the fluorescence of a region of interest that did not contain a cell, over the 
duration of the video. Background was subtracted from cell fluorescence intensities. 
 
Spike Detection 
Data sets of fluorescent values recorded at a rate of 0.206 s from GCamp6f-
expressing unstimulated neurons in the myenteric plexus of the proximal large 
intestine were analyzed with the MLspike software for Matlab downloaded from 
GitHub (https://github.com/MLspike/spikes) (71). MLspike determines a new 
baseline to subtract from the raw fluorescence data to allow accurate modelling. The 
software uses a version of the Viterbi algorithm to obtain the most probable spike 
train. From the model, fluctuating baseline, model-estimated spike train, and most 
probable spike times were extracted. Polynomial coefficients (p2) was changed from 
0.5 to 0.55 and (p3) from 0.01 to 0.03 for GCaMP6F fluorescence as recommended 
(71). The minimum range for baseline (bmin) was changed from 0.7 to 0.5 as 
determined by observed fluorescence values.  
 
GCaMP6F Fluorescence in Ex Vivo Intestinal Preparation 
Small intestinal tissue was quickly harvested from ChAT-Cre mice, flushed and 
placed in oxygenated (95% O2, 5% CO2), ice cold Krebs-Henseleit solution for 1 
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hour followed by 15 min at room temperature. A segment was cut along the 
mesentery, and pinned flat (mucosa facing down) on a Sylgard-lined recording 
chamber (Warner Instruments, PH1) in oxygenated Krebs-Henseleit solution. C21 
was added at 10nM and GCaMP6F fluorescence was detected on an upright 
microscope (Zeiss, Oberkochen, Germany- Examiner D1). 
 
3’ mRNA-sequencing 
Tissue collection and RNA extraction 
Mice were cervically dislocated and GI tract was removed. 1cm of tissue above and 
below the cecum were dissected and cleaned to represent tissue from the distal small 
intestine and proximal large intestine, respectively. Tissue was homogenized in 
TRIzol (ThermoFisher Scientific, Waltham. MA- Cat. No. 15596018) solution using 
bead-based homogenizing methods, and total RNA was extracted using chloroform 
per manufacturer’s instructions. 
Library Preparation, Sequencing, and Analysis 
The cDNA libraries were prepared using the QuantSeq 3’mRNA-Seq Library Prep 
Kit FWD for Illumina (Lexogen, Greenland, NH) supplemented with UMI (unique 
molecular index) as per the manufacturer’s instructions. Briefly, total RNA was 
reverse transcribed using oligo (dT) primers. The second cDNA strand was 
synthesized by random priming, in a manner that DNA polymerase is efficiently 
stopped when reaching the next hybridized random primer, so only the fragment 
closed to the 3’ end gets captured for later indexed adapter ligation and PCR 
amplification. UMIs were incorporated to the first 6 bases of each read, followed by 
4 bases of spacer sequences. UMIs are used to eliminate possible PCR duplicates in 
sequencing datasets and therefore facilitate unbiased gene expression profiling. The 
basic principle behind the UMI deduplication step is to collapse reads with identical 
mapping coordinates and UMI sequences. This step helps increase the accuracy of 
sequencing read counts for downstream analysis of gene expression levels. The 
processed libraries were assessed for its size distribution and concentration using 
Bioanalyzer High Sensitivity DNA Kit (Agilent Technologies, Santa Clara, CA- Cat. 
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No. 5067-4626 and -4627). Pooled libraries were diluted to 2 nM in EB buffer 
(Qiagen, Hilden, Germany, Cat. No. 19086) and then denatured using the Illumina 
protocol. The libraries were pooled and diluted to 2 nM using 10 mM Tris-HCl, pH 
8.5 and then denatured using the Illumina protocol. The denatured libraries were 
diluted to 10 pM by pre-chilled hybridization buffer and loaded onto an Illumina 
MiSeq v3 flow cell for 150 cycles using a single-read recipe according to the 
manufacturer's instructions. Single-end 75bp reads (max 4.5M reads) were obtained. 
De-multiplexed sequencing reads were generated using Illumina BaseSpace.  
UMI specific workflows that were developed and distributed by Lexogen 
were used to extract reads that are free from PCR artifacts (i.e., deduplication). First, 
the umi2index tool was used to add the 6 nucleotide UMI sequence to the identifier 
of each read and trims the UMI from the start of each read. This generates a new 
FASTQ file, which is then processed through trimming and alignment. Second, after 
the quality and polyA trimming by BBDuk (Website-https://jgi.doe.gov/data-and-
tools/bbtools/bb-tools-user-guide/bbduk-guide/) and alignment by HISAT2 (version 
2.1.0) (72) , the mapped reads are collapsed according to the UMI sequence of each 
read. Reads are collapsed if they have the same mapping coordinates (CIGAR string) 
and identical UMI sequences. Collapsing reads in this manner removes PCR 
duplicates. Read counts were calculated using HTSeq (73) by supplementing 
Ensembl gene annotation (GRCm38.78). Raw read counts were run through 
ShinySeq to obtain differentially expressed genes and downstream gene ontology 
analyses (74).  
 
Proteome Preparation 
Protein extraction 
Mice were sacrificed 45 minutes after C21 administration and cecal contents were 
isolated and resuspended in 400ul of phosphate buffered solution, and centrifuged at 
x20,000g to spin down cells and lysate. Protein was isolated from resulting 
supernatant using Wessel-Flüegge’s methanol/chloroform extraction method (75). 
Briefly, MeOH and chloroform was added to sample at a 4:1 and 1:1 ratio, 
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respectively. Next, water dH2O was added at a 3:1 ratio, samples were vortexed and 
centrifuged at x20,000g. Resulting precipitated protein was collected and washed 
with methanol. Precipitated protein was centrifuged and was left to air dry, and stored 
in -20C until protein digestion.  
 
In-solution Protein Digestion and Desalting 
Precipitated protein sample was dissolved in 40ul of 8M Urea (100mM Tris-HCl 
pH8.5). 1.25ul of 100mM Tris(2-carboxyethyl)Phosphine was added and incubated 
at room temperature (RT) for 20 minutes. 1.8ul of 250mM iodoactaminde was 
added and incubated at RT in the dark. 1ul of 0.1µg/ul of Lysyl endopeptidase was 
added and incubated for 4 hours in the dark. Sample was adjusted down to 2M Urea 
by adding 120ul of 100mM Tris-HCl pH8.5. 1.6ul of 100mM CaCl2 and 2.5ul of 
.2µg/ul trypsin was incubated overnight in the dark. Add 8.5ul of 100% formic acid 
to make a 5% FA solution. Desalt mixture by HPLC using C8 peptide microtrap 
(Microm Bioresources). Peptides were lyophilized and diluted to 1 ug/ul in 0.5% 
formic acid prior to LC-MS/MS analysis. 
LC-MS/MS 
Samples were analyzed on a Q Exactive HF mass spectrometer coupled to an EASY 
nLC 1200 liquid chromatographic system (Thermo Scientific, San Jose, CA). 
$SSUR[LPDWHO\QJRISHSWLGHVZHUHORDGHGRQDȝP,'îFPFROXPQZLWK
DȝPHOHFWURVSUD\ WLS 3LFR)ULW IURP1HZ2EMHFWLYH:REXUQ0$ LQ-house-
packed with ReproSil-Pur C18-$4ȝP'U0DLVFK$PPHUEXFK*HUPDQ\
Solvent A consisted of 2% MeCN in 0.2% FA and solvent B consisted of 80% MeCN 
in 0.2% FA. A non-linear 60 minute gradient from 2% B to 40% B was used to 
separate the peptides for analysis. The mass spectrometer was operated in a data-
dependent mode, with MS1 scans collected from 400-1650 m/z at 60,000 resolution 
and MS/MS scans collected from 200-2000 m/z at 30,000 resolution. Dynamic 
exclusion of 45 s was used. The top 12 most abundant peptides with charge states 
between 2 and 5 were selected for fragmentation with normalized collision energy of 
28. 
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Peptide and Protein Identification 
Thermo .raw files were converted to .ms1 and .ms2 files using RawConverter 
1.1.0.18 (76) operating in data dependent mode and selecting for monoisotopic m/z. 
Tandem mass spectra (.ms2 files) were identified by database search method using 
the Integrated Proteomics Pipeline 6.5.4 (IP2, Integrated Proteomics Applications, 
Inc., http://www.integratedproteomics.com). Briefly, databases containing forward 
and reverse (decoy) (77, 78) peptide sequences were generated from in silico trypsin 
digestion of either the mouse proteome (UniProt; Oct. 2, 2019) or protein sequences 
derived from large comprehensive public repositories (ComPIL 2.0) (79). Tandem 
mass specta were matched to peptide sequences using the ProLuCID/SEQUEST 
(1.4) (80, 81) software package. The validity of spectrum-peptide matches were 
assessed using the SEQUEST-defined parameters XCorr (cross-correlation score) 
and DeltaCN (normalized difference in cross-correlation scores) in the DTASelect2 
(2.1.4) (82, 83) software package. Search settings were configured as follows: (1) 
5ppm precursor ion mass tolerance, (2) 10ppm fragment ion mass tolerance, (3) 1% 
peptide false discovery rate, (4) 2 peptide per protein minimum, (5) 600-6000Da 
precursor mass window, (6) 2 differential modifications per peptide maximum 
(methionine oxidation: M+15.994915 Da), (7) unlimited static modications per 
peptide (cysteine carbamidomethylation: C+57.02146 Da), and (8) the search space 
included half- and fully tryptic (cleavage C-terminal to K and R residues) peptide 
candidates with unlimited (mouse database, custom metagenomic shotgun database) 
or 2 missed cleavage events (ComPIL 2.0). 
Differential Analysis of Detected Proteins using Peptide-Spectrum Matches 
(Spectral Counts) 
Detected proteins were grouped by sequence similarity into "clusters" using CD-HIT 
4.8.1 (84-86) at the following similarity cut-offs: 65%, 75%, 85%, and 95%. The 
following is an example command line input: "cd-hit -i fastafile.fasta -o outputfile -c 
0.65 -g 1 -d 0". Tandem mass spectra identified as peptides (peptide spectrum 
matches, PSMs) were mapped to CD-HIT generated clusters. PSMs mapping to >1 
cluster were discarded. Cluster-PSM tables were generated and differential analysis 
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was performed in DESeq2 (1.25.13) (87). Briefly, count data (PSMs) were modeled 
using the negative binomial distribution, and the mean-variance relationship was 
estimated. Variance was estimated using an information sharing approach whereby a 
single feature's (or cluster's) variance was estimated by taking into account variances 
of other clusters measured in the same experiment. Feature significance calling and 
ranking were performed using estimated effect sizes. Multiple testing correction was 
performed by Benjamini-Hochberg method within the DESeq2 package. Volcano 
plots were generated in Prism (GraphPad). 
Differential Analysis of Detected Proteins using Ion Intensity (Precursor Intensity) 
Detected proteins were grouped into "clusters" by sequence similarity using CD-HIT 
4.8.1 (84-86) at the following similarity cut-offs: 65%, 75%, 85%, and 95%. The 
following is an example command line input: "cd-hit -i fastafile.fasta -o outputfile -c 
0.65 -g 1 -d 0". Using the Census software package (88, 89) (Integrated Proteomics 
Pipeline 6.5.4), peptide ion intensities were calculated from .ms1 files. Peptide ion 
intensities were assigned to their parent peptide, then parent peptides were mapped 
to their appropriate CD-HIT generated clusters. Ion intensities belonging to parent 
peptides that map to >1 CD-HIT cluster were discarded. Cluster-ion intensity tables 
were generated.  
Ion intensity data were analyzed using the DEP package (90) operating in R. 
Intensity values were automatically Log2 transformed in DEP. The cluster list was 
subsequently filtered with the 'filter_proteins' function such that clusters with missing 
values above a 65% threshold were discarded. Remaining intensities were further 
transformed by the 'normalize_vsn' function (91). Missing data in remaining clusters 
were imputed using a mixed approach. Clusters where either the control or treatment 
group contained only null entries were classified as 'missing not at random' (MNAR) 
and imputed with 0 values. All other groups were treated as 'missing at random' 
(MAR) and imputed using the maximum likelihood method ('MLE') (92). Note that 
for a given cluster, missing values for treatment groups were imputed separately by 
treatment group. Differential expression analyses were performed on filled-in 
cluster-ion intensity tables using the 'test_diff' function (93) and multiple testing 
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correction was performed using the 'add_rejections' function. Volcano plots, PCA 
plots, and heat maps were also generated using R. 
Network Analysis using STRING Database 
Upregulated proteins with a nominal p-value < 0.2 were searched against protein-
protein interactions in the STRING database (http://www.string-db.org) where high 
confidence interactions were selected for. Briefly, the STRING database sources 
protein-protein interactions from primary databases consisting of genomic context 
predictions, high-throughput lab experiments, (conserved) co-expression, automated 
textmining, and pervious knowledge in databases (94).  
Metaproteome Analysis using Unipept 
Upregulated tryptic, microbial peptide sequences with nominal p-value cutoff of p < 
0.2 were input into Unipept (http://unipept.ugent.be) (95, 96), equating leucine and 
isoleucine and filtering duplicate peptides. Briefly, Unipept indexes tryptic peptide 
sequences from the UniProtKB and details peptides with NCBI’s taxonomic 
database. Lowest common ancestor is calculated for each tryptic peptide.  
 
Metagenome Preparations 
Fecal Collection 
AAV-PHP.S:hSYN1-hM3Dq-mRuby (1012 VGs) was delivered systemically to TH-
Cre and ChAT-Cre mice. 3-4 week after infection, C21 (3mg/kg) was administered 
daily for 10 consecutive days. Fecal pellets were collected in sterile containers one 
day before initial C21 dose, and between doses thereafter.  
Fecal sample DNA extraction and Library Preparation 
DNA was extracted with the Qiagen MagAttract PowerSoil DNA kit as previously 
described (Marotz et al 2017) . Our standard protocol is optimized for an input 
TXDQWLW\ RI ௗQJ '1$ SHU UHDFWLRQ 3ULRU WR OLEUDU\ SUHSDUDWLRQ LQSXW '1$ LV
transferred to a 384-well plate and quantified using a PicoGreen fluorescence assay 
(ThermoFisher, Inc). Input DNA is then normali]HGWRௗQJLQDYROXPHRIௗȝ/
of molecular-grade water using an Echo 550 acoustic liquid-handling robot 
(Labcyte, Inc). Enzyme mixes for fragmentation, end repair and A-tailing, ligation, 
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and PCR are prepared and added in approximately 1:8 scale volumes using a 
Mosquito HV micropipetting robot (TTP Labtech). Fragmentation is performed at 
ௗ&IRUௗPLQIROORZHGE\HQG-repair and A-WDLOLQJDWௗ&IRUௗPLQ 
Sequencing adapters and barcode indices are added in two steps, following 
the iTru adapter protocol (97). Universal adapter “stub” adapter molecules and 
ligase mix are first added to the end-repaired DNA using the Mosquito HV robot 
and ligDWLRQSHUIRUPHGDWௗ&IRUௗK8QOLJDWHGDGDSWHUVDQGDGDSWHUGLPHUVDUH
then removed using AMPure XP magnetic beads and a BlueCat purification robot 
(BlueCat Bio). 7.5-ȝ/PDJQHWLFEHDGVROXWLRQLVDGGHGWRWKHWRWDODGDSWHU-ligated 
sample volume, washeG WZLFH ZLWK  (W2+ DQG WKHQ UHVXVSHQGHG LQ ௗȝ/
molecular-grade water. 
Next, individual i7 and i5 are added to the adapter-ligated samples using the 
Echo 550 robot. Because this liquid handler individually addresses wells, and we 
use the full set of 384 unique error-correcting i7 and i5 indices, we are able to 
generate each plate of 384 libraries without repeating any barcodes, eliminating the 
problem of sequence misassignment due to barcode swapping (98, 99). To ensure 
that libraries generated on different plates can be pooled if necessary, and to 
safeguard against the possibility of contamination due to sample carryover between 
runs, we also iterate the assignment of i7 to i5 indices each run, such that each 
unique i7:i5 index combination is only repeated once every 147,456 libraries. 
ௗȝ/RIHOXWHGEHDG-ZDVKHGOLJDWHGVDPSOHV LVDGGHGWRௗȝ/RI3&R master 
mix and PCR-DPSOLILHGIRUௗF\FOHV7KHDPSOLILHGDQGLQGH[HGOLEUDULHVDUHWKHQ
SXULILHGDJDLQXVLQJPDJQHWLFEHDGVDQGWKH%OXH&DWURERWUHVXVSHQGHGLQௗȝ/
ZDWHUDQGௗȝ/RIILQDOSXULILHGOLEUDU\WUDQVIHUUHGWRD-well plate using the 
Mosquito HV liquid-handling robot for library quantitation, sequencing, and 
storage. 384 samples are then normalized based on a PicoGreen fluorescence. 
Shallow shotgun metagenome sequencing and diversity analysis 
The Illumina data for each HiSeq lane was uploaded to Qiita, a tool with 
standardized pipelines for processing and analyzing metagenomic data (100). 
Adapter sequences were removed from the reads using the Atropos v.1.1.15 (101) 
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command (from the qp-shogun 0.1.5 pipeline) and the trimmed sequences were 
downloaded from Qiita. The reads for each sample were filtered of any potential 
mouse contamination using Bowtie2 v.2-2.2.3 (102). The filtered reads were then 
aligned to the Web of Life (WoL) reference phylogeny (103) with Bowtie2 using 
an adapted SHOGUN pipeline (104). The WoL contains 10,575 bacterial and 
archaeal genomes with each genome representing an OTU. Sequencing reads that 
did not map to a single reference genome as well as reads that mapped to multiple 
genomes were not included in the analysis. If an OTU had a relative abundance less 
than 0.01% in a given sample, the OTU was not included for that sample. 
Additionally, OTUs with fewer than 5 assigned reads were not considered. The 
samples were rarefied to a depth of 12,750 reads and those with fewer than the 
rarefaction depth were excluded. The QIIME2 v.2019.7 (105) DEICODE plugin 
was used to calculate the Aitchison distance, a compositional beta diversity metric, 
and perform Robust Aitchison PCA to create biplots that visualize relationships 
between features and samples (106). The QIIME2 diversity plugin was used to 
calculate the other alpha and beta diversity metrics used in this study. 
Metagenomic based functional profiling 
The filtered reads were also analyzed using HUMAnN2 v2.8.1 (107) to establish 
functional profiles for the samples. HUMAnN2 is a pipeline that begins by using 
MetaPhlAn 2 to compile custom databases of reference genomes based on the 
species detected in a sample (108). HUMAnN2 then maps the filtered onto these 
custom databases and the reads that do not map to any of the references are then 
subjected to a translated search against UniProt Reference Clusters or UniRef 
(109). Here, the UniRef90 database was used for the translated search and installed 
according to the HUMAnN2 documentation. The results from both the search 
performed using the custom reference genome database and the search against the 
UniRef90 database were combined and the gene families identified in each sample 
were reported in units of read per kilobase (RPKs) to account for gene length. 
HUMAnN2 also compared the gene families found in a sample with the MetaCyc 
pathways database (110) and output a table reporting the pathway abundances 
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found in each sample. After rarefying gene family tables to a depth of 166,000 
RPKs and using a depth of 22,600 for pathway abundances, the QIIME2 diversity 
and DEICODE plugins were used to calculate alpha and beta diversity metrics. 
Metabolomics Preparations 
Sample Preparation 
Frozen fecal and cecal samples were transported on dry ice for metabolomics 
analysis. The samples were weighed out and an extraction solvent (1:1 methanol to 
water with an internal standard of 1 µM sulfamethazine) was added at a 1:10 
milligram to microliter ratio. The samples were then homogenized using a 
TissueLyser II (Qiagen) for 5 minutes at 25 hertz followed by a 15 minute 
centrifugation at 14,000 rpm. From the supernatant, 120 µL were transferred to a 96 
deepwell plate (Eppendorf) and then these samples were lyophilized using a 
CentriVap Benchtop Vacuum Concentrator (Labconco) and stored at -ႏ8SRQ 
the time for data acquisition, the lyophilized plates were resuspended in a 1:1 
methanol to water solvent spiked with 1 µM of sulfadimethoxine. The plates were 
vortexed for 2 minutes, centrifuged at 14,000 rpm for 15 minutes and 120 µL of the 
supernatant was transferred to a 96 well autosampler plate(Eppendorf). Plates were 
VWRUHGDW&SULRUWR/&06DQDO\VLV 
Data Acquisition 
The untargeted metabolomics analysis was completed using an ultra-high 
performance liquid chromatography system (Thermo Dionex Ultimate 3000 
UHPLC) coupled to ultra-high resolution quadrupole time of flight (qTOF) mass 
spectrometer (Bruker Daltonics MaXis HD). A Phenomenex Kinetex column (C18 
ȝPPP[PPZDVXVHGIRUFKURPDWRJUDSKLFVHSDUDWLRQ$QLQMHFWLRQ
volume of 5 µL was used per sample and a flow-rate of 0.500 mL was used 
throughout the analysis. The mobile phase consisted of solvent A: 100% LC-MS 
grade water spiked with 0.1% formic acid and solvent B: 100% LC-MS grade 
acetonitrile spiked with 0.1% formic acid. The chromatographic gradient was as 
follows: 0.0–ௗPLQ%–ௗPLQ–100% B; 9.0-ௗPLQ%-
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ௗPLQ-5% B; 11.5-12.5 min, 5% B. The data was collected using electrospray 
ionization in positive mode. Sample data was saved as .d file folders. 
Data Processing 
The raw .d data files were converted to mzXML format using Bruker Compass 
DataAnalysis 4.1 software. The resulting .mzXML file, the original .d file folders, 
and basic prep information sheet were stored on the UC San Diego MassIVE data 
repository under the accession number MSV000084550. For the MS1 level feature 
detection, the open-source software MZmine version 2.51 was used. The parameters 
used are as follows: 1) Mass Detection (Centroid, Noise Level MS1 1E3, MS2 1E2); 
2) ADAP Chromatogram Builder (Min Group size in # of scans = 3, Group Intensity 
Threshold = 3E3, Min Highest Intensity = 1E3, m/z tolerance 0.01 m/z or 10.0 ppm); 
3) Chromatogram Deconvolution (Local Minimum Search > Chromatographic 
Threshold 0.01%, Minimum in RT range 0.50 min, <Minimum Relative Height 
0.01%, Minimum Absolute Height 3E3, Min Ratio of Peak Top/Edge 2, Peak 
Duration Range 0.05-0.50 min; m/z Calculation Auto, m/z range for MS2 pairing 
0.01 Da, and RT Range for MS2 Pairing 0.1 min); Isotopic Peaks Grouper (m/z 
Tolerance 0.01 m/z or 10.0 ppm, Retention Time Tolerance 0.3 min, Maximum 
Charge 4, Representative Ion Most Intense); Join Aligner (m/z Tolerance 0.01 m/z 
or 10.0 ppm, Weight for m/z 75, Retention Time Tolerance 0.3 min, Weight for RT 
25); Gap-Filling Peak Finder (Intensity Tolerance 20%, m/z Tolerance 0.005 m/z or 
10.0 ppm, Retention Time Tolerance 0.2 min). The resulting feature table was saved 
as a .csv file and .mgf file for use in GNPS and MetaboAnalyst. 
Molecular Networking and Statistical Analysis 
Molecular networking was performing using the feature networking tool available on 
the Global Natural Products Social Molecular Networking portal (GNPS) accessed 
via the following link:  
https://gnps.ucsd.edu/ProteoSAFe/index.jsp?params=%7B%22workflow%22:%22
FEATURE-BASED-MOLECULAR-
NETWORKING%22,%22library_on_server%22:%22d.speclibs;%22%7D.  
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The annotations obtained using this workflow fall under MSI level 2 or 3 and were 
used for feature analysis. The .mgf and .csv outputs from MZmine v2.51 were used 
to run the workflow. The GNPS workflow parameters used we as follows: Precursor 
Ion Mass 0.02 Da, Fragment Ion Mass Tolerance 0.02 Da, Min Pairs Cos 0.7, 
Minimum Matched Fragments 6, Maximum Shift Between Precursors 500 Da, 
Network TopK 10, Maximum Connected Component Size (Beta) 100, and the files 
were row sum normalized. Default parameters were used for the rest of the settings. 
The visualizations and statistical analyses were performed using QIIME 2 2019.10, 
MetaboAnalyst and Cytoscape v3.7.2. 
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Conclusion 
Neurons, in general, detect chemical stimuli and transmit electrical impulses 
over large biological distances at remarkable speeds (1). In the brain, experiential 
stimuli motivate neural plasticity and learning, and this defines the network by which 
information is propagated from one cell to another, resulting in predictable 
physiological or behavioral outputs (2). In the GI tract, the ENS adapts and responds 
to incredibly diverse molecular cues and must do so throughout the entire length and 
surface area of the intestines- the largest and most expansive internal organ. Often 
coined as the “second brain” (3), perhaps it is the exposure and entrainment of GI 
neurons to molecular stimuli, over brief and lengthy biological time scales, that 
establishes its physiological “identity”. These exposure events could ultimately 
determine the host’s response, tolerance, and susceptibility to the environment and 
disease. And as we process these complex and dynamic molecular environments, and 
work to maintain host and microbial homeostasis, aging and neurodegeneration of 
the GI nervous system are not so different from that found in the brain.  
The CNS is responsible for reacting and adapting to environmental cues 
processed by our physical senses. The GI nervous system integrates such signals from 
the brain but receives additional molecular input from the luminal environment. The 
brain dictates the environments we are exposed to and our initial reactions to it. 
However, it is the GI tract, and innervation of it, that processes the chemical cues and 
propagates this information as electrical impulses throughout the body. It is through 
this network that the GI tract is inextricably linked to the rest of the body. Thus, 
dysregulation of the GI nervous system may have a larger role, than previously 
believed, in impacting GI physiology and beyond. As advances in experimental tools 
help us understand the active role that GI innervation has in shaping the intestinal 
tissue, luminal environment, and the systemic milieu, novel hypotheses on disease 
etiologies will emerge, promoting the study of therapeutics that target the ENS for 
both GI and peripheral related diseases. 
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